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 Summary 
 
Tuberculous meningitis (TBM) continues to be an important cause of mortality and 
neurological disability in resource-limited countries. Many questions remain about the 
best approaches to prevent, diagnose, and treat TBM, and there are still too few answers. 
 
The aim of this dissertation was to challenge current management strategies in 
childhood TBM. 
 
Accurate prediction of outcome in TBM is of critical importance when assessing the efficacy 
of different interventions. I conducted a retrospective cohort study of 554 children with 
TBM less than 13 years of age admitted to Tygerberg Children’s Hospital over a 20 
year period (1985-2005) and reclassified all patients according to the criteria of all the 
currently available staging systems in childhood TBM (chapter 4). In this study, I found that 
the “Refined Medical Research Council (MRC) staging system after 1 week” had the 
highest predictive value of all TBM staging systems. It is created by subdivision of stage 
2 (2a and 2b) of the existing MRC staging system. Additionally, I proposed and validated 
a simplified TBM staging system which is less dependent on clinical ability and 
neurological expertise than current staging systems. The simplified staging system was 
termed the “Tygerberg Children’s Hospital Scale” (TCH) and relies solely on the patient’s 
ability to visually fixate and follow and the motor response to pain on both sides. It 
demonstrated excellent predictive power of outcome after 1 week and did not differ 
significantly from the “Refined MRC staging system” in this regard. 
 
The optimal anti-TB drug regimen and duration of treatment for TBM is unknown. It has 
been suggested that intensive short-course (6 months) anti-TB therapy may be sufficient 
and safe. I conducted a prospective descriptive study of 184 consecutively treated children 
w i t h  TBM and found that short-course intensified anti-TB therapy aimed at treating TBM 
patients (anti-TBM therapy) is sufficient and safe in both HIV-uninfected and HIV-
infected children with drug susceptible TBM (chapter 5). The overall study mortality of 
3.8% at completion of treatment compares favourably with the median mortality rate of 33% 
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 (range 5-65%) reported in a recent review describing outcome in TBM treatment studies. 
 
TB-immune reconstitution inflammatory syndrome (IRIS) is a potentially life-threatening 
complication in HIV-infected children with TB of the central nervous system. Little is 
known about the incidence, case fatality, underlying immunopathology and treatment 
approaches in HIV-infected children with neurological TB-IRIS. In a case series, I found 
that neurological TB-IRIS should be considered when new neurological signs develop after 
initiation of antiretroviral therapy (ART) in children with TBM (chapter 6.1). Manifestations 
of neurological TB-IRIS include headache, seizures, meningeal irritation, a decreased 
level of consciousness, ataxia and focal motor deficit. I also discussed the rational for 
using certain treatment modalities, including thalidomide. 
 
Neurological tuberculous mass lesions (tuberculomas and pseudo-abscesses) may develop or 
enlarge in children on anti-TBM treatment. These lesions respond poorly to therapy, and 
may require surgical excision, but may be responsive to thalidomide, a potent inhibitor of 
tumour necrosis factor-alpha (TNF-alpha). The optimal dose and duration of thalidomide 
therapy and the correlation with magnetic resonance imaging (MRI) is yet to be explored. 
The primary objective of our next study was to investigate whether serial MRI is useful 
in evaluating treatment response and duration of thalidomide therapy (chapter 6.2). A 
secondary objective was to determine the value of thalidomide in the treatment of these 
lesions. In a prospective observational study over three years, serial MRI was performed 
in 16 consecutive children compromised by TB pseudo-abscesses who were treated with 
thalidomide. The rapid clinical response of most patients suggests that thalidomide provides 
substantial clinical benefit in this clinical context. I also identified a MRI marker of cure 
that is evolution of lesions from early stage “T2 bright” with edema to “T2 black.” This 
finding could be useful in the future management of these patients. 
 
Transcranial Doppler imaging (TCDI) is potentially a valuable investigational tool in 
children with TBM, a condition often complicated by pathology relevant to Doppler 
imaging such as raised intracranial pressure (ICP) and cerebral vasculopathies. Serial TCDI 
was performed on 20 TBM children with the aim of investigating cerebral haemodynamics 
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 and the relationship between pulsatility index (PI) and ICP (chapter 6.3). In this study, I 
found that TCDI-derived pulsatility index (PI) is not a reliable indicator of raised ICP in 
children with tuberculous hydrocephalus which I attributed this to individual variation of 
tuberculous vascular disease, possibly compromising cerebral vascular compliance and 
resistance. The study did confirm the efficacy of medical therapy in children with 
tuberculous communicating hydrocephalus. In all cases, the ICP normalized within 7 days 
after initiation of acetazolamide and furosemide. 
 
In the same cohort of children with TBM I also measured cerebral blood flow velocities 
(BFV) in the anterior cerebral artery  (ACA), middle cerebral artery (MCA) and posterior 
cerebral artery (PCA) on admission and after day 3 and 7.  I found persistent high BFV in all 
the basal cerebral arteries suggesting stenosis due to  vasculitis rather than functional 
vasospasm. Additionally, I found that complete MCA occlusion, subnormal mean MCA 
velocities (less than 40 cm/s) and a reduced PI (less than 0.4) correlated with radiological 
proven large cerebral infarcts. No side-to-side differences in MCA BFV or subnormal PI’s 
were detected in four TBM children with territory infarcts on admission. I attributed this to 
the occlusion of a limited number (one or two) of the 9 MCA perforators which has been 
shown not to affect the hemodynamics of the MCA. 
 
I concluded by highlighting the many questions that remain about the best a p p r o a c h e s  to 
prevent, diagnose, and treat TBM (chapter 2).  In a second literature review, aimed at 
clinicians working in resource-limited countries, I describe novel approaches to the 
management of childhood TBM, including a treatment algorithm for tuberculous 
hydrocephalus, the role for short-course intensified anti-TBM treatment and home-based 
anti-TBM treatment (chapter 3). 
 
Even with the best diagnostic and treatment modalities, outcome in childhood T B M  will 
remain poor if diagnosis is delayed. Our efforts should be on increased awareness and earlier 
diagnosis. 
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 Opsomming 
 
Tuberkuleuse meningitis (TBM) bly ‘n belangrike oorsaak van mortaliteit en neurologiese 
ongeskiktheid in lande met beperkte hulpbronne. Baie vrae oor die beste benaderings tot 
voorkoming, diagnose en behandeling van TBM bly bestaan en daar is steeds te min antwoorde. 
 
Die doel van die verhandeling was om huidige behandelingstrategieë van tuberkuleuse 
meningitis (TBM) in kinders uit te daag. 
 
Akkurate voorspelling oor die uitkoms van TBM is van kritieke belang wanneer 
doeltreffendheid van verskillende ingrypings beoordeel word. Ek het ‘n retrospektiewe kohort 
studie van 554 kinders jonger as 13 jaar met TBM wat in Tygerberg Kinderhospitaal toegelaat is 
oor `n  tydperk  van  twintig  jaar  (1985  tot  2005) uitgevoer en al die pasiënte volgens  die  
kriteria  van  al  die  huidig  beskikbare  stadiëringsisteme vir kinder TBM geherklassifiseer 
(hoofstuk 4). Die waarde van die verskillende stadiëringsisteme in die voorspelling van 
neurologiese uitkoms is toe bepaal. In hierdie studie het ek bevind dat die “Verfynde Mediese 
Navorsings Raad  (MNR) stadiëringsisteem na 1 week” die TBM stadiëringsisteem  met  die  
hoogste voorspellende waarde was om neurolgiese uitkoms te voorspel. Dit is geskep deur 
onderverdeling van stadium 2 (2a en 2b) van die bestaande gemodifiseerde MNR 
stadiëringsisteem. Daarbenewens het ek ’n vereenvoudigde stadiëringsisteem vir TBM wat 
minder afhanklik van kliniese vermoëns en neurologiese kundigheid sal wees as die bestaande 
stadiëringsisteme daargestel en getoets. Die vereenvoudigde  stadiëringsisteem is die  “Tygerberg  
Kinderhospitaal  Skaal  (TKH)”  genoem   en  dit  is  slegs  gebaseer op `n pasiënt se vermoë 
om visueel te fikseer en te volg en die motoriese respons tot pyn aan beide kante van die 
ligaam. Dit het uitstekende voorspellingswaarde gehad vir uitkoms na die eerste week van 
siekte en het in hierdie verband nie betekenisvol verskil van die “Verfynde MNR 
stadiëringsisteem” nie. 
 
Die optimale anti-TB middel regimen en duurte van behandeling vir TBM is onbekend. 
Sommige kenners stel voor dat ‘n intensiewe kort-kursus (6 maande) van anti-TB behandeling 
veilig en voldoende mag wees. Ek het ‘n prospektiewe beskrywende studie op 184 
opeenvolgende kinders met TBM uitgevoer en bevind dat intensiewe kort-kursus   anti-TB   
behandeling  gemik  op  die  behandeling van kinders  met TBM (anti-TBM behandeling) in 
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 beide menslike immuniteitgebrekvirus (MIV)-ongeïnfekteerde en MIV-geïnfekteerde kinders met 
middel-gevoelige TBM voldoende en veilig was (hoofstuk 5 ). Die mortaliteit in my studie met 
voltooing van behandeling vergelyk gunstig met die mediane mortaliteit van 33% (reikwydte 
5-65%) wat onlangs in ‘n oorsig van uitkoms in TBM gerapporteer is. 
 
TB immuun rekonstitusie inflammatoriese sindrome (IRIS) is ‘n potensieël lewensbedreigende 
komplikasie in MIV-geïnfekteerde kinders met TB van die sentrale senuwee sisteem (SSS). Min 
is oor die voorkoms, mortaliteit, onderliggende immunopatologie en behandelingsbenaderings in 
MIV-geïnfekteerde kinders met neurologiese TB-IRIS bekend. In `n gevalle-reeks het ek gevind 
dat neurologiese TB-IRIS oorweeg moet word as nuwe neurologiese tekens na aanvang van 
antiretrovirale terapie (ART) in MIV-geïnfekteerde kinders met TBM ontwikkel (hoostuk 6.1). 
Simptome en tekens van neurologies TB-IRIS behels hoofpyn, konvulsies, meningiale 
prikkeling, ‘n verlaagde vlak van bewussyn, ataksie en fokale motoriese uitval. Ons bespreek 
ook die rasionaal vir die gebruik van sekere behandelingsmodaliteite, insluitende thalidomied. 
 
Neurologiese tuberkuleuse massaletsels (tuberkulome en pseudo-absesse) mag ontwikkel of 
vergroot in kinders op anti-TBM behandeling. Hierdie letsels reageer swak op terapie, vereis 
soms chirurgiese verwydering, maar kan op talidomied behandeling reageer, ‘n kragtige 
inhibeerder van tumor nekrose faktor-alfa (TNF-α). Die optimale dosis en duurte van 
thalidomide behandeling en die korrelasie met magnetiese resonansbeelding (MRB) moet nog 
ondersoek word. Die primêre doel van my volgende studie was om te bepaal of seriële MRB 
van waarde is om die respons op behandeling te evalueer asook die duurte van talidomied 
behandeling. Die sekondêre doelwit was om die waarde van talidomied in die behandeling van 
hierdie letsels te bepaal. In ‘n prospektiewe waarnemingstudie wat oor 3 jaar gestrek het is 
seriële MRB uitgevoer op 16 opeenvolgende kinders met TB pseudo-absesse  wat  behandel  is 
met talidomied (hoofstuk 6.2). Die spoedige kliniese  verbetering  van  die meeste  pasiënte  dui  
daarop dat thalidomied `n aansienlike kliniese voordeel bied in hierdie kliniese konteks. 
Verder het ek `n MRB merker van genesing geïdentifiseer naamlik evolusie van die letsel van 
vroeë stadium “T2 helder” met edeem na “T2 swart”. Hierdie bevinding is van groot waarde in 
die toekomstige behandeling van TBM pasiënte wat hierdie komplikasie ontwikkel. 
 
Transkraniale Doppler beelding (TKDB) is potensieël `n waardevolle ondersoekmetode in 
kinders met TBM, `n toestand  wat  dikwels  gekompliseer  word  deur  patologie verwant aan 
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 Doppler beelding soos verhoogde intrakraniale druk (IKP) en serebrale vaskulopatieë. Seriële 
TKBD is op 20 TBM kinders uitgevoer om serebrale hemodinamika en die verband tussen die 
pulsatiele indeks (PI) en IKP te ondersoek (hoofstuk 6.3). In hierdie studie het ek gevind dat 
TKDB-afgeleide PI nie `n betroubare aanduiding van verhoogde IKD in kinders met 
tuberkuleuse hidrokefalus is nie en dit aan individuele variasies van tuberkuleuse vaskulêre siekte 
toegeskryf, wat serebrale vaskulêre toegeeflikheid en weerstand benadeel. Die studie het die 
doeltreffendheid van mediese behandeling in kinders met kommunikerende tuberkuleuse 
hidrokefalus bevestig. In alle gevalle het die IKP binne 7 dae na aanvang van asetosoolamied en 
furosemied genormaliseer. 
 
In dieselfde groep TBM kinders het ek die serebrale bloedvloei-snelhede (BVS) in die anterior 
serebrale arterie (ASA), middel serebrale arterie (MSA) en posterior serebrale arterie (PSA) met 
toelating en  na dag 3 en 7  gemeet. Ek het volgehoue hoё BVS in al die basale arteries gevind 
wat op stenose sekondêr tot vaskulitis eerder as funksionele vasospasma dui. Daarbenewens het 
ek  gevind  dat  volledige  MSA  afsluiting, subnormale gemiddelde MSA snelhede (minder as 
40 sentimeter per sekonde) en `n verminderde PI (minder as 0.4) met radiologies-bewysde groot 
serebrale infarksies gekorreleer het. Geen kant-tot-kant verskille in MSA BVS of subnormale 
PI’s is in vier TBM kinders met kleiner infarksies met toelating bespeur nie. Ek skryf dit toe aan 
die afsluiting van `n beperkte aantal (een of twee) van die nege MSA perforators wat nie nie 
die hemodinamika van die MSA beïnvloed nie. 
 
Ek het afgesluit om al die vrae wat nog bestaan oor die beste benadering ten opsigte van 
voorkoming, diagnose and behandeling van TBM uit te wys (hoofstuk 2). In die tweede 
literatuuroorsig, wat  gemik is op dokters wat werk in  hulpbron-beperkte  lande, beskryf ek nuwe 
benaderings tot die hantering van pediatriese TBM, insluitend `n behandelingsalgoritme vir 
tuberkuleuse hidrokefalus, die rol van kort- kursus versterkte anti-TB behandeling vir TBM en 
tuis-gebaseerede anti-TBM behandeling (hoofstuk 3). 
 
Selfs met die beste diagnostiese en behandelingsmodaliteite, is die uitkoms van kinder TBM 
swak indien diagnose vertraag word. Ons pogings  moet  daarom  op groter bewustheid  en 
vroeёr diagnose berus. 
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Introduction 
 
The true worldwide burden of childhood tuberculosis (TB) remains unknown. In 2012, the 
World Health Organization (WHO) estimated the global burden of TB in children (under 15 
years of age) at 530 000.1 However, the actual burden of childhood TB is thought to be much 
higher due to the difficulties related to accurate diagnosis of TB in young children. South 
Africa is one of the 22 high TB burden countries that account for 80% of the world’s TB 
cases.1 The annual risk of TB infection (ARTI) in Southern African townships has been 
reported to be as high as 4% per annum.2 Epidemiological studies report a good correlation 
between the incidence of tuberculous meningitis (TBM) in children 0-4 years of age per 
100 000 population and the percentage ARTI multiplied by five.3 This implies an annual 
childhood TBM incidence in these townships of 20 per 100 000 children. A recent study in 
the Western Cape province of South Africa further highlighted the importance of TBM by 
finding it to be the commonest cause of paediatric bacterial meningitis.4  
 
The aim of this dissertation was to challenge current management strategies in childhood 
TBM. Unlike pulmonary TB, which has been the subject of numerous clinical trials in adults 
and children, the evidence base of various aspects of TBM diagnosis, management and 
prognosis is limited leading to substantial differences and uncertainties in management 
protocols.  
 
Eight years ago in a review in The Lancet Neurology, Dr Guy Thwaites argued that 
prevention and treatment of TBM posed many questions for which there were too few 
answers5. Last year, my colleague Prof Johan Schoeman was invited by The Lancet 
Neurology to write an updated review on TBM in adults and children. He kindly invited  
Dr Guy Thwaites (for his expertise on adult TBM) and me to join him. The aim of the review 
(see chapter 2), in which all three authors contributed equally, was to determine whether there 
are now answers to the questions that were previously posed and to reassess the challenges 
that face those tasked with the prevention, diagnosis, and treatment of TBM in children and 
adults. We concluded that many questions remain about the best approaches to prevent, 
diagnose and treat TBM, and there are still too few answers.6  
 
TBM continues to be an important cause of neurological disability in resource-limited 
countries.  In a second review article (see chapter 3), aimed at clinicians working in resource-
limited countries, I describe novel approaches to the management of childhood TBM, 
2
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including a treatment algorithm for tuberculous hydrocephalus, the role for short-course 
intensified anti-TB treatment and home-based treatment for childhood TBM cases.7     
 
The first challenge that confronts a physician managing a very ill child with TBM relates to 
accurate prediction of outcome. Parents expect physicians to prognosticate outcome as 
accurately as possible, which is often difficult because of limited information in this regard. 
Accurate outcome prediction is also critically important when assessing the efficacy of 
interventions, such as different anti-TB drug regimens and the benefits of adjuvant therapy 
such as immune-modulating agents. However, accurate prediction of outcome in childhood 
TBM is difficult due to the protracted course of the disease, diversity of underlying 
pathological mechanisms, unpredictability of injury-induced cerebral plasticity and variation 
of host immunity.  
 
Several different staging systems, including the modified Medical Research Council (MRC), 
the Glasgow Coma Scales (GCS) on its own, Acute Physiological and Chronic Health 
Evaluation (APACHE) II and the TBM acute neurology score (TBAN) have been proposed to 
predict outcome in TBM.8-11 It is unclear from the literature which of these staging systems 
has the highest predictive value.  
 
The most widely used “modified MRC staging system” does not distinguish unilateral from 
bilateral motor involvement, which is important, as bilateral cerebral infarction often occurs 
in children with advanced TBM.12 My previous clinical experience suggests that the modified 
stage 2 disease-category is too inclusive, as children without neurological deficit and only 
slight drowsiness (GCS 14/15) are grouped together with children with neurological deficit 
and GCS of 10-13/15.  
 
The benefit of clinical staging systems is that it can be applied to patients in both developed 
and developing countries, as it does not rely on radiologic or laboratory findings. Limitations 
of staging systems are that staging criteria may be difficult to apply in a standard manner for 
children in whom assessment of the sensorium is difficult. Accurate staging often requires 
skilled medical personnel. There is a need for a simplified, universal clinical staging system 
that can be applied to patients with TBM in resource-limited countries.  
 
The initial staging may be influenced by other factors apart from the TBM itself which may 
affect level of consciousness on presentation. These include the effect of seizures, drugs and 
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hydration state. It is therefore possible that staging once the patient is stabilized may be of 
more value prognostically than the staging at first contact.  
 
The hypothesis of the first study (chapter 4) was that more accurate prediction of outcome in 
childhood TBM is achievable by refinement of the current staging systems. Additionally, I 
believed that a simplified TBM outcome system is achievable. Study questions were: Which 
of the current TBM staging systems has the highest predictive value? Is more accurate 
predicting of outcome in TBM possible by refinement of the modified MRC staging system? 
Is a simplified TBM staging system achievable for use by unskilled health care workers in 
resource-poor countries? Does staging after 1 week of diagnosis improve outcome prediction? 
Which clinical factors are associated with significant stage improvement after the first week 
of treatment?     
 
 The second challenge relates to what the most appropriate antimicrobial treatment is for 
childhood TBM. Effective antimicrobial treatment must treat the active infection by 
eliminating actively replicating bacilli, thus reducing the probability of sequelae and death. It 
must prevent relapse by eliminating dormant bacilli and be safe to use over prolonged periods.  
 
The optimal anti-TB drug regimen and duration of treatment for TBM is unknown.13 Current 
treatment regimens for TBM are based on expert opinion rather than randomized controlled 
trails.14 The WHO guidelines recommend that TBM should be treated for 12 months: a two-
month four-drug intensive phase (RHZE, compromising rifampicin [R], isoniazid [H], 
pyrazinamide [Z] and ethambutol [E]) followed by a 10-month two-drug (HR) continuation 
phase treatment regimen.15 As the WHO has to consider the circumstances under which TB 
will be treated worldwide, the suggested regimen is most likely based on the importance of 
preventing relapse, the unavailability of certain drugs (e.g. ethionamide) and an unwillingness 
to give pyrazinamide for more than 2 months in many settings. After meningeal inflammation 
has subsided, rifampicin has poor cerebrospinal fluid (CSF) penetration leaving the child 
effectively on isoniazid (INH) monotherapy for most of their treatment. This can be 
problematic in areas with high prevalence of INH resistance. In addition, the poor CSF 
penetration of ethambutol renders its inclusion in the regimen questionable.  
 
Some authors have suggested that intensive short-course (6 months) chemotherapy may be 
safe and sufficient in children with TBM.16 The short intensified treatment regimen advocated 
in the Western Cape with higher INH and pyrazinamide dosages, longer administration of 
4
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pyrazinamide and substitution of ethambutol with ethionamide provides higher CSF 
concentrations of anti-TB drugs for the entire duration of treatment. An additional benefit is 
that it may also overcome INH-monoresistance.17 It may thus be superior to the regimen 
currently advocated by the WHO. However, change of international policy would require a 
comparative randomized controlled trial (RCT). Although a RCT would be the preferred 
study method, a large sample size would be required to separate out the effects of 
combination treatments. Wolbers et al. addressed this question by comparing 2 approaches 
(RCT vs. 2x2 factorial design) using a design of a new trial in TBM as an example.18 In their 
trial example, the combination of 2 drugs added to standard treatment is assumed to reduce 
the hazard of death by 30% and the sample size of the combination trial to achieve 80% 
power was 750 patients. An adequately powered 2x2 factorial design (to detect the effect of 
individual drugs) would require at least 8-fold the sample size (6000 patients) of the 
combination trial. Another issue is that of ethics: would it be ethically acceptable for a study 
site, which has a good outcome and low mortality amongst their TBM cases, to participate in 
a RCT comparing regimens that may be inferior to what they currently use? 19 Recruitment of 
patients for the longer WHO regimen may also be difficult if an alternative option of 6 
months of treatment is available.  
 
Although it is desirable to solely rely on RCT to guide clinical practice, in some cases it is 
simply not feasible. RCT are typically restricted to evaluating specific discrete interventions 
one at a time.20 This restriction limits their ability to directly assess complex interactions 
within a study arm (presence of raised intracranial pressure (ICP)/hydrocephalus, degree of 
vasculitis, HIV co-infection), and whether the benefits or harm of a treatment are drug-
specific or disease specific. Such issues can only be addressed when each factor is evaluated 
in isolation from the others, which can make the cost to conduct RCT that evaluate all these 
issues prohibitive. 
 
The challenges of conducting a RCT and our hesitancy to change our standard anti-TB 
treatment regimen, led me to conduct a non-inferiority trial with the aim of comparing  
efficacy and safety of our short-course intensified anti-TB regimen with other published 
regimens. The hypothesis of the second study (chapter 5) was that our short intensified anti-
TB treatment is safe and sufficient in both HIV-uninfected and HIV-infected children with 
drug-susceptible TBM.  
   
5
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It is uncertain whether HIV-infected and uninfected children with TBM have different 
outcomes. Although one study found that the in-hospital mortality differed significantly 
between HIV-infected and HIV-uninfected patients (63% versus 18%, odds ratio 7.4, 95% 
confidence interval 3.0-18.5, p<0.0001), several other studies reported similar death rates 
during hospitalization between HIV-infected patients (13-72%) and HIV-uninfected patients 
(21-64%).21, 22 This is why I explored the question whether there is a difference in survival 
prior to treatment completion between the two groups.    
 
No studies have explored the risk of TB relapse and mortality after treatment completion 
between HIV-infected and HIV-uninfected children. This is why I explored the question of 
whether there is a difference in outcome between HIV-infected and HIV-uninfected children 
after treatment completion.  
 
The literature regarding the optimal management of tuberculous hydrocephalus is confusing.23 
Although there is general agreement that the hydrocephalus should be treated, modes of 
therapy (medical or surgical) and the timing of surgery are unclear. Most studies do not 
determine the type of hydrocephalus before shunt surgery is performed. Complications of 
shunt surgery in children with tuberculous hydrocephalus are high with frequent shunt 
obstructions and shunt infections requiring repeated revisions. It is my experience that 
knowledge of the type of hydrocephalus is the key to the rational management of tuberculous 
hydrocephalus and that the majority of children with communicating tuberculous 
hydrocephalus can effectively be treated solely by diuretic therapy. A previous study at our 
institution found no difference in outcome between medically treated or shunted TBM 
children.24 My study hypothesis was that there is no difference in outcome (after correcting 
for stage of disease, age and HIV status) between children with tuberculous hydrocephalus 
who were medically treated or shunted.  
 
In-hospital treatment is widely recognized as the gold standard of treatment for children with 
TBM due to the complexity of care and serious consequences of non-compliance.25 Long-
term in-hospital TBM treatment is seldom feasible in resource-poor countries due to bed 
shortages and budgetary constraints. A previous study at our institution found that home-
based treatment after initial hospital stabilization is feasible in selected patients under close 
supervision.25 No studies have compared whether there is a difference in outcome (after 
correcting for stage of disease, HIV-status and age) between in-hospital and home-based 
treated children with drug-susceptible TBM. My study hypothesis was that there is no 
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difference in outcome between in-hospital and home-based treated children with drug-
susceptible TBM (after correcting for stage of disease, age and HIV status).  
    
The treatment of TBM-related complications is often challeging, particularly in HIV co-
infected patients. TB-immune reconstitution inflammatory syndrome (IRIS) is a potentially 
life-threatening complication in HIV-infected children with TB of the central nervous system 
(CNS). Only a few case reports and one case series of TB-IRIS of the CNS have been 
reported in adults, but none in children.26, 27 The aim of the third study (chapter 6.1) was to 
describe the neurological and neuro-radiological features of CNS TB-IRIS in HIV-infected 
children on antiretroviral therapy (ART) and to discuss possible management strategies. Study 
questions were: What are the neurological signs and symptoms associated with childhood 
CNS TB-IRIS? What are the neuro-radiological signs associated with childhood CNS TB-
IRIS?  
  
Neurological tuberculous mass lesions (tuberculomas and pseudo-abscesses) may develop or 
enlarge in children on anti-TB treatment.28 The pathogenesis underlying these lesions remains 
unclear but is thought to be immune mediated.29 Treatment is complicated by the fact that the 
lesions are unresponsive to conventional anti-TB treatment and corticosteroids. Adjunctive 
thalidomide, a potent inhibitor of tumour necrosis factor-alpha (TNF-α) has been shown to 
enhance resolution of chronic tuberculous pseudoabscesses and optochiasmatic 
arachnoiditis.30, 31 Standard practice at our hospital is to treat children with these 
complications with thalidomide. The optimal duration of thalidomide therapy and the 
correlation with magnetic resonance imaging (MRI) is yet to be explored. In a prospective 
observational study over 3 years (chapter 6.2), I requested that serial MRI’s be performed in 
16 consecutive children compromised by TB pseudoabcesses who were treated with 
thalidomide. My hypothesis was that tuberculous pseudo-abscesses that clinically progress 
despite conventional anti-TB therapy are responsive to adjuvant thalidomide and that 
sequential MRI may provide a marker for cure. Study questions were: Are neurological 
tuberculous pseudo-abscesses responsive to adjuvant thalidomide? What are the adverse 
effects associated with thalidomide treatment? Does serial MRI in children with pseudo-
abscesses contribute to the evaluation of treatment response and duration? Can MRI assist in 
identifying the nature of the necrotizing process with tuberculous mass lesions? Is there a 
MRI marker that indicates cure?  
 
Tuberculous hydrocephalus is often complicated by raised intracranial pressure (ICP).32 In 
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children with TBM, especially when comatose, it is desirable to have knowledge of the ICP as 
elevated ICP can be life threatening. A non-invasive method of measuring ICP in children 
with TBM would potentially be of great value, as it may assist with assessment of shunt 
function, confirm fenestration patency in patients with non-communicating tuberculous 
hydrocephalus who underwent endoscopic third ventriculostomy and assist with evaluating 
the therapeutic effects of ICP-lowering drugs such as acetazolamide and furosemide. 
 
Vascular involvement in the course of TBM has long been established in pathological as well 
as angiographic studies.33 Cerebrovascular changes are thought to be manifold, including 
narrowing of large basal arteries, probably representing vasospasm and diameter alterations of 
small to medium-sized arteries and arterioles by arteritis.34 Opinion is divided as to whether 
narrowing of the large basal arteries represents functional spasm or organic stenosis.34 
Angiographic studies do not differentiate stenosis from spasm as a cause of vessel narrowing. 
 
Transcranial Doppler imaging (TCDI) is a safe, portable, non-invasive and inexpensive 
method of assessing cerebral hydro- and haemodynamics.35 It can be repeated multiple times 
and can be used for serial monitoring. TCDI has the potential to become a valuable 
investigational tool in children with TBM; a condition often complicated by pathology 
relevant to Doppler imaging such as raised ICP/hydrocephalus and vascular 
stenosis/occlusion. The hypothesis of my fifth study (chapter 6.3) was that TCDI is a valuable 
investigative tool in the monitoring of children with tuberculous hydrocephalus and 
vasculopathy. Serial TCDI recordings were performed on 20 TBM children by one 
investigator as a bedside investigation using a GE Healthcare Vivid S5 high-end ultrasound 
machine with a 2-Mhz probe.36 Recordings were performed on admission and repeated on day 
3 and 7. Lumbar CSF pressure was recorded immediately after TCDI upon admission, and 
after 3 and 7 days. In the same cohort of TBM children I also measured cerebral blood flow 
velocity (BFV) in the anterior cerebral artery (ACA), middle cerebral artery (MCA) and 
posterior cerebral artery (PCA) on admission and after day 3 and 7. Study questions were: 
Can TCDI predict raised ICP in children with TBM? Can TCDI detect the level of the CSF 
block in children with TBM? Can TCDI identify shunt dysfunction in children with 
tuberculous hydrocephalus? How effective is diuretic therapy at reducing raised ICP in TBM 
children with communicating hydrocephalus? Does diuretic therapy affect cerebral BFV? Can 
TCDI predict the development of infarcts? Does vasospasm mediate stroke early in the course 
of TBM disease?   
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Tuberculous meningitis: more questions, still too few answers
Guy E Thwaites, Ronald van Toorn, Johan Schoeman
Tuberculous meningitis is especially common in young children and people with untreated HIV infection, and it 
kills or disables roughly half of everyone aﬀ ected. Childhood disease can be prevented by vaccination and by giving 
prophylactic isoniazid to children exposed to infectious adults, although improvements in worldwide tuberculosis 
control would lead to more eﬀ ective prevention. Diagnosis is diﬃ  cult because clinical features are non-specifi c and 
laboratory tests are insensitive, and treatment delay is the strongest risk factor for death. Large doses of rifampicin 
and fl uoroquinolones might improve outcome, and the benefi cial eﬀ ect of adjunctive corticosteroids on survival 
might be augmented by aspirin and could be predicted by screening for a polymorphism in LTA4H, which encodes 
an enzyme involved in eicosanoid synthesis. However, these advances are insuﬃ  cient in the face of drug-resistant 
tuberculosis and HIV co-infection. Many questions remain about the best approaches to prevent, diagnose, and treat 
tuberculous meningitis, and there are still too few answers.
Introduction
8 years ago in a Review in The Lancet Neurology,1 Thwaites 
and Hien argued that the prevention and treatment of 
tuberculous meningitis posed many questions for which 
there were too few answers. The aim of this update Review 
is to determine whether there are now answers to those 
questions and to reassess the challenges that face those 
tasked with the prevention, diagnosis, and treatment of 
tuberculous meningitis in children and adults.
Are we doing better at preventing tuberculous 
meningitis?
Tuberculous meningitis represents roughly 1% of all cases 
of tuberculosis, but is disproportionately important 
because it kills or severely disables about half of the people 
aﬀ ected. The successful prevention of pyogenic bacterial 
meningitis through vaccination has also meant that in 
many parts of the world tuberculosis is the most common 
cause of bacterial meningitis.2 Tuberculous meningitis 
aﬀ ects all age groups, but is especially common in young 
children and in people with untreated HIV infection. 
Incidence is directly related to the prevalence of pulmonary 
tuberculosis; therefore, optimisation of global tuberculosis 
control is the key to prevention.3,4 WHO estimated that in 
2010 there were 8·8 million new cases of tuberculosis of 
all forms worldwide and 1·45 million deaths from the 
infection.5 The absolute numbers of new tuberculosis 
cases started to fall from a peak around 2006–07, and 
tuberculosis mortality has been falling from a peak of 
about 3 million deaths per year in the late 1990s. Although 
these numbers are encouraging, they disguise great 
regional variation. In metropolitan London, UK, for 
example, the number of new tuberculosis cases has 
doubled in the past 10 years.6 A similar increase has been 
seen in the Western Cape province of South Africa, where 
tuberculous meningitis is the most common childhood 
meningitis.7
One of the unequivocal benefi ts of Bacillus Calmette–
Guérin (BCG) vaccination is protection against 
disseminated forms of childhood tuberculosis, especially 
meningitis.8 Several new tuberculosis vaccines have 
entered phase 1 and phase 2 clinical trials with the aim of 
providing enhanced protection against pulmonary 
tuberculosis,9 which if successful will also reduce the 
incidence of tuberculous meningitis. The identifi cation 
and treatment of individuals with latent tuberculosis also 
helps to prevent tuberculous meningitis. In particular, 
isoniazid prophylaxis is highly eﬀ ective for the prevention 
of tuberculous meningitis in young children exposed to 
household contacts with pulmonary tuberculosis.10
Have we improved the two-step model of the 
pathogenesis of tuberculous meningitis?
Eight decades ago Rich and McCordock11 showed 
experimentally that tuberculous meningitis does not 
result from direct haematogenous spread of 
Mycobacterium tuberculosis to the meninges. In serial 
autopsies of fatal childhood tuberculous meningitis they 
identifi ed tuberculous granulomas (or Rich foci) that 
released bacteria into the subarachnoid space.11 This two-
step model of tuberculous meningitis pathogenesis has 
remained largely unchallenged ever since.12
However, how M tuberculosis leaves the lung, enters the 
brain, and causes the subsequent cerebral pathology 
remains unclear. Haematogenous dissemination 
probably occurs early in the infection, before it has been 
controlled by the adaptive immune response.13 In human 
beings, this early haematogenous dissemination explains 
why individuals with impaired T-cell responses (eg, 
untreated HIV infection) are especially susceptible to 
disseminated disease; why children with BCG-primed 
T-cell responses are protected against miliary tuberculosis 
and meningitis; and why polymorphisms in genes 
involved in the early, innate immune response (TIRAP,14 
TLR215) are associated with the development of 
tuberculous meningitis. Although a few studies have 
shown no benefi t for vitamin D supplementation in 
active pulmonary tuberculosis,16 an association between 
tuberculous meningitis and low sunshine hours 
3 months before disease17 suggests a possible role for 
vitamin D in bacterial dissemination.
Findings from epidemiological studies lend support to 
the hypothesis that some strains of M tuberculosis are more 
likely than others to cause tuberculous meningitis. 
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Investigators of a case-control study in Vietnam reported 
that strains from the Euro-American lineage of 
M tuberculosis were signifi cantly less likely than those of 
the Indo-Oceanic or East Asian Beijing lineages to cause 
meningitis,18 although they could not provide a mechanistic 
explanation for this fi nding.19 The genes that enable the 
bacteria to cross the blood–brain barrier have been 
investigated with transposon mutants and in-vitro and in-
vivo models,20–22 culminating in the identifi cation of one 
bacterial gene, Rv0931c (also known as pknD), that encodes 
a serine/threonine protein kinase necessary for brain 
endothelial invasion.23 Whether or not naturally occurring 
variants of this gene in M tuberculosis isolates aﬀ ect the 
development of tuberculous meningitis is unknown.
Why are there still delays in clinical recognition 
and diagnosis?
The peak incidence of tuberculous meningitis is in 
children aged 2–4 years.24 Early clinical diagnosis is 
notoriously diﬃ  cult and often delayed, with disastrous 
consequences for patients. Early diagnosis and treatment 
of tuberculous meningitis has long been recognised as 
the single most important factor determining outcome.25
The clinical features of tuberculous meningitis are well 
described (table 1).1 The classic presentation is as a 
subacute meningitic illness. The diﬃ  culty is that neck 
stiﬀ ness is usually absent during early disease in patients 
of all ages.25,26 Tuberculous men ingitis therefore needs to 
be recognised early from non-specifi c symptoms of 
general ill health, rather than from classic signs of 
meningitis. In young children these non-specifi c 
symptoms include poor weight gain, low-grade fever, and 
listlessness.27 In infants, most early symptoms are related 
to the primary pulmonary infection, which occurs before 
development of tuberculous meningitis. In adults, 
malaise and anorexia precede worsening headache and 
vomiting. The only factor that diﬀ erentiates the 
symptoms of tuberculous meningitis from common 
illnesses such as infl uenza is their persistence,28 although 
this feature is often missed if a patient does not see the 
same health professional consistently.28 Thus early, 
curable tuberculous meningitis can progress to the fi nal 
stages of coma, opisthotonus, and death.
Although the neurological manifestations of advanced 
tuberculous meningitis are well described,1,29 once the 
signs of advanced disease (including meningeal 
irritation, coma, seizures, signs of raised intracranial 
pressure, cranial nerve palsies, hemiparesis, and 
movement disorders) are seen the diagnosis is usually 
apparent, but at a serious cost to the patient. Occasionally 
tuberculous meningitis can present acutely, with these 
normally late signs already apparent and without a 
distinct prodromal period.25 Organism genotype,30,31 drug 
resistance,32 HIV co-infection,33,34 and BCG immunisation 
status35,36 do not consistently modify disease presentation.
Several studies have defi ned the clinical features most 
predictive of tuberculous meningitis (table 2).37–43 The 
strongest of these features, across all studies, is 
symptom duration longer than 5 days. Diagnostic rules 
have been developed on the basis of these predictive 
Symptoms Clinical signs CSF examination
Children Early symptoms are non-specifi c and include 
cough, fever, vomiting (without diarrhoea), 
malaise, and weight faltering
Initial apathy or irritability that progresses 
to meningism, decreased level of 
consciousness, signs of raised intracranial 
pressure (often bulging anterior fontanelle 
and abducens nerve palsy), and focal 
neurological signs (most often hemiplegia)
Usually clear and colourless; raised numbers of 
white cells (0·05x109–1·00x109/L), with mixture of 
neutrophils and lymphocytes; raised protein 
(0·5–2·5 g/L); ratio of CSF to plasma glucose <0·5 in 
95% of cases
Adults Non-specifi c prodrome of malaise, weight loss, 
low-grade fever, and gradual onset of 
headache over 1–2 weeks; followed by 
worsening headache, vomiting, and confusion, 
leading to coma and death if untreated
Variable degrees of neck stiﬀ ness; cranial 
nerve palsies (VI>III>IV>VII) develop as 
disease progresses and confusion and 
coma deepen; monoplegia, hemiplegia, or 
paraplegia in about 20% of cases
High opening pressure (>25 cm H2O) in 50% of 
cases; raised numbers of white cells 
(0·05x109–1·00x109/L), with mixture of neutrophils 
and lymphocytes; raised protein (0·5–2·5 g/L); ratio 
of CSF to plasma glucose <0·5 in 95% of cases
Table 1: Common clinical features of tuberculous meningitis in children and adults1
Children37 Children and adults38,40 Adults39,41–43
History and 
examination
Duration of symptoms >6 days; optic 
atrophy; abnormal movements; focal 
neurological defi cit
Duration of symptoms >5 days; 
Glasgow coma score <15 or focal 
neurological defi cit
Duration of symptoms ≥6 days; age <36 years; rural 
dwelling; focal neurological defi cit; fever*; neck stiﬀ ness*; 
coma*
CSF fi ndings Neutrophils <50% of total white cells Clear appearance; white cell count 
>1·00x109/L; lymphocytes >30% of total 
white cells; protein >1·0 g/L; ratio of CSF 
to plasma glucose <0·5
Clear appearance; white cell count <0·75×10⁹/L; 
neutrophils <90% of total white cells; ratio of CSF to 
serum glucose ≤0·2; lymphocytes >0·20×10⁹/L; low CSF 
pressure*; raised leucocyte numbers*
Other fi ndings ·· ·· Blood white cell count <15×10⁹/L; if HIV infected, CD4 cell 
count <200 per µL; negative cryptococcal antigen test
*Compared with cryptococcal meningitis in HIV-infected individuals.
Table 2: Discriminatory clinical features for the diagnosis of tuberculous meningitis in children and adults
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variables, but only the rule developed in Vietnam has 
been tested in diﬀ erent populations (panel).39 The 
Vietnam rule was originally described as 86% sensitive 
and 79% specifi c for tuberculous meningitis diagnosis 
in adults; subsequent studies in Turkey,44 Vietnam,45 and 
India41 have reported sensitivities ranging from 96% to 
98% and specifi cities ranging from 68% to 88%. The 
major limitation of the rule, however, was exposed by a 
study of 86 HIV-infected Malawian adults with 
meningitis, in which it was 78% sensitive and 43% 
specifi c.46 Cryptococcal meningitis accounted for the 12 
false positive results.
Two studies42,43 have identifi ed clinical features that 
distinguish tuberculous meningitis from cryptococcal 
meningitis in HIV-infected patients. The fi rst43 showed 
that tuberculous meningitis could be diagnosed with 98% 
specifi city and 47% sensitivity if the patient had a CD4 cell 
count of less than 200 per µL, a ratio of CSF to plasma 
glucose of 0·2 or less, a total number of CSF lymphocytes 
greater than 200 cells per µL, and a negative CSF 
cryptococcal antigen test. The second42 reported that, 
compared with cryptococcal meningitis, tuberculous 
meningitis was associated with more neck stiﬀ ness, 
higher body temperature, reduced consciousness, lower 
CSF pressures, and higher CSF leucocyte numbers. A 
CSF cryptococcal antigen test has high positive and 
negative predictive value and is an essential test in 
patients with a protracted meningitic illness.47
Has laboratory diagnosis of tuberculous 
meningitis improved?
Microscopy
The diagnostic utility of CSF Ziehl-Neelsen staining and 
microscopy for acid-fast bacilli is variable and often very 
poor. Meticulous microscopy of large CSF volumes 
improves sensitivity,48 but it rarely exceeds 60%.49 
Investigators of a study from China reported that simple 
modifi cation to the Ziehl-Neelsen stain, through 
enhancement of CSF intracellular bacterial staining by 
pretreatment with Triton X-100, resulted in acid-fast 
bacilli, most of which were intracellular, being seen in 48 
of 48 CSF samples from 29 patients with tuberculous 
meningitis.50 These impressive results need to be 
replicated in larger studies, but the modifi cation could be 
a simple solution to a longstanding problem.
Nucleic acid amplifi cation techniques
In a meta-analysis51 of studies reported before 2002 that 
examined the use of nucleic acid amplifi cation techniques 
(NAATs) for the diagnosis of tuberculous meningitis, the 
investigators calculated that commercial NAATs were 56% 
sensitive (95% CI 46–66) and 98% specifi c (97–99). 
Guidelines recommend NAATs can confi rm a diagnosis of 
tuberculous meningitis, but cannot rule it out.52 More 
recent data suggest that sensitivity might be improved by 
real-time PCR,53–57 and by assaying CSF fi ltrates rather than 
sediments,58 although these fi ndings need to be confi rmed.
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, 
USA) uses real-time PCR and is set to become the 
cornerstone of commercial molecular diagnosis of 
tuberculosis.59 It potentially has sensitivity and specifi city 
values equivalent to those from in-vitro CSF culture, 
confi rming M tuberculosis in CSF and its susceptibility to 
rifampicin within 2 h, although its value in the diagnosis 
of tuberculous meningitis is uncertain. A meta-analysis60 
of studies reported up to October, 2011, estimated that 
Xpert MTB/RIF was 80·4% sensitive compared with 
culture for the diagnosis of extrapulmonary tuberculosis. 
A study in India of Xpert MTB/RIF for the diagnosis of 
extrapulmonary tuberculosis61 included 142 CSF samples 
and reported that the assay was nearly 12 times more 
sensitive than microscopy for the diagnosis of 
tuberculous meningitis. The cost of processing one 
Xpert MTB/RIF test, however, was 82 times higher than 
the cost of microscopy. Larger studies to assess Xpert 
MTB/RIF for the diagnosis of tuberculous meningitis 
are urgently needed.
Interferon-gamma release assays
A few studies have examined the diagnostic use of 
interferon-gamma release assays on CSF for the 
diagnosis of tuberculous meningitis.62–65 Their fi ndings 
suggest that indeterminate results are common, unless 
CSF volumes of 5–10 mL are tested, and that the assays 
are specifi c (70–90%), but have low sensitivity (50–70%). 
South African investigators have suggested that the 
specifi city of CSF interferon-gamma release assays is 
suﬃ  ciently high, when combined with other negative 
microbiological tests, to make a useful rule-in test.62 In 
view of the CSF volumes necessary, however, whether 
these assays have any advantage compared with NAATs 
is unclear.
Panel: The Vietnam diagnostic rule39
Entry criteria
• Adult (age >15 years) with meningitis and ratio of CSF to 
plasma glucose <0·5
Clinical features and scores
• Age ≥36 years (score +2)
• Age <36 years (score 0)
• Blood white cell count ≥15×10⁹/L (score +4)
• Blood white cell count <15×10⁹/L(score 0)
• History of illness ≥6 days (score –5)
• History of illness <6 days (score 0)
• CSF white cell count ≥0·75×10⁹/L (score +3)
• CSF white cell count <0·75×10⁹/L (score 0)
• CSF neutrophils ≥90% of total white cells (score +4)
• CSF neutrophils <90% of total white cells (score 0)
Interpretation
• Total score ≤4 = tuberculous meningitis
• Total score >4 = alternative diagnosis
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Rapid detection of drug resistance
The standard laboratory methods to test for drug 
susceptibility in M tuberculosis are too slow to support 
clinical decision making in tuberculous meningitis. 
Patients with drug-resistant disease have usually died 
before the results are returned.66–68 The microscopic 
observational drug susceptibility assay has the potential to 
deliver timely resistance results,69 although fi ndings from 
one study70 suggested that the assay detected M tuberculosis 
within CSF, but could not simultaneously defi ne its 
resistance profi le. Therefore, the only way to diagnose 
drug-resistant tuberculous meningitis with suﬃ  cient 
speed at present is through CSF NAATs and the detection 
of genetic mutations that confer drug resistance. However, 
this approach is limited by the low sensitivity of CSF 
NAATs and uncertainty about which mutations best 
predict resistance for some drugs. Commercial NAATs for 
the concurrent detection of bacterial presence and 
rifampicin resistance are available (eg, INNO-LiPA Rif.TB 
and Xpert MTB/RIF), since almost all the mutations that 
confer rifampicin resistance are contained within a well-
defi ned segment of the rpoB gene. Resistance to other 
drugs is less easily detected by these methods. For example, 
the resistance genes identifi ed in 20% of isoniazid-
resistant strains are diverse and poorly characterised.
Neuroimaging
Brain CT can reveal basal hyperdense exudates on 
precontrast scans, and basal meningeal enhancement, 
infarcts, hydrocephalus, and tuberculomas can be seen in 
contrast-enhanced CT. In combination, these features are 
highly suggestive of tuberculous meningitis in both adults 
and children.24,71 However, about 30% of children with early 
tuberculous meningitis will have a normal brain CT.72
MRI is superior to CT at defi ning the neuroradiological 
features of tuberculous meningitis, especially when they 
involve the brainstem (fi gure 1).73 MRI with diﬀ usion-
weighted imaging enhances the detection of early 
infarcts and border-zone encephalitis (cytotoxic oedema 
that underlies the tuberculous exudates).73 Gadolinium-
enhanced MRI allows visualisation of leptomeningeal 
tubercles, which are present in about 90% of children74 
and 70% of adults with the disease.75 MRI is also valuable 
for the identifi cation and monitoring of tuberculous 
meningitis-related cranial neuropathies. The most 
important of these neuro pathies is optochiasmatic 
arachnoiditis, which requires urgent intervention to 
reduce the risk of blindness (fi gure 2).74 Magnetic 
resonance angiography can be used to identify vascular 
involvement, which is present in 60% of cases and most 
often aﬀ ects the terminal portions of the internal carotid 
arteries and proximal parts of the middle and anterior 
cerebral arteries.76
The MRI appearances of intracranial tuberculomas 
depend on the pathological maturation of the lesion.77 Non-
caseating (non-necrotising) tuberculomas are usually 
hypointense on T1-weighted images and hyperintense on 
T2-weighted images; the entire lesion shows homogeneous 
enhancement after contrast administration. Solid caseating 
(necrotising) tubercu lomas appear hypointense or 
BA
DC
Figure 1: The value of MRI for detection of tuberculous meningitis
(A) Normal brain CT scan of a 3-year-old child with stage 3 tuberculous 
meningitis. (B) A T2-weighted, fl uid–attenuated, inverse-recovery MRI image 
taken 5 days later showed several infarcts (arrows) in the basal ganglia. MRIs with 
diﬀ usion-weighted imaging (C) and apparent diﬀ usion coeﬃ  cient (D) show 
restriction of diﬀ usion and bilateral cytotoxic oedema in the basal ganglia.
BA
Figure 2: Tuberculous meningitis-associated optochiasmatic arachnoiditis
(A) Initial T1-weighted post-gadolinium MRI scan of a 7-year-old boy with blindness caused by severe tuberculous 
meningitis-related optochiasmatic arachnoiditis shows enhancement of the whole suprasellar cistern with 
displacement and compression of the optic nerve anteriorly. A ring-enhancing tuberculous abscess is also visible in 
the right temporal lobe. (B) After 3 months of adjuvant thalidomide the patient regained full vision and follow-up 
MRI shows a substantial improvement of the optochiasmatic arachnoiditis despite asymptomatic enlargement of 
suprasellar and temporal lobe abscesses.
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isointense on T1-weighted images and isointense to 
hypointense on T2-weighted images (T2 black), with rim 
enhancement. Liquefi ed caseating tuberculomas have the 
MRI appearance of an abscess; the liquefi ed centre 
becomes hypointense on T1-weighted images and hyper-
intense on T2-weighted images, with rim enhancement 
after contrast administration. Tuberculous abscesses are 
larger than tuberculomas (often >3 cm in diameter), 
solitary, thin walled, and often multi-loculated.77 Magnetic 
resonance spectroscopy can help to discriminate 
tuberculous and non-tuberculous brain lesions, since 
tuberculous lesions have raised lipid peaks.78
Are we using the right drugs and doses in 
antituberculosis chemotherapy?
The principles of tuberculous meningitis treatment are 
still derived from observational studies and clinical 
practice rather than from controlled trials. They include 
the importance of starting antituberculosis chemotherapy 
early; the recognition that isoniazid and rifampicin are 
the key components of the regimen; the potentially fatal 
consequences of interrupting treatment during the fi rst 
2 months; and the perceived need for long-term 
treatment (9–12 months) to prevent disease relapse.
Table 3 shows the recommended fi rst-line treatment 
regimens for children and adults with tuberculous 
meningitis.52,79–81 The ability of the blood–brain barrier to 
limit intracerebral concentrations of antituberculosis 
drugs is an important consideration in the treatment of 
tuberculous meningitis. Table 4 shows the estimated 
CSF penetration of fi rst-line and second-line 
antituberculosis agents.82–85 CSF penetration has 
particular relevance for consideration of which drug 
should accompany rifampicin, isoniazid, and 
pyrazinamide in the standard regimen, and for the 
treatment of drug-resistant tuberculous meningitis.
Most regulatory bodies recommend either streptomycin 
or ethambutol as the fourth drug in standard treatment, 
although neither penetrates the CSF well in the absence 
of infl ammation,83 and both can produce serious adverse 
reactions, especially in patients with impaired renal 
function. Streptomycin should not be given to patients 
who are pregnant or who have renal impairment, and 
streptomycin resistance is fairly common worldwide.5 
Ethambutol-induced optic neuritis is a concern, 
especially in the treatment of comatose patients, although 
at the standard dose of 15–20 mg/kg the incidence is less 
than 3%.86 Some centres, including our own in Cape 
Town, South Africa (Department of Paediatrics and Child 
Health, Tygerberg Children’s Hospital, University of 
Stellenbosch), advocate ethionamide, which can 
penetrate healthy and infl amed blood–brain barriers and 
is safer than ethambutol and streptomycin.87
The fl uoroquinolones could represent highly eﬀ ective 
fourth drugs and are an essential component of treatment 
regimens for multidrug-resistant cases. Investigators of a 
randomised comparison88 of ciprofl oxacin (750 mg every 
12 h), levofl oxacin (500 mg every 12 h), and gatifl oxacin 
(400 mg every 12 h) added to conventional four-drug 
tuberculous meningitis treatment noted that CSF 
penetration (measured by the ratio of plasma to CSF area 
under the concentration-time curve) was greater for 
levofl oxacin (median 0·74) than for gatifl oxacin (median 
0·48) or ciprofl oxacin (median 0·26). Ciprofl oxacin has 
the least in-vitro activity against M tuberculosis and, in view 
of its poor CSF penetration, should never be used for 
treatment of tuberculous meningitis. Overall, however, 
fl uoro quinolones seemed to add antituberculosis activity 
WHO79,80 and UK52 recommendations Cape Town paediatric intensive regimen81
Daily dose in children Daily dose in adults Route of administration Duration Daily dose Route Duration
Antituberculosis drugs
Isoniazid 10–20 mg/kg 
(maximum 500 mg)
300 mg Oral 12 months 20 mg/kg 
(maximum 400 mg)
Oral 6 months
Rifampicin 10–20 mg/kg 
(maximum 600 mg)
450 mg (weight <50 kg) or 
600 mg (weight ≥50 kg)
Oral 12 months 20 mg/kg 
(maximum 600 mg)
Oral 6 months
Pyrazinamide 15–30 mg/kg 
(maximum 2 g)
1·5 g (weight <50 kg) or 
2·0 g (weight ≥50 kg)
Oral 2 months 40 mg/kg 
(maximum 2 g)
Oral 6 months
Ethambutol 15–20 mg/kg 
(maximum 1 g)
15 mg/kg Oral 2 months Not recommended
Ethionamide Not recommended ·· 20 mg/kg 
(maximum 1 g)
Oral 6 months
Adjunctive corticosteroids
Prednisolone 4 mg/kg* 2·5 mg/kg* Intravenous initially, then switch 
to oral when safe to do so
4 weeks then reduce to 
stop over 4 weeks
2 mg/kg (maximum 
60 mg)
Oral 1 month, then reduce to 
stop over 2 weeks
Dexamethasone 0·6 mg/kg* 0·4 mg/kg* Intravenous initially, then switch 
to oral when safe to do so
Reducing each week to 
stop over 6–8 weeks
·· ·· ··
*No data exist to compare the relative eﬃ  cacy of dexamethasone with prednisolone, but they are widely regarded as equivalent for the treatment of tuberculous meningitis; either can be used, with the choice 
based on ease of administration.
Table 3: First-line treatment regimens for tuberculous meningitis in children and adults 
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to the standard regimen and to improve outcome, 
provided they were started before the onset of coma. 
Moxifl oxacin probably penetrates the CSF at least as well 
as levofl oxacin, possibly accumulates in the CSF, and has 
the theoretical advantage of greater in-vitro activity against 
M tuberculosis than levofl oxacin.89 In high doses, 
fl uoroquinolones can cause seizures;90 whether such 
seizures are more likely to occur in the treatment of 
tuberculous meningitis than in the treatment of non-
meningitic or neurological infection is uncertain.
Investigators in Indonesia have tested the hypothesis 
that treatment intensifi cation, through use of high-dose 
intravenous rifampicin and the addition of moxifl oxacin, 
would enhance bacterial killing and improve outcome.91 
60 adults with tuberculous meningitis were randomly 
allocated to treatment with daily rifampicin at either 
standard dose (450 mg, about 10 mg/kg) orally or high 
dose (600 mg, about 13 mg/kg) intravenously, and either 
400 mg or 800 mg oral moxifl oxacin or 750 mg 
ethambutol for the fi rst 14 days of treatment. High-dose 
intravenous rifampicin led to a three-times increase in 
the plasma and CSF area under the concentration-time 
curve compared with the standard oral dose and was 
associated with a substantial drop in mortality (65% vs 
35%), which could not be accounted for by HIV status or 
baseline disease severity.
This fi nding provides compelling evidence that the 
chemotherapeutic regimen for tuberculous meningitis 
needs to be optimised and that the recommended doses 
of rifampicin might be too low because of its poor CSF 
penetration.82 The results of a large randomised 
controlled trial (ISRCTN61649292) to compare standard 
with intensive therapy (rifampicin 15 mg/kg every 24 h 
and levofl oxacin 500 mg every 12 h as the fourth drug) 
are eagerly awaited.92
Lengthy in-hospital treatment of tuberculous 
meningitis is not possible in many low-resource settings. 
Home-based treatment, after initial in-hospital 
stabilisation, is feasible in selected patients and under 
close supervision.93 The optimum treatment regimen is 
uncertain, and despite recommendations for 9–12 months 
of treatment,52,79 some evidence suggests that 6 months of 
intensifi ed therapy is safe and eﬀ ective in HIV-uninfected 
children with drug-susceptible disease (table 3).81,94,95
What challenges does drug-resistant 
tuberculous meningitis present?
Drug-resistant tuberculous meningitis is a serious and 
increasingly widespread clinical problem. The challenge is 
to detect drug-resistant disease quickly enough to start 
alternative drugs and thereby prevent death.66,68 Isoniazid-
resistant tuberculous meningitis has been associated with 
signifi cantly longer times to CSF sterility,96 but a 
detrimental eﬀ ect on outcome was not seen so long as 
pyrazinamide was used throughout treatment.68 However, 
data from the USA97 and from a prospective study of HIV-
infected Vietnamese adults with tuberculous meningitis66 
suggest that isoniazid-resistant disease has a higher 
mortality than drug-susceptible disease when treated with 
standard regimens. When isoniazid resistance is combined 
with rifampicin resistance (ie, multidrug resistance), death 
occurs in almost all patients before the results of 
conventional drug susceptibility tests are returned.32,66,68
Table 5 lists some potentially eﬀ ective regimens for the 
treatment of drug-resistant tuberculous meningitis. Use of 
pyrazinamide throughout treatment might counter the 
potential adverse eﬀ ect of isoniazid resistance,68 as might 
the substitution of isoniazid with either levofl oxacin or 
moxifl oxacin (although no clinical data have been reported 
to support this strategy). Multidrug-resistant tuberculous 
meningitis requires the early use of second-line 
antituberculosis drugs to prevent death.68 WHO guide lines 
recommend an injectable drug (eg, amikacin, capreomycin) 
with a fl uoroquinolone (eg, moxifl oxacin), and at least two 
other active drugs for the initial phase of treatment of 
multidrug-resistant pulmonary tubercu losis.80,98 No 
equivalent recommendations exist for tuberculous 
meningitis; choice of drug should be determined by 
probable susceptibility and CSF penetration (table 4).84
When, why, and how should adjunctive 
anti-infl ammatory therapy be used?
Over the past 60 years, seven randomised controlled 
trials involving 1140 people with tuberculous meningitis 
have established that adjunctive corticosteroids reduce 
Standard daily dose for 
adults
Estimated ratio 
of CSF to plasma 
concentration
Comments
Isoniazid 300 mg 80–90% Essential drug; good CSF penetration 
throughout treatment
Rifampicin 450 mg (weight <50 kg) 
or 600 mg (weight ≥50 kg)
10–20% Essential drug, despite relatively poor 
CSF penetration; higher doses might 
improve eﬀ ectiveness
Pyrazinamide 1·5 g (weight <50 kg) 
or 2·0 g (weight ≥50 kg)
90–100% Excellent CSF penetration throughout 
treatment
Ethambutol 15 mg/kg 20–30% Poor CSF penetration once meningeal 
infl ammation resolves
Streptomycin 15 mg/kg 
(1 g maximum)
10–20% Poor CSF penetration once meningeal 
infl ammation resolves
Kanamycin 15 mg/kg 10–20% Poor CSF penetration once meningeal 
infl ammation resolves
Amikacin 15–20 mg/kg 10–20% Poor CSF penetration once meningeal 
infl ammation resolves
Moxifl oxacin 400 mg 70–80% Good CSF penetration
Levofl oxacin 1000 mg 70–80% Good CSF penetration
p-Aminosalicylic 
acid
10–12 g No data Probably very poor CSF penetration 
unless meninges are infl amed
Ethionamide or 
protionamide
15–20 mg/kg 
(1 g maximum)
80–90% Good CSF penetration
Cycloserine 10–15 mg/kg 80–90% Good CSF penetration
Linezolid 1200 mg 40–70% Variable interindividual CSF 
pharmacokinetics
Capreomycin 15–20 mg/kg No data ··
Table 4: CSF penetration of fi rst-line and second-line antituberculosis drugs82–85
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death and disability from tuberculous meningitis by 
about 30%.99 National guidelines recommend adjunctive 
corticosteroids for all patients with the disease (table 3).52,80
How corticosteroids reduce mortality from tuberculous 
meningitis is an important question, since such 
knowledge could help in the identifi cation of key 
infl ammatory pathways and suggest targeted treatments, 
but until recently the mechanism of action was 
unknown.75,100 A polymorphism in LTA4H, which encodes 
the enzyme leukotriene A4 hydrolase that controls the 
balance of proinfl ammatory and anti-infl ammatory 
eicosanoids and determines expression of tumour 
necrosis factor α (TNFα), aﬀ ects tuberculosis susceptibility 
in both zebrafi sh and human beings.101 Zebrafi sh were 
unable to control mycobacterial replication within 
granulomas if they had genetically determined high 
expression of LTA4H (TT homozygote) and an excessive 
infl ammatory response, or low expression of LTA4H (CC 
homozygote) and an inadequate infl ammatory response. 
Heterozygous (CT) zebrafi sh had an intermediate 
infl ammatory response and were able to control the 
infection. Furthermore, in human beings adjunctive 
corticosteroids were only of benefi t to major allele 
homozygous adults (hyperinfl ammatory) with tuberculous 
meningitis, and corticosteroid treatment of those with a 
hypoinfl ammatory phenotype was detrimental.102
These fi ndings need to be replicated in a diﬀ erent 
population, but they lend support to the assertion that 
future adjunctive therapies should target eicosanoids and 
TNFα more precisely. Some clinical data suggest that 
thalidomide (a TNFα antagonist) and anti-TNFα 
antibodies might be more eﬀ ective than corticosteroids 
in controlling adverse infl ammatory complications of 
tuberculous meningitis. Small case series have suggested 
adjunctive thalidomide could be eﬀ ective in the treatment 
of intractable tuberculomas and vision-threatening 
optochiasmatic arachnoiditis.103–105
Aspirin too might have a role—it inhibits the 
expression of proinfl ammatory eicosanoids and TNFα in 
in zebrafi sh with the hyperinfl ammatory phenotype and 
thereby reduces mycobacterial burden.102 Furthermore, 
two controlled trials showed that adjunctive aspirin 
reduced the incidence of hemiplegia, stroke, and death 
from tuberculous meningitis.106,107 These fi ndings are too 
preliminary to lead to changes in treatment guidelines, 
but they should stimulate research into the potential role 
of aspirin in the treatment of tuberculous meningitis and 
into whether the selection of all immunomodulatory 
therapies for the disease should be determined by LTA4H 
genotype. New adjunctive drugs for further study include 
chloroquine,108 interferon gamma,109 alisporivir, and 
desipramine (alisporivir and desipramine might control 
infl ammation by inhibiting mitochondrial reactive 
oxygen species).110
When do complications of tuberculous 
meningitis require neurosurgery?
Common complications
The major complications of tuberculous meningitis are 
hydrocephalus, stroke, and tuberculoma formation. All 
generally present within the fi rst 3 months of treatment 
and can be fatal if not detected and treated quickly. Some 
require the immediate attentions of a neurosurgeon; 
others can be managed pharmacologically. Little evidence 
exists to help to defi ne the best approach for each 
complication.
Tuberculous hydrocephalus
Hydrocephalus is the most common serious complication 
of tuberculous meningitis. It is more common in 
children than adults, occurring in more than 80% of 
paediatric patients at presentation.111,112 Hydrocephalus is 
rare in early tuberculous meningitis (Medical Research 
Council stage 1), but almost invariably present once neck 
stiﬀ ness and loss of consciousness have developed, and 
can present with any sign of acute or chronic intracranial 
hypertension. Often, however, hydrocephalus is not 
suspected clinically and the diagnosis is only evident on 
cranial CT. Imaging can be normal in early-onset CSF 
obstruction, in which case the diagnosis of developing 
hydrocephalus is suggested by high opening lumbar CSF 
pressures.113 In children with tuberculous meningitis, 
clinical signs of raised intracranial pressure are poorly 
associated with hydrocephalus as shown by CT.114 The 
Regimens Comments
Isoniazid resistance (with or 
without streptomycin resistance)
2REZFq followed by 10REZ, 
or 2REZ followed by 10RE
Studies68 suggest that isoniazid resistance has little eﬀ ect on outcome as long as pyrazinamide is used for 6 months; 
fl uoroquinolones (either moxifl oxacin or levofl oxacin) might improve outcome in meningitis
Rifampicin monoresistance 2HZEFq followed by 
10HZE, or 2HZEIa followed 
by 10HZE
An injectable drug (eg, streptomycin or amikacin) or a fl uoroquinolone for the fi rst 2 months might improve outcomes in 
severe disease; if possible, serum concentrations of aminoglycosides (streptomycin and amikacin) should be monitored, and 
hearing loss should be checked for by audiology if treatment is used long term (>1 month)
Resistance to isoniazid and 
rifampicin (multidrug resistance)
6ZE*FqIaX followed by 
18ZEFq
Regimens should be tailored to individual susceptibility patterns when possible; a 6-month intensive phase with an injectable 
drug, a fl uoroquinolone, and at least three other active drugs, followed by a continuation phase of 12–18 months with at least 
three active drugs (one of them a fl uoroquinolone) is suggested by WHO98
Numbers in the regimen abbreviations indicate the number of months of treatment with the specifi ed drug combination. R=rifampicin. Z=pyrazinamide. E=ethambutol. Fq=fl uoroquinolone. H=isoniazid. 
Ia=injectable agent. X=another drug (eg, ethionamide, cycloserine, or linezolid). *Use both Z and  E if susceptible; replace either with other drugs (eg, ethinoamide, cycloserine, linezolid,) if not susceptible to 
make a total of at least fi ve active drugs in the initial phase of treatment.
Table 5:  Potential regimens for the treatment of tuberculous meningitis, by pattern of drug resistance
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association between lumbar CSF pressure and extent of 
hydrocephalus is also poor.113
No optimum management strategy for tuberculous 
hydrocephalus is universally accepted.115 In our centre in 
Cape Town, South Africa, the treatment protocol is based 
on insights gained from investigating the associations 
between many serial lumbar CSF pressure recordings 
and CT fi ndings, diﬀ erent treatment methods, and 
clinical outcomes.113,116,117 Most cases (70–80%) have 
communicating hydrocephalus (basal cistern block); the 
rest have non-communicating hydrocephalus (mainly 
fourth-ventricular outlet ob struction). The level of CSF 
block is assessed by contrast ventriculography or air 
encephalography and not by conventional imaging 
alone.118 Air encephalography (5–10 mL of air injected via 
lumbar puncture) can be safe, eﬀ ective, and inexpensive 
for this purpose (fi gure 3).119
Medical treatment (acetazolamide and furosemide) 
normalises intracranial pressure in 80% of children with 
communicating hydrocephalus within a month, and 
most have normal lumbar CSF pressure (<15 cm H2O) 
after a week of treatment.113,116 Indications for 
ventriculoperitoneal shunting in tuberculous meningitis 
include failed medical treatment and non-communicating 
hydrocephalus.120 Shunt complications are common 
(30% of cases), thus endoscopic third ventriculostomy 
has become an alternative surgical treatment option.120,121 
Success rates of this procedure are roughly 65%, with 
failure often caused by distorted anatomy of the third 
ventricle fl oor in the acute phase of the disease.122
Tuberculous vasculitis and stroke
The poor outcome from tuberculous meningitis is mainly 
a manifestation of the extent of ischaemic brain damage at 
presentation, resulting from infl ammation, necrosis, and 
thrombosis of blood vessels involved in the basal cisternal 
meningeal reaction (fi gure 4).111,116 The distal internal 
carotid and proximal middle cerebral arteries, and the 
perforating branches of the proximal middle cerebral 
arteries, are preferentially involved.123 Intimal proliferation 
leads to an obliterative vasculopathy that is particularly 
prominent in chronic, partly treated tuberculous 
meningitis (fi gure 4).124 Despite the frequency of vasculitis 
and associated hypercoagulability in acute tuberculous 
meningitis, pathological evidence for superimposed 
arterial thrombosis is scarce.123,125 Cerebral vasospasm 
might cause stroke, but this possibility has been diﬃ  cult 
to prove. Infarcts, particularly at the basal ganglia, have 
been seen in children (about 40% of fatal paediatric cases) 
and adults (about 30% of fatal adult cases) at autopsy.122
The most common clinical manifestation of tuberculous 
meningitis-related stroke is hemiplegia, which is more 
common in young children than in adults, and in patients 
with advanced disease.106,107,126 The course of hemiplegia 
varies; even severe hemiplegia can fully resolve, whereas 
new hemiplegia can sometimes develop during 
treatment.25,126,127 Size, morphology, and number (but not 
location) of infarcts on CT are related to clinical recovery.126
No adjunctive treatment has consistently reduced the 
incidence of stroke or changed the course of hemiplegia 
in tuberculous meningitis. Corticosteroids did not 
signifi cantly aﬀ ect the number of new infarcts seen on 
CT or MRI, or the extent of residual hemiplegia in 
children or adults.75,128 Only aspirin might reduce the 
incidence of stroke,106,107 but this eﬀ ect needs to be 
confi rmed in larger studies.
Tuberculomas
Cerebral tuberculomas can occur in isolation or in 
association with tuberculous meningitis, and their 
location and size determines their clinical presentation. 
BA
Figure 3: Air encephalography to determine the level of the block that is causing hydrocephalus
(A) Air present in the lateral ventricle (arrow) on a lateral skull radiograph suggests communicating hydrocephalus 
in a child with tuberculous meningitis. (B) Air present in basal cisterns (arrow), but not in the ventricular system, is 
typical of non-communicating hydrocephalus in a child with tuberculous meningitis. The absence of air 
supratentorially (over the cerebral convexities) in both (A) and (B) is typical in tuberculous meningitis because of 
the associated basal cisterns block.
BA
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Figure 4: Pathogenesis of tuberculous meningitis-associated stroke
(A) Axial section of fi xed brain at the level of the suprasellar and ambient cisterns from a patient with tuberculous 
meningitis. In the predominantly proliferative form of tuberculous vasculitis, the infl ammatory reaction entirely fi lls 
the interstices of the basal cisterns (pink arrows=suprasellar; green arrows=ambient), infi ltrating the blood vessels 
and frequently aﬀ ecting them. The reaction in the proximal parts of the sylvian and interhemispheric cisterns is 
attenuated (black arrows). The border-zone reaction (blue arrow) shows the composite changes of persisting 
infl ammatory ischaemia, including congestion, vasoproliferation, astrocytosis, phagocytosis, and oedema. Nerve 
cells in the region are invariably aﬀ ected. (B) The infl ammatory reaction (haematoxylin and eosin preparation) in a 
micrograph of brain tissue from another patient with tuberculous meningitis. The micrograph shows the exudative 
(green star), necrotising (white star), and proliferative (black star) components of the infl ammatory reaction in 
tuberculous meningitis. The blood vessels (black arrows) have undergone coagulative or gummatous necrosis, 
including thrombosis. The artery (green arrows) shows substantial proliferative reaction and infl ammatory 
infi ltration, including near-occlusion of the lumen, consistent with so-called Heubner’s endarteritis.
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They are often silent and unsuspected; a focal seizure in 
an otherwise healthy child is the most common mode of 
presentation in tuberculosis-endemic populations.129 
Tuberculomas can also manifest with focal neurological 
signs or raised intracranial pressure due to obstruction 
of CSF pathways.
Tuberculomas can develop or enlarge despite ap-
propriate antituberculosis treatment. This develop ment 
usually occurs within 3 months of treatment and should 
not be ascribed to drug resistance.130 Indeed, clinically 
silent tuberculomas are evident on MRI in about 80% of 
adults with tuberculous meningitis after 9 months of 
successful treatment.75
Intracranial tuberculous abscesses present similarly to 
tuberculomas, but tend to have a more accelerated clinical 
course and are notoriously resistant to therapy, sometimes 
requiring total surgical excision for cure.131 In our 
experience, children with tuberculous abscesses respond 
well to treatment with adjuvant thalidomide (2–5 mg/kg 
daily),131 although treatment might be needed for several 
months. Clinical improvement follows a reduction in 
perilesional oedema and precedes regression of lesion 
size on MRI. Occasionally, abscesses can enlarge despite 
treatment and persist for years in children who remain 
clinically well. Adjuvant interferon gamma has been used 
with success to treat two adults with intractable cerebral 
abscesses.109
When is the best time to start antiretroviral 
therapy for HIV-associated tuberculous 
meningitis?
HIV-associated tuberculous meningitis is fatal in more 
than 60% of cases.132 One of the key clinical questions is 
whether to start antiretroviral therapy at the same time as 
antituberculosis chemotherapy, or to wait until the brain 
infection has been controlled. Immediate antiretroviral 
therapy could increase the risks of drug toxicity and the 
development of immune reconstitution infl ammatory 
syndrome; however, a deferred start could allow other 
opportunistic infections to develop and complicate 
management. Investigators of a controlled trial that 
compared immediate with deferred antiretroviral therapy 
in 253 Vietnamese adults with HIV-associated tuber-
culous meningitis reported that timing of antiretroviral 
therapy did not aﬀ ect 9-month mortality or the time to 
new AIDS events or death.132 However, signifi cantly more 
grade 4 adverse events occurred in the group given 
immediate antiretroviral therapy, providing some 
support for the delayed option, especially in patients with 
CD4 cell counts higher than 100 per µL.
Tuberculous meningitis-associated immune recon-
stitution syndrome after the start of antiretroviral therapy 
remains a serious clinical concern.108,133 The clinical 
predictors of its development were studied in a cohort of 
34 South African patients with HIV-associated tuberculous 
meningitis who started antiretroviral therapy 2 weeks after 
the start of antituberculosis chemo therapy (given with 
adjunctive corticosteroids).134 16 of the 34 patients developed 
tuberculous meningitis-associated immune reconstitution 
infl ammatory syn drome a median of 14 days after starting 
anti retro viral therapy, the most common manifestations 
being worsening headache and neck stiﬀ ness. Compared 
with the patients who did not develop tuberculous 
meningitis-associated immune reconstitution infl amm-
atory syndrome, those who did had a signifi cantly longer 
illness duration, more extraneural tuberculosis, and higher 
CSF neutrophil numbers, and a higher proportion had 
M tuberculosis cultured from CSF. The combination of 
high CSF TNFα and low interferon γ concentrations at 
diagnosis was predictive of immune reconstitution 
infl ammatory syndrome.
Corticosteroids are the mainstay of treatment for 
immune reconstitution infl ammatory syndrome, with 
interruption of antiretroviral therapy reserved for life-
threatening complications.135 Other immunomodulatory 
agents have been used, including thalidomide, 
chloroquine, mycophenolate mofetil, and cyclosporine.108,133
Conclusions
Although great strides have been made in our 
understanding of tuberculous meningitis in the 8 years 
since the previous Review,1 there are still many 
unanswered questions. Tuberculous meningitis remains 
the most lethal form of tuberculosis. The best way to 
improve survival is through early diagnosis and treatment, 
but this goal will remain elusive without replacement of 
the poor diagnostic tests currently available. New 
diagnostic approaches are urgently needed, especially 
with the evidence that intracerebral killing of bacteria 
might be enhanced by use of fl uoroquinolones and 
increased doses of rifampicin. The benefi ts of these 
treatment advances will not be fully realised unless given 
early in the disease. The link between LTA4H genotype 
and the eﬀ ect of corticosteroids on survival oﬀ ers a 
glimpse of the future, when targeted immunomodulatory 
treatments could potentially be selected on the basis of a 
patient’s genotype. These advances present new questions, 
which join those still unanswered, such as how to improve 
survival in HIV-infected patients and those with drug-
resistant organisms, and how best to manage the common 
complications of tuberculous meningitis.
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Update on the Diagnosis and Management
of Tuberculous Meningitis in Children
Ronald van Toorn, FCP and Regan Solomons, MMED
Tuberculous meningitis (TBM), the most devastating manifestation of tuberculosis, is often
missed or overlooked because of nonspeciﬁc symptoms and difﬁculties in diagnosis. It con-
tinues to bean important causeof neurologic handicap in resource-poor countries.Owing to the
suboptimal performanceofdiagnostic testsof TBM,diagnosis relieson thoroughhistory, clinical
examination, and relevant investigations. The development of affordable, accurate diagnostic
tests for TBM in resource-poor settings remainsapriority. Short intensiﬁed treatment is safe and
effective in both human immunodeﬁciency virus (HIV)-infected and HIV-uninfected children.
Treatment of tuberculous hydrocephalus depends on the level of the cerebrospinal ﬂuid
obstruction. Corticosteroids reduce risk of neurodisability and death inHIV-uninfected children.
Thalidomide should be considered in children compromised by tuberculosis abscesses and
tuberculous-related optochiasmic arachnoiditis. In resource-poor countries, home-based TBM
treatment after initial in-hospital stabilization is feasible in carefully selected patients. Early
diagnosis and treatment of TBM is the single most important factor determining outcome.
Semin Pediatr Neurol 21:12-18 C 2014 Elsevier Inc. All rights reserved.
Introduction
Tuberculous meningitis (TBM) is the most devastating mani-
festation of tuberculosis (TB) and it continues to be an important
cause of neurologic handicap in resource-poor countries.
A recent study in theWestern Cape Province of South Africa
(SA) found TBM to be the commonest cause of pediatric
meningitis.1 SA is one of the 22 high-TB burden countries that
account for 80% of all TB cases. The estimated incidence of TB
in SA is 1000 or more per 100,000 people. One of the
Millennium Development Goals targets is to halt and start to
reverse the rising incidence of TB and halve the 1990
prevalence and death rates by 2015.2 Unfortunately, most
African regions, including SA, are not on track to achieve this
objective owing to reasons such as resource constraints,
conﬂict and instability, and generalized human immunodeﬁ-
ciency virus (HIV) epidemics.
The bacille Calmette-Guerin (BCG) vaccine is currently the
only available vaccine against TB and is widely administered
within the Expanded Programme for Immunization by the
World Health Organization (WHO). It provides protection
against disseminated TB and TBM (73%; 95% conﬁdence
limits 67%-79%) but has highly variable and often low efﬁcacy
against pulmonary TB in adults.3 The effect of BCGvaccination
on transmission of Mycobacterium tuberculosis (M.tb) is there-
fore limited. The variable efﬁcacy of BCG vaccination together
with the not inconsequential threat of multidrug-resistant
(MDR) TB highlights the necessity of new vaccine develop-
ment, but this is hindered by the lack of immune correlates,
suboptimal animal models, and limited funding.4
Clinical Manifestations
TBM may present at any age but is less common at the
extremes of life. The peak incidence is in children between 2
and 4 years of age.5 Early clinical diagnosis is notoriously
difﬁcult and often delayed, with disastrous consequences.
Although delayed diagnosis of TBM is common, very young
infants, patients with another coexisting illness, and those from
non–TB-endemic regions carry the highest risk for missed
diagnosis. The classic presentation of TBM is as a subacute
meningitic illness. The resulting dilemma is that the classic sign
of meningitis, neck stiffness, is usually absent during the early
disease stage in children and adults.6 Early diagnosis and
treatment of TBM has been long recognized as the single most
important factor determining outcome.5
Although much effort has gone into improving diagnostic
investigations, these may not be requested if the possibility
12 1071-9091/14/$-see front matter & 2014 Elsevier Inc. All rights reserved.
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of meningitis has not crossed the physician’s mind. This is
applicable to health practitioners in resource-poor as well as
resource-equipped countries where the increase in migrant
populations could potentially lead to an increased incidence of
TBM. It is therefore important to recognize TBM during the
early stage, mainly characterized by nonspeciﬁc symptoms of
general ill health rather than speciﬁc, classic signs ofmeningitis.
In young children, these include poor weight gain, low-grade
fever, and listlessness. Most early symptoms relate to under-
lying pulmonary TB present inmost infants who develop TBM
as a complication of primary infection. The only factor differ-
entiating these symptoms of TBM from common illnesses such
as inﬂuenza is their persistence7; however, this is often not
recognized because caregivers may not return to the same
health professional (especially if the treatment failed) and often
do not inform subsequent doctors of previous diagnoses and
treatments of the current illness.7 Thus early-stage, fully cur-
able TBM may progress to the ﬁnal stages of coma, opistho-
tonus, and death following this course of events.
In older children, common nonspeciﬁc symptoms of early
TBM are fever, headache, and vomiting, closely representing a
ﬂu-like illness. Recent close contact with an infectious pulmo-
nary TB patient is an important diagnostic clue. Once the
classic neurologic signs of advanced TBM (including menin-
geal irritation, coma, seizures, signs of raised intracranial
pressure [ICP], cranial nerve palsies, hemiparesis, and move-
ment disorders) appear, the diagnosis is usually apparent but at
a considerable cost to the patient. However, it should be noted
that the initial presentation of TBM may be severe and
accompanied by any of the aforementioned “late” signs and
without a distinct prodromal period. Organism genotype,
resistance patterns (MDR TB), coinfection with HIV, or BCG
immunization status do not consistently modify the disease
presentation as described earlier.6
Complications of TBM
Tuberculous Hydrocephalus and Raised
Intracranial Pressure
Hydrocephalus occurs in up to 80% of patients with TBM.5 In
70% of cases, the hydrocephalus is of a communicating nature.
This occurs when the exudate that ﬁlls the basal cisterns causes
a bottleneck obstruction of the cerebrospinal ﬂuid (CSF)
pathways at the level of the tentorium. In 20% of cases, CSF
obstruction occurs when the basal exudates obstruct the
outﬂow foramina of the fourth ventricle leading to a non-
communicating hydrocephalus. Other rare causes of non-
communicating hydrocephalus are obstruction of the foramen
ofMonro or the aqueduct by strategically located tuberculomas.
Tuberculous hydrocephalus is often complicated by raised
ICP.5 Studies have shown that clinical diagnosis of the presence
and degree of raised ICP is unreliable, especially in children
with closed anterior fontanels.8 The value of computed
tomography (CT) is limited by the poor correlation that exists
between the degree of hydrocephalus (ventricular size) and
severity of ICP.9 Signs of raised ICP may also mimic signs of
brainstem dysfunction.10 It is therefore often difﬁcult to
distinguish between raised ICP and brainstem ischemia in a
deeply comatose child with stage III TBM.
Tuberculous Cerebrovascular Disease
Stroke is a common, most devastating complication of TBM.
Vessel pathology appears to be a consequence of its immersion
in the local inﬂammatory exudate.11 The terminal segments of
internal carotid artery and proximal portions of the middle and
anterior cerebral arteries are most frequently involved. Anti-
tuberculous chemotherapy is relatively ineffective in preventing
the vascular complications, suggesting an immune mechanism.
This has led to clinical intervention studies aimed at halting the
progressive nature of the vasculitis.12
Tuberculosis–Immune Reconstitution
Inﬂammatory Syndrome
TB-immune reconstitution inﬂammatory syndrome (IRIS) of
the central nervous system often manifests as a life-threatening
condition and should be considered when new neurologic
symptoms or signs develop shortly after initiation of antire-
troviral therapy (ART) in children.13 Two clinical scenarios
may occur: “unmasking” IRIS, when subclinical, previously
unrecognized TB infection ﬂares up after starting ART, and
“paradoxical” IRIS, diagnosed when new or worsening symp-
toms of TB develop despite adherence to appropriate anti-
tuberculous treatment in a patient in whom combination ART
was initiated.13 The neurologic manifestations described
include neck stiffness, intracranial and spinal tuberculousmass
lesions, radiculomyelitis, hydrocephalus, visual compromise,
and seizures.13 Paradoxical TBM-IRIS tends to occur within
3 weeks of initiation of ART in children.13
The frequency and mortality of neurologic TB-IRIS in
children is not well documented; only 1 case series has been
published.14 In adults, TBM-IRIS complicates the course of
treatment of HIV-associated TBM in 47% of cases, despite the
use of adjunctive corticosteroid therapy.15Mortality is high (up
to 30%) in those affected.14
As yet, nomeans exist to predict the syndrome. The optimal
time to initiate ART in children or adults with HIV-associated
TBM is unknown. A recent randomized, double-blind,
placebo-controlled trial of immediate vs deferred ART in adult
Vietnamese patients with TBM showed that HIV-associated
TBM in the study population had such a poor prognosis that
the timing of ART made no appreciable difference regarding
survival probability.16 Early initiation of ART was not asso-
ciated with an increased risk of IRIS. Corticosteroids are the
mainstay of treatment for TBM-IRIS, with interruption of ART
reserved for life-threatening complications. Other immuno-
modulatory agents that have beenused to treat IRIS in a limited
number of patients include thalidomide, chloroquine, myco-
phenolate mofetil, and cyclosporine.13
TB Mass Lesions
Tuberculomas of the central nervous system may occur in
isolation or in associationwith TBM. Intracranial tuberculomas
Tuberculous meningitis in children 13
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are often silent and unsuspected, especially if no clinical
evidence of TB is present. A focal seizure in an otherwise
normal child is the most common mode of presentation in TB
endemic populations. Tuberculomas may also manifest with
focal neurologic signs or raised ICP due to obstruction of
cerebrospinal pathways. The diagnosis is dependent on neuro-
imaging as the evaluation of CSF and cultures had unremark-
able ﬁndings in most patients. Most tuberculomas resolve
uneventfully in response to antituberculous treatment. Corti-
costeroids (prednisone 2 mg/kg/d) should be reserved for cases
with paradoxically enlarging tuberculomas.
TBmass lesions (large tuberculomas or abscesses) are known
to develop or enlarge despite appropriate anti-TB treatment.
This phenomenon, the result of IRIS, is oftenmore severe in the
setting of HIV coinfection and may be life threatening.13 The
clinical manifestations depend on the size and location of the
lesion(s) and include focal neurologic signs, ataxia, spastic
paraplegia, and raised ICP due to obstruction of CSF pathways.
In our experience, TB abscesses are responsive to thalidomide,
a potent tumor necrosis factor alpha (TNF-α) inhibitor.12
Diagnosis
Owing to the suboptimal performance of diagnostic tests of
TBM, the diagnosis in children relies on a thorough assessment
of all the evidence derived from a careful evaluation of medical
history, clinical examination, and relevant investigations.
Approximately 60% of children with TBM have radiological
evidence of pulmonary TB.5
There have been efforts to create clinical prediction rules to
differentiate TBM from other forms of meningitis, especially
in resource-poor settings.When comparing TBM and bacterial
meningitis in adults using a composite clinical reference
standard, sensitivities of 86%-97% and speciﬁcities of 71%-
97% were obtained.17,18 When using a microbiologically
proven M.tb reference standard, sensitivities (86%-96%) and
speciﬁcities (71%-79%) were similar.17,19 However, a predic-
tion rule performed less well in an area of high HIV
seroprevalence (sensitivity 78% and speciﬁcity 43%).20
As the CSF in both TBM and viral meningitis is clear and
lymphocyte predominant, distinguishing between them is
more difﬁcult. A recent prediction rule, consisting of a
diagnostic scoring system, performed well with sensitivity of
92% and speciﬁcity of 94%.21
Despite numerous reports in the literature describing clinical
prediction rules, standardized diagnostic criteria are lacking.22
The tuberculin skin test showed a sensitivity of 61% in a
large retrospective cohort of children with TBM.5 However,
sensitivity decreases (34%) when HIV coinfection is present
because of the high rate of false-negative results.23 In a
population of young BCG vaccinated infants (o6 months),
speciﬁcity was found to be decreased owing to high false
positivity. Furthermore, a positive tuberculin skin test
implies exposure to TB, but it cannot delineate active TB
disease.24
Although a meta-analysis of the use of interferon gamma
release assays (IGRAs) in adults with pulmonary TB performed
in 2011 showed that there is no value for the diagnosis of active
TB,25 CSF IGRA showed sensitivities of 59%-84% and
speciﬁcities of 73%-89%.26-29 However, the large volume of
CSF needed to obtain enough cells to perform IGRA30 is a
limiting factor in children where much smaller CSF volumes
are obtained.
A systematic review conducted in 2003 evaluated the test
accuracy of nucleic acid ampliﬁcation tests (NAATs) in the
diagnosis of TBM.31 The studies with commercial NAATs
revealed a pooled sensitivity and speciﬁcity of 56% and 99%,
respectively. The review concluded that commercial NAATs
provided valuable information when positive; however, owing
to poor sensitivity, a negative result did not exclude TBM.31
The WHO has recently endorsed the Xpert MTB/RIF assay
(Xpert; Cepheid, Sunnyvale, CA) for both smear microscopy-
positive and -negative sputum specimens.32When using Xpert
for CSF specimens, promising sensitivities of 59%-84% and
speciﬁcities 73%-89% were obtained.33,34
Neuroimaging plays an important role in the diagnosis of
TBM, especially during the early stage of the disease and in
cases of diagnostic uncertainty. CT is most often used in
resource-poor countries and a combination of hyperdense
exudates on precontrast CT, basal meningeal enhancement,
infarctions, and hydrocephalus is highly suggestive (Fig. 1).35
Bilateral basal ganglia infarcts are particularly characteristic of
TBM, and this ﬁnding on CT suggest a high likelihood of
brainstem involvement. Approximately one-third of children
with stage 1 TBM disease have normal ﬁndings on a CT scan.6
In case of TBM, magnetic resonance imaging (MRI) is
superior to CT for diagnosis, by detecting basal enhancement
and granulomas in more patients, and for prognosis, by
detecting many more infarcts in strategic locations such as
the brainstem (Fig. 2).36 Gadolinium-enhanced MRI allows
Figure 1 Contrasted computed tomography image showing a combi-
nation of hydrocephalus, basal meningeal enhancement, and
infarction.
R. van Toorn and S.M. Regan14
29
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
detection of miliary leptomeningial tubercles, which have been
reported to be present in 88% of children with TBM.37 MRI is
also valuable for identiﬁcation of optochiasmic arachnoiditis,
which requires urgent intervention to reduce the risk of
blindness.38 Magnetic resonance angiography is useful for
the assessment of vascular involvement. The vessels most
commonly affected include the terminal portions of the
internal carotid arteries as well as the proximal parts of the
middle and anterior cerebral arteries.
Treatment
Fluid Management
Hyponatremia occurs in up to 85% of children with TBM and
is thought to be secondary to either syndrome of inappropriate
antidiuretic hormone or cerebral salt wasting.
Fluid restriction has traditionally been recommended to
counter the presumed threat of syndrome of inappropriate
antidiuretic hormone and reduce the risk of cerebral edema.
However, there is no evidence that indicates that ﬂuid
restriction is beneﬁcial in children with meningitis. It may
precipitate hypovolemia, which should be avoided at all costs
as maintenance of adequate cerebral perfusion is of critical
importance in patients with TBM. TBM is known to induce
a hypercoagulable state, which would then increase the risk
of venous thrombosis and infarction in the setting of inad-
equate cerebral perfusion.39 A safer option is to partially correct
symptomatic hyponatremia (associated with seizures) by slow
infusion of 5% hypertonic saline.
Antimicrobial Therapy
There is limited evidence regarding the most appropriate
treatment regimen for TBMor optimal duration of treatment.40
The WHO recommends a 12-month treatment plan (2RHZE/
10RH) for children with suspected or conﬁrmed TBM. Short,
intensiﬁed anti-TBM therapy is advocated by several groups as
similar completion and relapse rates have been reported when
a 6-month therapy was compared with a 1-year therapy.41
High-dose intravenous rifampicin may also be associated with
a survival beneﬁt in adult patients with severe disease.
Local experience is that short, intensiﬁed therapy (6RHZEth
for HIV-uninfected and 9RHZEth for HIV-infected children) is
safe and effective in children with drug-susceptible TBM.41
This regimen was prospectively evaluated in 184 consecutive
children with TBM and resulted in a good outcome in 80% of
cases and mortality of 3.8%.41 The incidence of antitubercu-
lous drug-induced hepatotoxicity in the study was low (5%),
and in all cases, the original regimen was restarted without
recurrence.41 The rational for using ethionamide as the fourth
drug is that it has goodCSF penetration and less adverse effects
compared with those of streptomycin and ethambutol.
Another advantage is that isoniazid monoresistant TBM may
be overcome when ethionamide and pyrazinamide are used
continuously for a 6-month period.42
In resource-poor countries, lengthy in-hospital treatment of
TBM is often not a realistic option. Local experience is that
home-based TBM treatment after initial in-hospital stabiliza-
tion is feasible in carefully selected patients under close
supervision.43
MDR TBM should be considered in cases where there is
deterioration despite compliance with adequate antitubercu-
lous treatment. In such cases, it is vitally important to obtain
cultures from source contacts. Newer NAATs allows detection
of resistance against rifampicin and isoniazid. Second-line
agents for MDR TBM include levoﬂoxacin, amikacin, teriza-
done, and para-aminosalicylic acid.
Treatment of Tuberculous Hydrocephalus
Treatment of tuberculous hydrocephalus depends on the level
of CSF obstruction. Air encephalography is the most reliable
way of determining the level of CSF obstruction (Fig. 3).44 CT
Figure 2 (A) Computed tomography scan of a 13-year-old child presentingwith disseminatedTB and loss of consciousness.
The initial CT image only revealed bilateral periventricular hypodensities and hydrocephalus. (B and C) T1-weighted
postgadolinium MR image obtained 2 days later revealed basal meningeal enhancement and multiple ring enhancing
lesions (miliary nodules) in the cerebellar hemispheres. MR, magnetic resonance.
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is not a useful tool as panventricular dilatation occurs in both
communicating and noncommunicating types of hydrocepha-
lus.44 Communicating hydrocephalus can be treated with
medical therapy consisting of 50 mg/kg/d of acetazolamide
and1 mg/kg/d of furosemide in 3divideddoses) for a period of
4 weeks.9 This drug combination reduces CSF production by
blocking carbonic anhydrase activity and reduces ICP by
decreasing the rate of CSF production. It is our experience
that normalization of ICP occurs within days in more than
90% of children. Figure 4 illustrates our suggested treatment
algorithm for children with tuberculous hydrocephalus.
Adjunctive Anti-inﬂammatory Therapy
Corticosteroids
ACochrane systematic review of 7 clinical trials involving 1140
participants conducted in 2008 found that corticosteroids
reduce the risk of death (relative risk ¼ 0.78, 95% CI: 0.67-
0.91) or disabling neurologic deﬁcit (relative risk¼ 0.82, 95%
CI: 0.70-0.97) in HIV-uninfected TBM patients.45 The beneﬁt
of corticosteroids in HIV-infected patients has not been
demonstrated. There are also no controlled trials comparing
corticosteroid regimens. Local preference is to prescribe a dose
of 2 mg/kg/d of prednisone (maximum 60 mg/d) for the ﬁrst
month of treatment and then to gradually wean over the next 2
weeks.
Aspirin
The value of aspirin’s antithrombotic, anti-ischemic, and anti-
inﬂammatory properties in TBM was explored in 2 studies. A
TBM study in adults reported a signiﬁcant reduction in
mortality at 3 months (P ¼ 0.02).46 In contrast, a TBM study
on children found no signiﬁcant beneﬁt in morbidity (hemi-
paresis and developmental outcome) or mortality at
6 months.39
Thalidomide
TB abscesses are notoriously resistant to therapy and require
total surgical excision for cure.47 Surgical excision is often not
achievable because of the proximity of the abscesses to vital
brain structures and the lack of neurosurgical care in resource-
poor countries. TB abscesses often teem with tubercle bacilli,
which induce a strong cytokine response. The most important
cytokine implicated is TNF-α. Insufﬁcient TNF-α production
delays granuloma formation, which is required for control of
Figure 3 (3A) The lateral skull X-ray shows air in the basal cistern and lateral ventricles. This indicates communicating
hydrocephalus (arrow) due to basal cistern obstruction to the ﬂow of cerebrospinal ﬂuid. (3B) The lateral skull X-ray
shows only air at the level of the basal cistern (arrow). This indicates non-communicating hydrocephalus due to
obstruction of the 4th ventricle outlet foramen.
Suspected TBM
CT brain
Tuberculous hydrocephalus
Clinically compromised/ Signs of impending herniation
No Yes
Urgent neurosurgery for VP shunt
insertion. 
Air encephalography
Comm hydrocephalus
80% of cases                     
Non-comm hydrocephalus
20% of cases
Medical treatment
Acetozolamide 50mg/kg/day
Furosemide 1 mg/kg/day
Normalizes ICP within 1 week of therapy
> 90% of cases                       <10% of cases
- clinical improvement - clinical deterioration
CT brain (MRI brain preferable if available)
Brainstem infarction 
-Palliative care         
Worsening hydrocephalus
Figure 4 Tygerberg Children’s Hospital treatment algorithm for
tuberculous hydrocephalus. Comm = communicating, Non-
comm = non-communicating, VPS = ventriculo-peritoneal shunt,
ICP = intracranial pressure
R. van Toorn and S.M. Regan16
31
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
bacillary growth whereas excessive production leads to exten-
sive liquefaction necrosis as is evident in TB abscesses.
Thalidomide, 3-5 mg/kg/d, given orally, is our drug of choice
in childrenwhodevelop life-threatening TBmass lesions (IRIS)
despite the use of corticosteroids.12 The use of thalidomide
should also be considered in children with visual compromise
due to tuberculous optochiasmic arachnoiditis.38
Outcome in Childhood TBM
Prognosis in TBM largely depends on the stage the disease has
reached at the time of treatment intervention. Children with
stage I TBM disease are likely to have a normal outcome,
whereas children with stage III disease have a high risk of
mortality.41 MDR TBM in children has a poor clinical outcome
and is often associated with death.42 Inpatient mortality rates
are generally similar between HIV-infected and HIV-
uninfected children with TBM.41 However, mortality after
hospital discharge is substantially worse in HIV-infected
children with TBM because of HIV-related illnesses. Long-
term behavioral complications of TBM survivors include
general behavioral disinhibitions and internalized emotional
disorders.48
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B A C K G R O U N D :  The stage of tuberculous meningitis 
(TBM) at presentation is strongly associated with 
prognosis. 
O B J E C T I V E :  To compare different staging systems for 
TBM in predicting outcome.
M E T H O D S :  The associations of different staging systems 
with neurological outcome were assessed using clinical, 
diagnostic and outcome data of 554 TBM children ad-
mitted to Tygerberg Children’s Hospital from January 
1985 to April 2005.
R E S U LT S :  The refined Medical Research Council (MRC) 
scale after 1 week (84%, 95%CI 81–88) had the highest 
discriminatory power in predicting neurological mor-
bidity. The Glasgow Coma Score (GCS) on admission, 
GCS after 1 week, the ‘refined’ MRC scale on admission 
and Tygerberg Children’s Hospital (TCH) staging method 
all had excellent discriminatory powers in predicting 
outcome. Improvement of staging after 1 week occurred 
in children who did not have signs of raised intracranial 
pressure (P = 0.004) or brainstem dysfunction on ad-
mission (P = 0.030).
C O N C L U S I O N S :  The ‘refined’ MRC scale 1 week after 
diagnosis showed the best association with neurological 
outcome after 6 months of treatment. The excellent dis-
criminatory power of the TCH scale and its simplicity 
of use make it the ideal scale for use in resource-poor 
settings. 
K E Y  W O R D S :  tuberculous meningitis; staging systems; 
neurological outcome
THE MORTALITY and morbidity of childhood tu-
berculous meningitis (TBM) remains high despite the 
availability of effective anti-tuberculosis medication 
and improvements in neurosurgical critical care. Neu-
rological sequelae from TBM include cognitive im-
pairment and cerebral palsy.
Prediction of prognosis in children with TBM is 
diffi cult because of the protracted course of the dis-
ease, the diversity of underlying pathological mecha-
nisms, the unpredictability of injury-induced plastic-
ity and variations in host immunity. Other factors that 
contribute to poor outcome are multidrug resistance 
(MDR) and human immunodefi ciency virus (HIV) 
co-infection. Several studies have shown that the se-
verity of TBM at presentation is strongly associated 
with prognosis.1–3 Accurate staging is important when 
accessing the effi cacy of interventions, such as com-
paring different anti-tuberculosis drug regimens and 
the benefi ts of adjuvant therapy such as immune-
modulating agents.
Initially, only clinical indices were used to predict 
outcome in TBM, such as level of consciousness, gen-
eral condition and presence or absence of paresis. 
The British Medical Research Council (MRC) was 
the fi rst to propose a TBM staging system in 1948 
based on clinical assessment with three defi ned stages 
(early, medium and late) for patients on streptomycin 
(SM) treatment.1 Patients with early stage disease had 
a good outcome in 42% of cases compared to only 
7% of those with advanced disease. Mortality was 
46% in early disease and 86% in advanced disease.1 
First published in 1974, the Glasgow Coma Scale 
(GCS) was initially used to assess level of conscious-
ness in patients with traumatic head injury.4 Shortly 
thereafter, the GCS was used as part of several other 
scoring systems, including the British MRC TBM stag-
ing system. The MRC staging system using GCS scores 
to defi ne level of consciousness is thus referred to as 
the ‘modifi ed’ MRC staging system. 
More recently, different scoring systems, including 
the GCS on its own, Acute Physiology and Chronic 
Health Evaluation (APACHE) II and the TBM acute 
neurological score (TBAN) have been proposed to 
predict the outcome of TBM.5,6 The use of the GCS 
has also been validated in several studies that found 
it a useful predictor of outcome after 6 months in 
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both adult and childhood TBM.7–10 In a retrospective 
analysis of 43 adult TBM patients, the APACHE II 
scoring system was found to be at least as effective as 
the GCS and superior to the MRC system in predict-
ing discharge outcomes of adult patients.5 Among 
children with TBM, the sensitivity and specifi city of 
the TBAN score on day 0 (75% and 92%) and day 3 
(88% and 100%) was found to be superior to the 
MRC score (63% and 58%) with regard to predic-
tion of severe neurological sequelae.6 
The benefi t of clinical staging or scoring systems is 
that they can be applied to patients in both industri-
alised and developing countries, as they do not rely 
on radiological or laboratory fi ndings. Limitations of 
staging systems are that staging criteria may be diffi -
cult to apply in a standard manner for children in 
whom assessment of the sensorium is diffi cult. In ad-
dition, the initial staging may be infl uenced by fac-
tors other than TBM itself, which may affect levels of 
consciousness on presentation. These include the ef-
fect of seizures, drugs and hydration state. It is there-
fore possible that staging once the patient is stabilised 
may be of greater prognostic value than staging at 
fi rst contact. 
The aim of this present study was to evaluate the 
predictive value of several different scoring/staging 
systems in children with TBM at fi rst contact and 
a fter the fi rst week of hospitalisation. 
METHODOLOGY
Clinical data were obtained from a previous prospec-
tive study of 554 children aged <13 years with TBM 
admitted to Tygerberg Children’s Hospital from Jan-
uary 1985 to April 2005. These data were used to re-
classify patients according to the criteria of all the 
currently available staging systems in childhood TBM. 
The associations of the different staging systems with 
neurological outcome were then assessed. 
The following scoring systems were evaluated. 
1) Paediatric GCS. 2) The ‘modifi ed’ MRC scale, 
which categorises patients into three clinical stages: 
Stage 1 refers to patients who are alert and orientated 
(GCS 15) without focal neurological defi cit; Stage 2 
refers to patients with GCS 10–14, with or without 
focal neurological defi cit or GCS 15 with neurologi-
cal defi cit; while Stage 3 patients have a GCS <10, 
with or without focal neurological defi cit. 3) The ‘re-
fi ned’ MRC scale is similar to the ‘modifi ed’ MRC 
scale, with the exception that it divides Stage 2 into 
Stage 2a (patients with GCS 15 with neurological 
defi cit or GCS 13–14, with or without neurological 
defi cit) and Stage 2b (GCS 10–12, with or without 
focal neurological defi cit). 4) The TBAN (Tuberculo-
sis Acute Neurology) score was devised by research-
ers from the University of California as an objective 
marker for predicting severe neurological sequelae.6 
Weighted scores are assigned for clinical features such 
as mental status, seizures, cranial nerve abnormalities, 
focal motor abnormalities and increased muscle tone. 
A TBAN score of ⩾4 was found to be predictive of 
severe neurological sequelae. 5) The Tygerberg Chil-
dren’s Hospital (TCH) scale is a simplifi ed clinical 
staging system proposed by clinicians at the study site. 
Patients are categorised into four stages according to 
visual (fi xation and following) and motor (localisa-
tion of pain) ability: Stage 1 (able to fi xate and fol-
low and localise on both sides); Stage 2a (fi xates and 
follows but only localises pain on one side); Stage 2b 
(does not fi xate and follow but able to localise pain 
on one or both sides); and Stage 3 (does not fi xate 
and unable to localise pain).
Clinical data available allowed for evaluation of 
the Paediatric GCS on admission and after 1 week, the 
modifi ed MRC scale on admission and after 1 week, 
the refi ned MRC scale on admission and after 1 week, 
the TBAN score on admission and the TCH scale 
a fter 1 week. 
Diagnosis of TBM 
A defi nite diagnosis of TBM was made when Myco-
bacterium tuberculosis was isolated from cerebrospi-
nal fl uid (CSF). In all other cases, the diagnosis was 
‘probable TBM’, based on clinical signs of meningitis 
in the presence of characteristic CSF fi ndings (macro-
scopically clear, pleocytosis, elevated protein and re-
duced glucose). In addition, two of the following cri-
teria had to be present: 1) recent poor weight gain 
(crossing of percentiles on Road to Health Card), 
2) household contact with sputum smear-positive TB, 
3) computed tomography (CT) scan compatible with 
TBM, 4) chest radiography compatible with primary 
TB, 5) positive tuberculin skin test and 6) other clini-
cal specimens positive for acid-fast bacilli.
Treatment of TBM
All children with TBM were treated according to lo-
cal standard of care with a short, intensive four-drug 
regimen consisting of daily isoniazid 20 mg/kg, rifam-
picin 20 mg/kg, pyrazinamide 40 mg/kg and ethion-
amide 20 mg/kg for 6 months. Prednisone 2 mg/kg/day 
was given for the fi rst month of treatment. Institu-
tional practice is to perform lumbar puncture on all 
children with suspected TBM, even those with signs of 
raised intracranial pressure (ICP). Air encephalogra-
phy is then performed to determine whether the hydro-
cephalus is of communicating or non-communicating 
nature. TBM cases with non-communicating hydro-
cephalus are treated by ventriculoperitoneal (VP) 
shunting or third ventriculostomy, while communi-
cating hydrocephalus is managed medically with di-
uretics (50 mg/kg/day of acetazolamide and 1 mg/kg/
day of furosemide). Children presenting with signs of 
impending herniation are referred for emergency VP 
shunting (lumbar puncture contra-indicated). 
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Outcome of TBM 
After completing 6 months of treatment, motor func-
tion, intelligence, vision and hearing were tested. De-
velopmental quotient (DQ) was measured by the 
Bayley test or Griffi ths test depending on the age of 
the child. Patients were grouped as ‘normal’ (DQ > 
80), ‘mild intellectual impairment’ (DQ 50–80), or 
‘severe intellectual impairment’ (DQ < 50). Vision 
and hearing were classifi ed as normal, impaired vi-
sion or hearing, and blindness or deafness. Neurolog-
ical outcome was divided into four categories: 1) nor-
mal, including normal motor function, intelligence, 
vision and hearing; 2) mild sequelae, including hemi-
paresis, mild intellectual impairment and impaired 
vision and/or hearing; 3) severe sequelae, including 
quadriparesis, severe intellectual impairment, blind-
ness and/or deafness; and 4) death. Clinical outcome 
was defi ned as ‘good’ in the case of mild neurological 
sequelae or normal neurological outcome and ‘poor’ 
in the case of severe neurological sequelae or death.
Statistical analysis
Discrimination between the different scoring systems 
was tested using the area under the receiver operating 
curves (AUC). An AUC between 0.7 and 0.8 was clas-
sifi ed as ‘acceptable’, between 0.8 and 0.9 as ‘excel-
lent’, and between 0.9 and 1.0 as ‘outstanding dis-
crimination’. The best cut-off point was that which 
maximised the sum of specifi city and sensitivity. 
A maximum-likelihood model was fi tted to the 
data with the group whose stage did not change be-
tween admission and 1 week later and, as the refer-
ence group. Variables included in this model, with the 
reference categories in brackets, were: age, convul-
sions (no), clinical signs of raised ICP (no), brain stem 
signs (no), cranial nerve palsy on admission (no), se-
rum sodium level (normal), hydrocephalus (no) and 
need for VP shunting (yes). P < 0.05 was indicative 
of statistical signifi cance. 
The study was approved by the Human Research 
Ethics Committee of Stellenbosch University, Cape 
Town, Western Cape, South Africa.
RESULTS
The refi ned MRC scale after 1 week (84%, 95% con-
fi dence interval [CI] 81–88) has the highest discrimi-
natory power in predicting outcome in terms of AUC. 
GCS on admission (80%, 95%CI 74–85), GCS after 
1 week (83%, 95%CI 78–88), the modifi ed MRC 
scale after 1 week (82%, 95%CI 78–86) and the TCH 
scale (82%, 95%CI 75–89) all had excellent discrim-
inatory power in predicting outcome. The discrimi-
natory power of the modifi ed MRC scale on admis-
sion (75%, 95%CI 71–79), the refi ned MRC scale on 
admission (74%, 95%CI 70–79) and the TBAN score 
on admission (78%, 95%CI 75–89) was acceptable 
in terms of AUC.
There was no signifi cant difference in predictive 
power between the GCS on admission and that after 
1 week (P = 0.096). In contrast, the AUC signifi -
cantly improved in the modifi ed MRC scale after 
1 week (P = 0.001) and the refi ned MRC scale after 
1 week (P < 0.001). The predictive power of the re-
fi ned MRC scale after 1 week was not signifi cantly 
higher than the TCH score (P = 0.242). It was, how-
ever, signifi cantly higher than the TBAN score (P = 
0.027; Figure). 
Table 1 shows the motor outcome after 6 months 
using the refi ned MRC staging system after 1 week. 
Of note was that signifi cantly more children with se-
vere motor disability (spastic quadriplegia) were clas-
sifi ed as Stage 2b (P = 0.028) compared to Stage 2a. 
No difference was noted between Stages 2a and 2b re-
garding hemiplegics and normal motor outcome (P = 
0.75). Table 2 compares mean DQ after 6 months in 
refi ned MRC Stage 2a and 2b patients. Of note is that 
the mean developmental quotient of children in Stage 
2b was signifi cantly lower than that of Stage 2a chil-
dren (P = 0.001). Tables 3 and 4 compare motor and 
cognitive outcomes after 6 months between the dif-
ferent stages using the TCH staging system. 
Figure Comparison of the predictive values of refined MRC 
staging after 1 week with the TCH and TBAN scores. Refined 
MRC staging had the highest predictive value, significantly higher 
than TBAN, but not significantly higher than the TCH score. 
TBAN_1 wk = Tuberculous Meningitis Acute Neurology Score 
after 1 week; AUC = area under the receiver operating curves; 
TCH_1w = Tygerberg Children’s Hospital score after 1 week; Ref_
MRC_1w = refined MRC score after 1 week; MRC = British 
Medical Research Council.
Table 1 Motor outcome after 6 months using the refined 
MRC scale after 1 week (n = 483)
n
Stage 1
%
Stage 2a
%
Stage 2b
%
Stage 3
%
Normal 243 39.1 26.7 24.7  9.5 
Left hemiparesis  71  1.4 33.8 33.8 31.0 
Right hemiparesis  58  0 34.5 41.3 24.1 
Quadriparesis  60  0  3.3 23.3 73.3 
Death  51  0  1.9  1.9 96.0 
MRC = British Medical Research Council.
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Comparing the refi ned MRC staging system on 
admission and after 1 week, 51.1% (n = 269) of pa-
tients did not change stage and 45.1% (n = 237) im-
proved their staging, while only 3.8% (n = 20) dete-
riorated; 13% (n = 71) of the patients improved their 
staging by two or more categories. 
Variables analysed to determine their signifi cance 
regarding change of staging included age, convul-
sions, cranial nerve palsy, raised ICP, presence of 
brain stem signs, serum sodium level, hydrocephalus 
and need for VP shunting. Improvement of staging 
occurred in children who did not have raised ICP on 
admission (P = 0.004) or who did not have brain 
stem signs (P = 0.030).
DISCUSSION
The steep decline in mortality from TBM has been 
paralleled by a marked increase in the number of 
survivors, many with severe neurological sequelae. 
A recent large childhood TBM study documented 
neurological disability in as many as 75% of survi-
vors, despite an exceptionally low mortality rate of 
only 13%.8 
This study found that all the staging/scoring sys-
tems evaluated had discriminatory power in predict-
ing outcome after 6 months, ranging from acceptable 
to excellent. Refi ned MRC staging after 1 week had 
the highest discriminatory power in predicting out-
come in terms of AUC. Delaying the staging by 
1 week signifi cantly improved the predictive power 
of both the modifi ed MRC staging system (P = 0.001) 
and the refi ned MRC staging system (P < 0.001), but 
not the GCS (P = 0.096). This can be attributed to 
the fact that the GCS best motor response is deter-
mined using only the best unilateral response. Even se-
vere residual unilateral motor involvement on follow-
up would therefore not necessarily be accounted for 
on the GCS on admission. 
The TCH staging system is a simplifi ed staging 
system that relies only on a patient’s ability to visu-
ally fi xate and follow and to localise pain on both 
sides. It is less dependent on clinical ability and neu-
rological expertise than other staging systems, which 
makes it ideally suited for use in resource-poor envi-
ronments that also have the highest TB burdens. It 
has the further advantage of distinguishing unilateral 
from bilateral motor involvement, which is impor-
tant, as bilateral cerebral infarction often occurs in 
advanced TBM. The scale also illustrates the poor 
outcome that can be expected in TBM children who 
are not able to fi xate or localise on either side (Stage 
3) 1 week after admission (Tables 3 and 4). The TCH 
staging system showed excellent predictive power for 
outcome after 1 week, and did not differ signifi cantly 
from the refi ned MRC staging system in this regard 
(P = 0.242). 
The motivation for refi ning Stage 2 of the modi-
fi ed MRC staging system was to more accurately de-
lineate disease severity, as children without neurolog-
ical defi cit and only slight drowsiness (GCS 14) are 
staged together with children with neurological defi -
cit and a GCS of 10–13. This study found that the 
risk of severe motor defi cit (spastic quadriplegia; P = 
0.028) and the degree of intellectual disability (P = 
0.001) were higher in children classifi ed as Stage 2b 
compared to 2a (Tables 1 and 2). No difference was 
found between Stages 2a and 2b regarding the risk of 
hemiplegia, a fi nding most likely related to young 
children’s ability to overcome focal neurological defi -
cits (neuroplasticity). 
The majority of the children either improved their 
initial staging (45%) or stayed the same (51%); <4% 
regressed to a lower stage after 1 week. Neurological 
deterioration during the fi rst week of treatment has 
been described as a result of the progressive nature of 
TBM-associated vasculitis (development of new in-
farcts), which may occur despite optimal treatment. 
Clinical improvement may occur when comorbid fac-
tors are addressed, including correction of dehydra-
tion and electrolyte imbalances, control of seizures 
and relief of raised ICP. This study, however, found 
that factors such as age, convulsions, cranial nerve 
palsy, hydrocephalus (irrespective of type) and serum 
Table 2 Mean developmental quotient of children (n = 353) 
using refined MRC staging after 1 week
Mean DQ 95%CI
Stage 1 78.6 75.8–81.3
Stage 2a 68.3 65.0–71.4
Stage 2b 58.9 54.5–63.6
Stage 3 44.3 38.0–50.4
MRC = British Medical Research Council; DQ = development quotient; CI = 
confidence interval.
Table 3 Motor outcome after 6 months using TCH staging 
after 1 week (n = 162)
n
Stage 1
%
Stage 2a
%
Stage 2b
%
Stage 3
%
Normal 72 50.0 27.7 20.8  1.4 
Left hemiparesis 32  3.1 53.3 28.1 15.6
Right hemiparesis 27  3.7 51.8 22.2 22.2 
Quadriparesis 24  0 12.5 16.6 70.8 
Death  7  0  2.8  1.4 57.1
TCH = Tygerberg Children’s Hospital.
Table 4 Developmental outcome after 6 months using TCH 
staging (n = 162)
 Mean DQ 95%CI
Stage 1 76.3 71.4–81.6
Stage 2a 64.1 59.1–69.0
Stage 2b 57.7 50.8–64.6
Stage 3 28.1 19.4–36.7
TCH = Tygerberg Children’s Hospital; DQ = development quotient; CI = 
confidence interval.
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sodium (both high and low) did not change stage of 
disease after 1 week. The only variable associated with 
signifi cant stage improvement was absence of signs of 
brainstem dysfunction on admission. Persistent brain-
stem dysfunction as a poor prognostic indicator is 
confi rmed by magnetic resonance imaging studies 
which found that the presence of ischaemic brainstem 
lesions in children with TBM invariably leads to se-
vere cognitive and motor defi cits.11 Studies have also 
shown that a poor correlation exists between clinical 
signs of raised ICP in children with TBM and moni-
tored CSF pressure.12 This fi nding can be explained 
by the fact that parenchymal brain stem damage in 
TBM may mimic the signs of raised ICP. 
CONCLUSION
The ‘refi ned’ MRC scale 1 week after diagnosis showed 
the best association with neurological outcome after 
6 months of treatment. The excellent predictive power 
of the TCH scale and its simplicity of use make it 
ideal for use in resource-poor settings. Persistent brain-
stem dysfunction is an indicator of poor prognosis in 
children with TBM.
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Outcome  in  childhood  TBM i
C O N T E X T E  :   Le pronostic de la méningite tuberculeuse 
(TBM) est en association étroite avec le stade de la 
maladie.
O B J E C T I F  :   Comparer les différents systèmes de stadifi-
cation de la TBM en matière de prédiction des résultats.
M É T H O D E S  :   Les associations des différents systèmes de 
stadification avec les résultats neurologiques ont été 
évaluées en utilisant les données cliniques, celles de dia-
gnostic et celles des résultats chez 554 enfants atteints 
de TBM et admis à l’Hôpital des Enfants de Tygerberg 
(TCH) entre janvier 1985 et avril 2005.
R É S U LTAT S  :   Le système affiné du Medical Research 
Council (MRC) après 1 semaine a le pouvoir discrimi-
natoire le plus élevé pour prédire une morbidité neuro-
logique (84% ; IC95% 81–88). Le Score de Coma de 
Glasgow (GCS) à l’admission, le GCS après 1 semaine, 
l’échelle affinée du MRC à l’admission et la méthode de 
stadification du TCH ont tous un pouvoir discrimina-
toire excellent pour la prédiction du résultat. L’amélio-
ration du stade après 1 semaine est survenue chez les 
enfants qui à l’admission n’avaient pas de signes d’aug-
mentation de la pression intracranienne (P = 0,004) ou 
de dysfonctionnement du tronc cérébral (P = 0,030). 
C O N C L U S I O N S  :   La stadification affinée du MRC une 
semaine après le diagnostic s’est avérée avoir la meil-
leure association avec le résultat neurologique après 
6 mois de traitement. La puissance discriminatoire ex-
cellente de l’échelle TCH et sa simplicité d’emploi en 
font une échelle idéale pour l’utilisation dans les con-
textes à faibles ressources.
M A R C O  D E  R E F E R E N C I A :   La fase clínica de la meningi-
tis tuberculosa (TBM) en el momento de la consulta 
presenta una estrecha correlación con el pronóstico. 
O B J E T I V O :   Comparar los diferentes sistemas de clasifi-
cación evolutiva de la TBM con respecto al pronóstico 
del desenlace.
M É T O D O S :   Se evaluó la relación de los diferentes siste-
mas de clasificación con el desenlace neurológico a partir 
de datos clínicos, diagnósticos y de desenlace de 554 niños 
con TBM que ingresaron al hospital pediátrico Tyger-
berg (TCH) entre enero de 1985 y abril del 2005. 
R E S U LTA D O S :   La escala ‘modificada’ definida por el 
Medical Research Council (MRC) después de 1 semana 
(84%; IC95% 81–88) ofreció el mayor poder discrimi-
natorio en materia de pronóstico de la morbilidad neu-
rológica. La escala del coma de Glasgow (GCS) en el mo-
mento de la hospitalización y después de una semana, la 
escala ‘modificada’ del MRC al ingreso y el método de 
clasificación del TCH exhibieron un excelente poder 
discriminatorio en la predicción del desenlace. En los 
niños que no presentaban hipertensión intracraneal (P = 
0,004) ni disfunción del tronco encefálico (P = 0,030) 
al ingreso, se observó una mejoría de la clasificación 
después de 1 semana. 
C O N C L U S I Ó N :   La escala ‘modificada’ del MRC 1 se-
mana después del diagnóstico ofreció la mejor correla-
ción con el desenlace clínico 6 meses después del trata-
miento. El gran poder discriminatorio de la escala y su 
facilidad de aplicación la convierten en un método ideal 
en los entornos con escasos recursos.
R É S U M É
R E S U M E N
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ORIGINAL STUDIES
Background: The World Health Organization recommends 12-month treat-
ment (2RHZE/10RH) for children with tuberculous meningitis (TBM). 
Studies evaluating length of antituberculous treatment for TBM report 
similar completion and relapse rates comparing 6-month treatment with 
12-month treatment.
Methods: A prospective evaluation to determine whether short-course 
intensified treatment (6 RHZEth for HIV-infected and 9RHZEth for HIV-
infected) is sufficient and safe in children with drug-susceptible TBM.
Results: Of 184 children with TBM, median age 58 months and 90 (49%) 
male, 98 children (53%) presented at stage II TBM, 64 (35%) at stage 
III TBM and only 22 (12%) at stage I TBM. Ninety (49%) children were 
treated at home after the first month of therapy; all others received their 
full treatment in hospital. The HIV prevalence was 14% (22/155 children 
tested). Anti-TB drug-induced hepatotoxicity occurred in 5% (8 of 143 chil-
dren tested), all tested negative for viral hepatitis; in all 8 cases, the original 
regimen was restarted without recurrence. After treatment completion, 147 
(80%) children had a good outcome, 7 (3.8%) died. There was no difference 
in outcome between HIV-infected and HIV-uninfected children who com-
pleted treatment (P = 0.986) nor between TBM-hydrocephalic children who 
were medically treated or shunted (P = 0.166).
Conclusion: Short intensified treatment is safe and effective in both 
 HIV-infected and HIV-uninfected children with drug-susceptible TBM.
Key Words: pediatric, children, tuberculous meningitis, treatment
(Pediatr Infect Dis J 2014;33:248–252)
Recent World Health Organization (WHO) guidelines recom-mend that children with tuberculous meningitis (TBM) should 
be treated with 2 months of isoniazid (INH), rifampicin (RMP), 
pyrazinamide (PZA) and ethambutol followed by 10 months of 
INH and RMP.1 As the WHO has to consider the circumstances 
under which TB will be treated worldwide, this long duration of 
treatment was a compromise between the importance of preventing 
relapse and the unavailability of certain drugs (eg, ethionamide) 
and an unwillingness to give PZA for >2 months in many settings 
(personal communication P.R.D.).
However, a recent review found that all existing trials assess-
ing anti-TB treatment for TBM had limited power, poor methodol-
ogy and used varying treatment regimens with conflicting results.2 
The studies reviewed reported similar completion and relapse rates 
when 6 months therapy with at least INH, RMP and PZA was com-
pared with longer treatment regimens, suggesting that 6-month 
therapy for TBM may be sufficient. Shorter treatment regimens are 
cheaper, less labor-intensive and may improve patient compliance.
This study describes local experience with intensive 
 short-course anti-TB treatment of at least 6-month duration in a large 
cohort of children with drug-susceptible TBM over a 4-year period. 
The aim was to demonstrate noninferiority of our  short-course inten-
sive regimen compared with other published treatment  regimens.
MATERIALS AND METHODS
Setting
Tygerberg Children’s Hospital, a referral hospital in the 
Western Cape province of South Africa, provides specialized care 
to half the province’s 1.2 million children. A recent pediatric men-
ingitis survey identified TBM as the most common form of bacte-
rial meningitis in the Western Cape province.3
Study Population and TBM Definition
All children admitted consecutively to Tygerberg Children’s 
Hospital with TBM from January 1, 2006, through December 31, 
2009, aged 0–13 years, were included in the study. Children with 
multidrug-resistant TB (MDR-TB; ie, resistance to at least INH 
and RMP) were excluded but INH-monoresistant TBM cases were 
included. A definite diagnosis of TBM was made when Mycobacte-
rium tuberculosis was cultured from cerebrospinal fluid (CSF) and /
or polymerase chain reaction for M. tuberculosis tested positive in 
CSF. In all other cases, the diagnosis was “probable TBM” based 
on clinical signs of meningitis in the presence of characteristic CSF 
findings (macroscopically clear, pleocytosis usually with lymphocyte 
predominance, elevated protein and reduced glucose). In addition, 
two of the following criteria were required: other clinical specimens 
culture positive for M. tuberculosis and/or positive TB histology, a 
positive tuberculin skin test, a chest radiograph compatible with TB, 
a cranial computerized tomography or magnetic resonance imaging 
compatible with TBM, growth failure with crossing of weight-for-
age percentiles or finally, household contact with sputum smear-pos-
itive pulmonary TB. TBM stage was classified as TBM stage 1 [Glas-
gow Coma Scale (GCS) 15 with no focal signs], TBM stage II (GCS 
11–14 or GCS 15 with focal neurology) or TBM stage III (GCS < 11)
Treatment of TBM
Local practice is to treat TBM with a short, intensive 4-drug 
regimen consisting of daily INH 20 mg/kg (maximum 400 mg 
daily), RMP 20 mg/kg (maximum 600 mg daily), PZA 40 mg/kg 
(maximum 2 g daily) and ethionamide (ETH) 20 mg/kg (maximum 
750 mg daily), all given in a single daily dose, for 6 months duration. 
HIV-infected children, however, are treated for 9 months because of 
perceived slower response to treatment. Prednisone 2 mg/kg/d (max-
imum 60 mg/d) is given for the first month of treatment and gradu-
ally discontinued over the next 2 weeks. If the child’s isolate of M. 
tuberculosis or that of the source case is resistant to any of the drugs 
used or if the child deteriorates clinically on this regimen, alternative 
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN: 0891-3668/14/3303-0248
DOI: 10.1097/INF.0000000000000065
4IPSU*OUFOTJmFE5SFBUNFOUJO$IJMESFOXJUI%SVHTVTDFQUJCMF
5VCFSDVMPVT.FOJOHJUJT
Ronald van Toorn, FCP,* H. Simon Schaaf, MD,* Jacoba A. Laubscher, BCOMM,† Sabine L. van Elsland, MSc, *‡  
Peter R. Donald, MD,* and Johan F. Schoeman, MD*
Accepted for publication August 23, 2013. 
From the *Department of Pediatrics and Child Health, Stellenbosch University 
and Tygerberg Children’s Hospital, Western Cape; †Biostatistics Unit, Medi-
cal Research Council of South Africa, Tygerberg, Cape Town, South Africa; 
and ‡Department of Pediatric Infectious Diseases and Immunology, VU 
University Medical Center, Amsterdam, The Netherlands.
The authors have no funding or conflicts of interest to disclose.
Address for correspondence: Ronald van Toorn, Department of Pediatrics and 
Child Health, Stellenbosch University, PO Box 19063, Tygerberg, 7505, 
South Africa. E-mail: vtoorn@sun.ac.za.
Supplemental digital content is available for this article. Direct URL citations 
appear in the printed text and are provided in the HTML and PDF versions of 
this article on the journal’s website (www.pidj.com).
42
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
5IF1FEJBUSJD*OGFDUJPVT%JTFBTF+PVSOBM t 7PMVNF/VNCFS.BSDI Tuberculous Meningitis
© 2013 Lippincott Williams & Wilkins www.pidj.com | 249
anti-TB treatment is considered. Treatment of  INH-monoresistant 
TB involves the addition of a fluoroquinolone and terizidone with 
treatment for 9 months. Air-encephalography is used to distinguish 
between communicating and noncommunicating types of obstruc-
tive hydrocephalus. Institutional preference is to treat noncommu-
nicating hydrocephalus by ventriculo-peritoneal (VP) shunting or 
endoscopic third ventriculostomy, whilst communicating hydro-
cephalus is treated medically with diuretics (acetazolamide 50 mg/
kg/d and furosemide 1 mg/kg/d) during the first month of therapy to 
expedite normalization of intracranial pressure.
Once clinically stable, the child is medically evaluated 
and the family is screened by a social worker to determine suit-
ability for home-based therapy.4 Definite exclusion criteria for 
 home-based treatment included: no reliable caregiver; insufficient 
income and support network; regular visits to TB-clinic not pos-
sible and no other directly observed therapy supporter available 
and MDR-TB or untreated household TB source case.4 Caregivers 
of eligible patients were offered the choice of either in-hospital or 
home-based treatment. During the 6-month, home-based therapy, 
the mother and child were reviewed monthly assessing the clinical 
wellbeing of the child, adherence to treatment and adverse effects.
Evaluation for Adverse Effects
Local practice is to perform liver function tests [serum 
aspartate aminotransferase, alanine aminotransferase (ALT) and 
bilirubin] on admission and during the first 2 weeks of treat-
ment. Thereafter, children are observed clinically for symptoms 
of hepatotoxicity (jaundice, abdominal pain, new onset nausea 
and vomiting).
Anti-TB drug-induced hepatotoxicity (ADIH) severity 
was classified according to WHO adverse drug reaction terminol-
ogy5: grade 1 (mild): ALT <2.5 times upper limit normal (ALT 
51–125 U/L); grade 2 (mild) ALT 2.5–5 times upper limit normal 
(ALT 126-250U/L); grade 3 (moderate): ALT 5–10 times upper 
limit normal (ALT 251–500 U/L); grade 4 (severe): ALT >10 times 
upper limit normal (ALT >500 U/L). First-line treatment (with 
liver enzyme monitoring) is continued in asymptomatic children 
with WHO grade 1 hepatotoxicity. Children who developed more 
severe degrees of liver toxicity are commenced on liver-friendly 
regimens that include amikacin, ofloxacin, ethambutol and ter-
izidone (terizidone for good CSF penetration). Once the liver 
enzymes have normalized, stepwise rechallenge with first-line 
drugs is attempted. Nausea and vomiting was considered signifi-
cant if vomiting occurred for >2 consecutive days and where inter-
vention such as administering ETH in the evenings or antiemetics 
was required. Combination antiretroviral therapy (cART) consist-
ing of stavudine, lamivudine and efavirenz was initiated as soon 
after HIV diagnosis as possible.
Outcome
After treatment completion, motor function, intelligence, 
vision and hearing were tested. Developmental quotient (DQ) was 
measured by Griffith’s developmental scales. Patients were grouped 
as “normal” (DQ: > 80), “mild intellectual impairment” (DQ: 50–
80) or “severe intellectual impairment” (DQ: <50). Vision and hear-
ing were classified as normal, impaired and blindness or deafness.
Neurological outcome was divided into 4 categories: (1) 
normal, including normal intelligence, motor function, vision and 
hearing; (2) mild sequelae, including mild intellectual impairment, 
hemiparesis and impaired vision and/or hearing; (3) severe seque-
lae, including severe intellectual impairment, quadriparesis, blind-
ness and/or deafness and (4) death. Clinical outcome was defined as 
“good” in the case of normal outcome or mild neurological seque-
lae and defined “poor” in the case of severe neurological sequelae 
or death.
Relapse Rate
Patients who remained disease free (any form of TB) for 
a period of >2 years after treatment completion were considered 
cured. Relapse rate was determined by telephonic contact with the 
child’s caregiver at least 2 years after therapy completion or if the 
patient was reviewed in our neurology outpatient clinic after this 
time. The caregiver was requested to confirm the child’s identity by 
date of birth and questions were asked relating to the child’s clinical 
wellbeing and scholastic performance. If the caregiver expressed 
any concern, clinical review in neurology outpatients was offered.
Statistical Analysis
Outcome was categorized into good (normal/mild) and poor 
(severe/death) outcome. Bivariate associations with outcome were 
assessed by either the χ2 test or Fisher’s exact test (categorical vari-
ables) or an analysis of variance (continuous variables). A P-value 
<0.05 was indicative of statistical significance. Logistic regression 
was used to assess the association between outcome (“good” is ref-
erence) and either type of hydrocephalus or HIV infection. Results 
were expressed as odds ratios with 95% confidence intervals (CI). 
A multinomial logistic regression was used to assess the associa-
tion between outcome (normal as reference, mild and severe/death) 
and where the patients were treated (home based as reference ver-
sus in-hospital), adjusted for the stage of the disease. Results were 
expressed as relative risk ratios with 95% CI.
Ethics
Ethical approval (N11/07/244) was obtained from the Stel-
lenbosch University Human Research Ethics Committee.
RESULTS
Table 1 demonstrates the demographics, TBM staging, clini-
cal features, selected diagnostic tests and outcome of 184 consecu-
tive children <13 years of age with TBM. All children with stage 
I TBM had a good outcome compared with 97% with stage II dis-
ease and 47% with stage III disease. There was no difference in 
outcome after completion of treatment between HIV-infected and 
 HIV-uninfected children (odds ratios: 1.01, 95% CI: 0.34–2.96, P = 
0.986). The overall mortality before completion of anti-TB therapy 
was 3.8% (7 of 184 children). All seven children who died were 
moribund on admission (stage III disease) and three children died 
within 8-days of starting treatment. Cranial computerized tomogra-
phy on admission revealed extensive bilateral basal ganglia infarc-
tion (suggesting brainstem involvement) in all seven cases; only 
one of those who died was HIV infected.
Table 2 demonstrates the disease complications and drug 
adverse effects of the 184 TBM children. None of the children 
with communicating hydrocephalus required VP shunting and their 
outcome after completion of therapy was similar to those children 
with noncommunicating hydrocephalus who required VP shunting. 
(odds ratios: 0.55, 95% CI: 0.23–1.28, P = 0.166).
Liver enzyme levels before initiation of treatment were 
normal in 75 (90%) of the 83 children tested; none with baseline 
abnormal liver functions had ALT levels >2.5 times the normal 
upper limit. Only eight (5.6%) of the 143 children who underwent 
liver enzyme testing during treatment experienced ADIH (grade 3 
or 4 hepatotoxicity); viral hepatitis serology proved negative in all 
and none of the children were clinically jaundiced or had elevated 
serum bilirubin levels. The median age of the ADIH children was 
34 months (range 15–156 months) and the median duration on 
therapy was 44 days (range 8–105 days). In all cases, change to 
liver-friendly regimens resulted in normalization of liver enzymes 
(medium duration 7 days, range 3–16 days) and the original regi-
men was restarted (stepwise) without recurrence. None of the 
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22 HIV-infected children on cART developed grade 3 or 4 hepato-
toxicity. All eight children with grade 3 or 4 hepatotoxicity experi-
enced significant new onset vomiting. The prevalence of significant 
vomiting in children without ADIH was 6% (n = 11). In these cases, 
substituting ETH with ethambutol (three cases) or administering 
the ETH at night rather than in the morning solved the problem.
Table 3 demonstrates the duration of therapy and reasons 
for prolonged treatment (longer than 6 months) in the 177 TBM 
children who survived TMB upon completion of therapy. Figure 1 
illustrates the baseline and outcomes of the 184 TBM children who 
intended and received 6 months of treatment compared with those 
who required prolonged treatment because of other reasons. Table, 
Supplemental Digital Content 1, http://links.lww.com/INF/B704, 
demonstrates the characteristics of home-based treatment versus 
hospital-based treatment of all children presenting with TBM by 
stage of disease. In-hospital treated TBM children had a higher 
risk of a poor outcome, after adjustment for the stage of disease 
(relative risk = 4.55, 95% CI: 1.46–14.15, P = 0.009). No relapses 
were reported in 88 of the 90 children who completed home-based 
treatment. Two children on home-based treatment demised after 
completion of treatment; 1 had stage III disease and the other 
was HIV infected (postmortems not performed). Fifty-one chil-
dren were clinically reviewed in the neurology outpatient depart-
ment ≥2 years after treatment completion. In all other cases, the 
caregiver(s) or patient him/herself reported clinical wellbeing. Five 
children who qualified for home-based treatment were readmitted 
for hospital-based treatment. Reasons for readmission included: 
development of nonrelated ocular myasthenia gravis, paradoxical 
enlargement of a tuberculoma, TB immune reconstitution inflam-
matory syndrome, poor adherence and parental request (struggling 
to provide care). Of the 87 TBM children who survived in-hospital 
treatment, we established that no relapses occurred in 52 children, 
but the caregivers of 29 children could not be contacted. Six chil-
dren demised: five had previous stage III TBM and four of these 
(66%) were HIV-infected. Postmortems were not requested; death 
certificates stated either HIV infection or post-TBM complications. 
One child with stage III TBM died of HIV-related pneumonia >2 
years after completion of therapy.
TABLE 1. Demographics, TBM Staging, Clinical 
Features, Selected Diagnostic Tests and Outcome of 184 
Consecutive Children <13 Years of Age With TBM
Characteristic Number (%) Unless Specified
Age (median in months) 58 months (3–156 months)
Gender: Female 94 (51)
Stage of TBM (n = 184)
  TBM Stage 1 22 (11.9)
  TBM Stage 2 98 (53.3)
  TBM Stage 3 64 (34.8)
  Definite TBM 16 (8.7)
  Probable TBM 168 (91.3)
HIV status (n = 155) (as % of those tested)
  Uninfected 128 (82.6%)
  Infected 22 (14.2%)
  Exposed uninfected 5 (3.2%)
  Not tested 29
Positive TB cultures (as % of those tested)
  Gastric washings (155 tested) 43 (27.7%)
  Cerebrospinal fluid (136 tested) 16 (11.8%)—2 also polymerase  
chain reaction positive†
Treatment
  In-hospital treatment only 94 (51%)
  Home-based treatment after  
  stabilization
90 (49%)
Outcome after end of treatment
  Normal 79 (42.9%)
  Mild sequelae 68 (36.9%)
  Severe sequelae 30 (16.3%)
  Death 7 (3.8%)
Relapse rate of treatment survivors*
Home-based treatment (n = 90)
  No relapses (cured) 88
  Death 2
  Lost to follow up 0
In-hospital treatment (n = 87)
  No relapses (cured) 52
  Death 6
  Lost to follow up 29
*Relapse rate: children who remained disease free (any form of TB) for a period of 
>2 years after treatment completion were considered cured.
†CSF polymerase chain reaction testing for TB is not routinely performed.
TABLE 2. Disease Complications and Drug Adverse 
Effects of 184 TBM Children
Complication/Adverse Effect Number (%)
Hydrocephalus
No hydrocephalus 75 (40.8)
Communicating hydrocephalus 72 (39.1)
Noncommunicating hydrocephalus 37 (20.1)
VP shunted 34
Endoscopic third ventriculostomy 3
Anti-TB drug-induced hepatotoxicity
Not tested 41 (22.3)
Normal ALT< 50 U/L 111 (60.4)
Grade 1 (mild) ALT 51–125 U/L 18 (9.8)
Grade 2 (mild) ALT 126–250 U/L 6 (3,2)
Grade 3 (moderate) ALT 251–500 U/L 6 (3.2)
Grade 4 (severe) ALT> 500 U/L 2 (1.1)
Significant nausea and vomiting * 19 (10.3)
*Significant vomiting: vomiting occurring for >2 consecutive days and where sepa-
ration of drug administration (ETH in the evenings) or additional treatment (antiemet-
ics) was required. Of the 19 patients, 8 with significant vomiting had anti-TB drug-
induced hepatotoxicity.
TABLE 3. Duration of Treatment and Reasons for 
Prolonged Treatment (>6 Months) in the 177 TBM 
Children Who Survived Completion of Therapy
Treatment 
Duration
HIV Negative and Not  
Tested (n = 156) HIV Positive (n = 21)
6 months 130 (83.3%) — 6* (28.6%) —
7 months 6 (3.9%) 6 ADIH 0 (0.0%) —
8 months 5 (3.2%) 2 ADIH 0 (0.0%) —
3 poor adherence
9 months 11 (7.1%) 1 INH 
 monoresistance
12 (57.1%) —
1 HIV-exposed 
uninfected
4 TB- immune 
reconstitution 
inflammatory 
syndrome
5 TB mass lesions
12 months 2 (1.3%) 2 TB mass lesions 2 (9.5%) 2 TB mass 
lesions
15 months 0 (0.0%) — 1 (4.8%) 1 TB mass 
lesion
17 months 1 (0.6%) 1 INH resistance 
with TB mass 
lesion
0 (0.0%) —
18 months 1 (0.6%) 1 TB mass lesion 0 (0.0%) —
TB mass lesion refers to either large tuberculoma(s) or TB abscesses.
*All the HIV-infected TBM children who were treated for 6 months had either stage 
I or stage II disease.
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DISCUSSION
Treatment response in TBM is judged by early morbidity, 
mortality and relapse rates.6 The importance of early diagnosis and 
treatment is confirmed by the good outcome of stage I (100%) and 
stage II TBM (97%) cases compared with only 47% in stage III 
TBM. The overall mortality of 3.8% at completion of treatment 
compares favorably with the median mortality rate of 33% (range 
5–65%) reported in a recent review describing outcome in TBM 
treatment studies.2
The WHO recommends that children with TBM should be 
hospitalized, preferably for at least the first 2 months of treatment.1 
Long-term in-hospital TBM treatment, however, is seldom feasi-
ble in resource-poor countries due to bed shortages and budgetary 
constraints. A previously conducted observational study at our 
hospital found that childhood TBM can be successfully treated 
at home, provided that patients are carefully selected and meticu-
lously followed up by a dedicated health care team.4 The efficacy 
of home-based treatment and our intensive  short-course anti-
TB regimen is highlighted by the absence of relapses in the 88 
children that completed home-based TBM treatment  (follow-up 
period 2–5 years). The fact that not a single patient was lost to 
follow up in the home-based treatment group can be ascribed to 
the initial selection qualifying criteria for home-based treatment.
The prevalence of ADIH in the study population who under-
went liver function testing was 5.6% and only 4.3% developed 
symptomatic ADIH. In most resource-poor countries with high 
TB burden, liver function tests cannot be routinely performed. In 
those situations, one has to rely on clinical symptoms of hepato-
toxicity, such as jaundice, abdominal pain, nausea and vomiting. 
Of interest was that none of the children with ADIH developed 
jaundice or had elevated serum bilirubin levels. This is much lower 
than the incidence of abnormal liver functions (52.9%) and jaun-
dice (10.8%) reported in a recent literature review of 717 TBM 
children.7 All of the children who developed ADIH experienced 
new onset vomiting, which suggests that it is a more reliable 
clinical marker of hepatotoxicity compared with clinical jaundice. 
Reported risk factors for ADIH in children are female sex, slow 
acetylator status, malnutrition, disseminated TB disease and pre-
existent liver disease.7 The low prevalence of ADIH could be 
attributed to the high frequency of fast acetylator status (approxi-
mately 60%) in the study population.8 Baseline liver function test-
ing also did not demonstrate evidence of preexistent liver disease. 
Whether  HIV-infected children with TBM have an increased risk 
of ADIH is not determined; overlapping drug toxicities, drug-drug 
interactions and malnutrition are factors likely to increase the risk 
of ADIH in HIV-infected TBM children. However, none of the 
HIV- infected children in the study developed ADIH. Studies from 
developing countries report high rates of infectious viral hepatitis 
in children with suspected ADIH.9 Viral hepatitis serology proved 
negative in all study children with ADIH. This can partly be attrib-
uted to universal hepatitis B vaccination policy in South Africa 
since 1995. Although ADIH occurred within the first 2 months of 
treatment in 6 of the 8 children, the remaining 2 children devel-
oped ADIH during their final month of treatment confirming that 
ADIH can occur at any time during treatment.9
Whether intensified treatment improves the outcome of 
TBM is still to be determined. A recent Indonesian adult TBM 
study reported a 50% reduction in 6-month mortality without any 
increase in toxicity when high-dose intravenous RMP (13 mg/kg/d) 
was given for the first 2 weeks of treatment.10 Our experience is 
that high oral dose RMP (20 mg/kg/d) for 6–9 months duration is 
 well-tolerated by children.
The rational for using ETH as 4th drug in the regimen is 
that it has good CSF penetration (healthy and inflamed meninges) 
compared with streptomycin (20% in inflamed meninges only) 
or ethambutol (25–50% in inflamed meninges only).11 This is 
important as tuberculomas may occur in the absence of menin-
geal inflammation. Another advantage is that INH-monoresistant 
TBM may be overcome when ETH and PZA are used continu-
ously together with RMP for a 6-month period. This was con-
firmed by a recent study which reported no differences in outcome 
between children with INH-monoresistant TBM and those with 
HIV+ and INH resistant
9 Months (n = 25)
Prolonged treatment 
> 6 Months (n = 24)
TBM Stage n (%)
I 16 (11.9)
II 68 (50.4)
III 51 (37.8)
Outcome n (%)
Normal 58 (43.0)
Mild 49 (36.3)
Severe 22 (16.3)
Death 6 (4.4)
TBM Stage n (%)
I 4 (16.0)
II 16 (64.0)
III 5 (20.0)
Outcome n (%)
Normal 10 (40.0)
Mild 9 (36.0)
Severe 5 (20.0)
Death 1 (4.0)
TBM children 
(n = 184)
TBM Stage n (%)
I 2 (8.3)
II 14 (58.3)
III 8 (33.3)
Outcome n (%)
Normal 11 (45.8)
Mild 10 (41.7)
Severe 3 (12.5)
Death 0 (0.0)
Intended treatment 
6 Months (n = 135)
FIGURE 1. 5IFCBTFMJOFBOEPVUDPNFTPG5#.DIJMESFOXIPJOUFOEFEBOESFDFJWFENPOUITPGUSFBUNFOUXIPJOUFOEFE
BOESFDFJWFENPOUITPGUSFBUNFOUBOEUIPTFXIPSFRVJSFEQSPMPOHFEUSFBUNFOUCFDBVTFPGPUIFSSFBTPOT
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drug-susceptible TBM.9 The inclusion of ETH should therefore be 
considered in areas with high INH monoresistance (> 4% in pri-
mary TB cases) or in resource limited settings where drug resist-
ance rates are unknown.9 Use of ETH is also preferable to the use 
of an aminoglycoside with poor CSF penetration and considerable 
risk of hearing loss.12 The most frequent adverse effect observed 
during treatment with ETH is nausea and vomiting. Our experi-
ence is that almost all children respond favorable to administration 
of ETH at night separately from the other anti-TB medications. 
Recent studies found the prevalence of ETH-induced hypothyroid-
ism (20–50%) to be more common than previously recognized in 
children on second-line anti-TB drugs including ETH.13,14 Regular 
screening of thyroid functions is therefore indicated in TBM chil-
dren on prolonged or high-dose ETH.
Management of TBM in the setting of HIV is complex. 
Additional treatment considerations for HIV-infected children 
include the timing of initiation of cART and the potential for 
drug interactions. The optimal time to initiate cART in children with 
HIV-associated TBM is unknown.15 We will usually delay cART by 
2–4 weeks to reduce the risk of TB immune reconstitution inflam-
matory syndrome.16 Therapy is also prolonged for an additional 3 
months in HIV-infected cases because of perceived slower response 
to treatment. The similar result in outcome between  HIV-infected 
and HIV-uninfected children at completion of treatment can be 
attributed to the benefits derived from cART and/or longer treat-
ment duration of TBM.
Limitations of the study include the inability to contact the 
caregivers of the 29 children in the hospital-based treatment group 
and the fact that it was not a randomized controlled study com-
paring longer/shorter treatment regimens or home-based versus 
hospital-based treatment.
We believe that short intensified chemotherapy is suffi-
cient and safe in HIV-infected and HIV-uninfected children with 
 drug-susceptible TBM. Home-based treatment can be recom-
mended for the management of childhood TBM following adequate 
screening, counseling and support.
REFERENCES
 1. World Health Organization. Rapid advice: treatment of tuberculosis in chil-
dren. Geneva: World Health Organization; 2010. WHO/HTM/TB/2010.13.
 2. Woodfield J, Argent A. Evidence behind the WHO guidelines: hospital care 
for children: what is the most appropriate anti-microbial treatment for tuber-
culous meningitis? J Trop Pediatr. 2008;54:220–224.
 3. Wolzak NK, Cooke ML, Orth H, et al. The changing profile of pediatric 
meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr. 
2012;58:491–495.
 4. Schoeman J, Malan G, van Toorn R, et al. Home-based treatment of child-
hood neurotuberculosis. J Trop Pediatr. 2009;55:149–154.
 5. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis  drug-induced 
hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 
2008;23:192–202.
 6. Donald PR. The chemotherapy of tuberculous meningitis in children and 
adults. Tuberculosis (Edinb). 2010;90:375–392.
 7. Donald PR. Antituberculosis drug-induced hepatotoxicity in children. 
Pediatr Rep. 2011;3:e16.
 8. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in chil-
dren treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614–618.
 9. Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clini-
cal outcome in children with tuberculous meningitis. Pediatr Infect Dis J. 
2012;31:711–716.
 10. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing 
rifampicin and moxifloxacin for tuberculous meningitis: an open-label, ran-
domised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27–35.
 11. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in 
adults and children. Tuberculosis (Edinb). 2010;90:279–292.
 12. Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for 
multidrug-resistant tuberculosis. J Infect. 2013;66:320–329.
 13. Thee S, Zöllner EW, Willemse M, et al. Abnormal thyroid function tests 
in children on ethionamide treatment. Int J Tuberc Lung Dis. 2011;15: 
1191–1193.
 14. Hallbauer UM, Schaaf HS. Ethionamide-induced hypothyroidism in chil-
dren. South Afr J Epidemiol Infect. 2011; 26:161–163
 15. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction 
of tuberculous meningitis immune reconstitution inflammatory syndrome. 
Clin Infect Dis. 2013;56:450–460.
 16. van Toorn R, Rabie H, Dramowski A, et al. Neurological manifestations of 
TB-IRIS: a report of 4 children. Eur J Paediatr Neurol. 2012;16:676–682.
46
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
5IF1FEJBUSJD*OGFDUJPVT%JTFBTF+PVSOBM t Volume 33, Number 9, September 2014 Letters
© 2014 Lippincott Williams & Wilkins www.pidj.com | 993
In Reply: Short Intensified 
Treatment in Children 
With Drug-Susceptible 
Tuberculous Meningitis
child effectively on isoniazid monotherapy 
for most of their treatment. This can be a 
problem in areas with high prevalence of iso-
niazid resistance. In addition, the poor CSF 
penetration of ethambutol2 renders its inclu-
sion in the regimen questionable.
The short intensified treatment regi-
men used in the Western Cape for nearly 2 
decades with higher isoniazid and rifampin 
dosages, longer administration of pyrazina-
mide and substitution of ethambutol with 
ethionamide provides higher CSF concentra-
tions of anti-tuberculosis drugs for the entire 
duration of treatment.2 It may also overcome 
isoniazid-monoresistance3 and children 
appear to tolerate combination treatment 
with pyrazinamide better than adults.
Twelve years before the most recent 
WHO recommendations in 2010, this group 
published their experience with the same treat-
ment regimen, showing that it was effective 
and associated with one of the lowest mortal-
ity rates reported.4 It is disappointing that this 
regimen has not been evaluated further in 
other centers and that most authorities still rec-
ommend only 2 months of intensive treatment.
Despite demonstrating good out-
comes and a shorter duration of treatment, 
the study by van Toorn is observational 
without a randomized control group for 
comparison; it thus may provide insufficient 
evidence to change international policy. In 
addition, the regimen employs a drug usu-
ally reserved for second-line treatment, 
which could have implications for accept-
ability by tuberculosis programs. Further, 
recent WHO dosing recommendations may 
make it difficult to use the higher dosages 
described in the study, given the shortage of 
single drug formulations in many settings.5
However, these operational obstacles 
should not impede the identification of the 
best possible treatment regimen. An appro-
priately powered randomized controlled trial 
to address this question is long overdue. One-
hundred eighty-four children with TBM were 
enrolled in this study from a single center in 
4 years; patient numbers, although limited, 
should not be an impediment to conducting a 
multicenter trial. Such a trial should compare 
the standard WHO-recommended regimen 
with a shortened regimen using drugs with 
good CSF penetration for the full duration. 
Consideration should be given to using a fluo-
roquinolone (levofloxacin or moxifloxacin) 
instead of ethionamide, as many pediatricians 
are hesitant to use ethionamide because of its 
side-effect profile as well as cross-resistance 
with isoniazid. Particular attention should 
be paid to using standardized assessments of 
neurologic outcome and toxicity and the issue 
of blinding. Until better evidence is provided, 
children with TBM will continue to be treated 
with what is likely to be a suboptimal regimen.
Aslınur Ozkaya-Parlakay, MD
Ankara Hematology and Oncology 
Research Hospital 
Hasan Tezer, MD
Gazi University
Pediatric Infectious Disease Department
Ankara, Turkey 
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To the Editors:
We read with interest the results of the study by van Toorn et al. describing 
short intensified treatment for children with 
drug-susceptible tuberculous meningitis 
(TBM).1 The paper raises important questions 
regarding the most appropriate antimicrobial 
treatment regimen for children with TBM.
The World Health Organization 
(WHO) recommends giving 2 months of iso-
niazid, rifampin, pyrazinamide and ethambu-
tol followed by 10 months of isoniazid and 
rifampin. After meningeal inflammation has 
subsided, rifampin has poor penetration into 
the cerebrospinal fluid (CSF)2 leaving the 
Anna Turkova, MRCPCH
Imperial College Healthcare NHS Trust
London 
James A. Seddon, PhD
Department of Academic Paediatrics
Imperial College London 
Andrew J. Nunn, MSc
Diana M. Gibb, MD
Patrick P.J. Phillips, PhD
MRC Clinical Trials Unit at UCL
Institute of Clinical Trials and Methodology
London, United Kingdom
On behalf of the North London 
TB Journal Club 
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Reply:
We agree with the North London TB journal club about the impor-
tance of trials that would determine the 
most appropriate antimicrobial regimen 
for children with tuberculous meningitis 
(TBM). The study design advocated by the 
authors is a randomized controlled trial 
(RCT) of short intensified versus standard 
treatment (as advised by the World Health 
Organization).
Although a RCT would be the pre-
ferred study method, a large sample size 
Copyright © 2014 by Lippincott Williams & Wilkins
ISSN: 0891-3668/14/3309-0993
DOI: 10.1097/INF.0000000000000409
47
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Letters 5IF1FEJBUSJD*OGFDUJPVT%JTFBTF+PVSOBM t Volume 33, Number 9, September 2014
994 | www.pidj.com © 2014 Lippincott Williams & Wilkins
would be required to separate out the effects 
of combination treatments. Wolbers et al1 
addressed this question by comparing 2 
approaches (RCT vs. 2 × 2 factorial design) 
using a design of a new trial in TBM as an 
example. In their trial example, the combi-
nation of 2 drugs added to standard treat-
ment is assumed to reduce the hazard of 
death by 30% and the sample size of the 
combination trial to achieve 80% power was 
750 patients. An adequately powered 2 × 2 
factorial design (to detect effects of indi-
vidual drugs) would require at least 8-fold 
the sample size (6000 patients) of the com-
bination trial.
The short intensified TBM treatment 
regimen used in the Western Cape for nearly 
three decades is associated with a 3.8% 
mortality rate and a good outcome in greater 
than 80% of cases. A comparative superior-
ity trial would require an even larger sample 
size than in the examples above.
Another issue is that of ethics: would 
it be ethically acceptable for a study site, 
which has a good outcome and low mortal-
ity amongst their TBM cases, to participate 
in a RCT comparing regimens that may be 
inferior to what they currently use? We have 
recently declined participation in a TBM 
study for this reason. Such a RCT would 
only be acceptable if another regimen (such 
as the World Health Organization 12-month 
regimen) has at least shown similar or better 
results in other study sites.
Ronald van Toorn, FCP
H. Simon Schaaf, MD
Johan F. Schoeman MD
Department of Pediatrics and Child Health
Stellenbosch University and Tygerberg 
Children’s hospital
Western Cape, South Africa 
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Introduction: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS) is a potentially life-threatening complication in HIV infected children with tubercu-
losis (TB) of the central nervous system. HIV-associated TB-IRIS has not been previously
described in children with neurotuberculosis.
Objective: To describe the neurological and neuro-radiological features of 4 consecutive
cases of TB-IRIS in children with neurotuberculosis and to discuss possible management
strategies.
Results: Three patients treated for tuberculosis of the central nervous system experienced
paradoxical worsening of neurological symptoms when combination antiretroviral therapy
(cART) was initiated. Intracranial tuberculomas were unmasked in the 4th patient. All
patients developed new neurological signs within 10 days of cART initiation. Neurological
symptoms and signs included headache, seizures, meningeal irritation, decreased level of
consciousness, ataxia and focal motor deficit. Interventions included the temporary
discontinuation of cART and the use of corticosteroids in all patients. Three patients
received thalidomide and 1 chloroquine and mycophenolate mofetil. One patient died and
the others experienced prolonged hospitalization.
Conclusion: TB-IRIS should be considered when new neurological signs develop shortly after
initiation of cART in children. There is little data to guide the timing of initiation of cART
and the management of complications in children.
ª 2012 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.
1. Introduction
Tuberculosis (TB) associated immune reconstitution inflam-
matory syndrome (TB-IRIS) is a potentially life-threatening
complication in HIV infected children.
Paradoxical TB-IRIS refers to the development of new or
worsening symptoms of TB despite adherence to appropriate
TB treatment in a patient who initiated combination anti-
retroviral therapy (cART). The deterioration usually occurs in
the first 3 months after cART initiation. Unmasking TB-IRIS
occurs in patients where cART precedes tuberculosis diag-
nosis by up to 3 months.1 In resource-limited settings the
diagnosis of TB-IRIS is based on clinical and radiological signs
and its temporal relationship to the initiation of cART, no
specific diagnostic tests exist for the condition.2 Neither
recovery of CD4 cells or decline in viral load need to be present
for diagnosis.2 Differential diagnosis of TB-IRIS includes drug
resistant TB and other potential causes of failure of anti-TB
* Corresponding author. Tel.: þ27 21 938 9113; fax: þ27 21 938 4858.
E-mail address: vtoorn@sun.ac.za (R. van Toorn).
Official Journal of the European Paediatric Neurology Society
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 6 ( 2 0 1 2 ) 6 7 6e6 8 2
1090-3798/$ e see front matter ª 2012 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejpn.2012.04.005
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treatment, other infections, drug toxicity and HIV-related
conditions.
Risk factors for paradoxical TB-IRIS are disseminated TB,
low CD4 count at initiation of cART, and shorter interval from
TB treatment to cART initiation. Only a few case reports and
one case series of TB-IRIS of central nervous systemhave been
reported in adults and there are no published descriptions in
children.1,3,4Neurologicdeteriorationhasbeenreported in12%
of adult paradoxical TB-IRIS cases, manifestations included
radiculomyelopathy, new meningitis or exacerbations of
meningitis and or enlarging granulomas.3,4 In contrast to other
forms of paradoxical IRIS the morbidity and mortality is high.
Unmasking TB-IRIS may be difficult to distinguish from
incident TB cases but is thought to be associated with
increased inflammatory responses. Few cases are clearly
described in literature.
The main stay of therapy in TB-IRIS in adults are cortico-
steroids with interruption of cART reserved for patients with
severe life-threatening complications or where the compli-
cation can cause disability.5 It is not clear whether the use of
corticosteroids for TBmeningitis, the current standard of care,
prevents any cases of paradoxical TB-IRIS. Other immune-
modulating treatments are only described in case reports
with no reports in children. In the present paper we describe
our experience of CNS-related TB-IRIS in 4 HIV-infected
children.
2. Case 1
A 10 year old girl presented with a 1 day history of left-sided
partial seizures and vomiting. Clinical examination revealed
meningism and lethargy (Glasgow Coma Score 14/15). The
cerebrospinal fluid (CSF) findings were compatible with TB
meningitis and the computerized tomographic (CT) scan of
the brain showed mild meningovascular enhancement and
communicating hydrocephalus (Fig. 1 A). Chest X ray
demonstrated paratracheal lymphadenopathy supportive of
primary pulmonary TB. There was no household TB contact
and mantoux skin test proved unreactive. The patient was
started on rifampicin 20 mg/kg/day, isoniazid 20 mg/kg/day,
pyrazinamide 40 mg/kg/day, ethionamide 20 mg/kg/day and
prednisone 2mg/kg/day as well as acetazolamide 50 mg/kg/
day and furosemide 1 mg/kg/day. Insertion of a ven-
triculoperitoneal shunt resulted in improvement of the level
of consciousness but the patient remained lethargic and
irritable.
The serum Elisa test for HIV was reported as positive with
an absolute CD4 positive T-cell count of 55/mL (7%). The patient
was started on cART with stavudine, lamivudine and
efavirenz three weeks after TB therapy. Seven days later the
patient became drowsy and developed temperature spikes. A
repeat CT scan showed that the basal meningovascular
enhancement had increased from the previous scan (Fig. 1 B).
The repeat CD 4 positive T-cell count showed an absolute
count of 171/mL (11.7%) Paradoxical TB-IRIS was suspected and
the cART was stopped. Over the next 3 days the patient
developed severe neck stiffness, ataxia and bilateral upper
motor signs. Oral corticosteroids were replaced by high dose
intravenous dexamethazone. An uncontrasted CT scan now
showed that the basal cisterns were obliterated by granulo-
matous tissue. In addition, low density changes in the adja-
cent brain parenchyma and brainstem, indicative of
tuberculous borderzone encephalopathy were noted (Fig. 1 C).
Adjunctive thalidomide (2 mg/kg/day) were given during the
last week of illness but the patient continued to deteriorate
and died 2 weeks later.
3. Case 2
A 12 year old boy recently diagnosed with HIV infection
(absolute CD4 count 274/mL) presented with culture negative
TB meningitis. Initial response to anti-TB medication proved
favourable and cART consisting of abacavir, lamivudine and
efavirenz was introduced after 4 weeks of anti-TB therapy.
Fig. 1 e A: Contrasted CT scan on admission showing mild basal meningeal enhancement and obstructive hydrocephalus.
B: Contrasted CT scan 1 week following initiation of cART. Marked basal meningeal enhancement is present. C:
Uncontrasted CT scan 1 week after discontinuation of cART. The basal cisterns and Sylvian fissures are filled with dense
granulomatous tissue obliterating the CSF spaces.
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Following 1 week of cART, the patient complained of head-
ache, vomiting and drowsiness. Neurological examination
revealed features suggestive of raised intracranial pressure
(papilloedema) and cerebellar dysfunction (intention tremor
and dysdiadokinesis). Brain CT scan showed a large ring-
enhancing lesion in the left cerebellar hemisphere with
marked peri-lesional oedema (Fig. 2 A). The morphology of the
lesion (isodense intensity with irregular rim enhancement)
indicated a tuberculoma rather than a brain abscess. The 4th
ventricle was compressed, displaced and obstructive hydro-
cephalus was present (Fig. 2 B). Unfortunately no imaging was
done pre-cART, but the clinical and radiological findings sug-
gested that the tuberculoma and especially the peri-lesional
oedema probably increased on cART. A repeat absolute CD4
count after 10days of antiretroviral treatmentwas 90 m/L (8.3%).
cART was stopped and high dose intravenous dexamethasone
initiated. In spite of these measures, the patient developed
projectile vomiting and an emergency endoscopic third ven-
triculostomywas required to stabilize the patient. Biopsy of the
lesion was not attempted because of the danger of increasing
the amount of cerebellar swelling and possible pressure on the
brainstem. The patient responded dramatically to surgery and
was awake and ambulant one day post-operatively. Oral pred-
nisone 2 mg/kg/day was continued with the anti-TB chemo-
therapy. AMRI scan 10 days post-surgery and 9 days post-cART
interruption showed resolution of the hydrocephalus and
marked reduction of the peri-lesional oedema and mass effect
in the left cerebellar hemisphere (Fig. 2 C).
Since he remained severely immunosuppressed and at risk
of further life-threatening opportunistic infections, it was
considered urgent to re-initiate his cART. Repeat MRI a month
later demonstrated decreasing mass effect from the tuber-
culoma and thus re-initiation of cART with the same regimen
was attempted. Within 5 days he developed severe CNS IRIS
with raised intracranial pressure despite high dose predni-
sone. He was again treated with intravenous (IV) dexameth-
asone 0.15mg/kg/day but his symptoms persisted. Repeat MRI
showed increasing mass effect with midline shift and thus
cART was again discontinued 6 days after initiation. Despite
the interruption of cART the child had ongoing deterioration
of his neurological condition prompting the use of pulse IV
methylprednisolone at 10mg/kg/day for 3 days. Nomulti-drug
resistant (MDR)-tuberculosis source case was ever identified.
However, since a CSF TB culture with drug-susceptibility
testing (DST) had never been obtained, the possibility of
drug resistant TB was considered and therapy was upgraded
to a multi-drug resistant (MDR) regimen, with additional
amikacin 20 mg/kg/day, ofloxacin 20 mg/kg/day and ter-
izidone 20 mg/kg/day. In view of the failed 2nd attempt at
cART initiation due to CNS TB-IRIS, thalidomide 2 mg/kg/day
was introduced as an additional anti-inflammatory drug.
Unfortunately the patient then developed Stevens Johnson
reaction temporally associated with the initiation of the
additional MDR-TB drugs and thalidomide which necessitated
interruption of all drug therapy for a few days. In addition, he
also received intravenous immunoglobulin and his anti-TB
therapy was switched back to a drug-sensitive regimen.
Immunotherapy consisted of cyclosporin 6 mg/kg/day
together with chloroquine 3 mg/kg/day, in addition to the
ongoing high dose prednisone 2mg/kg/day. A third attempt at
re-initiation of cART was made 2 weeks later but he again
developed symptoms of raised intracranial pressure with
severe headache and vomiting after 48 h, and the cART was
discontinued. Finally, the introduction of mycophenylate
mofetil (MMF) 1200 mg/m2/day allowed for the cART
resumption without further relapse. Due to repeated therapy
interruptions, the cART regime was changed to ABC, 3 TC and
Lopinavir/r with additional ritonovir.
4. Case 3
A 14 year old HIV infected female on 2 months of anti-TB
therapy for culture negative stage 1 TBM developed fever
and left sided weakness within 5 days following the intro-
duction of cART (stavudine, lamivudine, efavirenz).Neuro-
logical examination revealed a dense left sided hemiparesis in
isolation. Contrasted CT imaging confirmed a right sided basal
Fig. 2 e A: Axial CT scan after 5 days of cART showing a large tuberculoma in the left cerebral hemisphere with peri-lesional
oedema causing mass effect. Displacement of the 4th ventricle resulted in obstructive hydrocephalus. B: Acute obstructive
hydrocephalus resulting from obstruction of CSF by tuberculoma in cerebellum. C: Contrasted axial CT done 20 days after
third ventriculostomy and 26 days after cART was stopped. The IRIS-related findings have markedly improved.
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ganglia infarct, with hydrocephalus, basal meningeal
enhancement and multiple ring-enhancing lesions predomi-
nantly in themedial aspect of the right temporal lobe (Fig. 3 A).
A repeat lumbar puncture showed clear CSF, 56 lymphocytes/
mm3, 19 polymorphs/mm3, protein of 1.83 g/L and glucose of
1.2 mmol/L. HIV RNA viral load was 27 copies/ml. The patient
was severely immune-compromised with an absolute CD4
count of 61 cells/mm3 (11.2%). The clinical and CT findings
suggested HIV-related tuberculosis IRIS and cART was
stopped. Multi-drug resistant tuberculosis was deemed
unlikely due to the absence of aMDR source case and since the
initial response to TB treatment was favourable. Therapy
consisted of ventriculoperitoneal shunt insertion, high dose
corticosteroids (2 mg/kg/day) and continuation of the same 4
drug anti-TB regime at a nearby TB hospital.
One month later, the child was re-admitted with progres-
sive headaches and irritability. Bilateral horizontal
nystagmus, intention tremor and dysdiadokinesis of the left
arm were evident on examination in addition to a markedly
improved left hemiplegia. CSF analysis once again confirmed
a lymphocytic meningitis but with an increased CSF protein
(4.8 g/L). Repeat CT showed improvement of the previously
reported hydrocephalus, less intense basal meningeal
enhancement but more numerous ring-enhancing cystic
structures filling the suprasellar, interpeduncular, as well as
prepontine and right cerebellar-pontine angle cisterns. MR
imaging 2 days later confirmed these lesions as multiple
intraparenchymal and subarachnoid TB abscesses (Fig. 3 B).
Antituberculosis treatment was empirically expanded with
terizidone 20 mg/kg/day, amikacin 20 mg/kg/day, ofloxacillin
20 mg/kg/day and ethambutol 20 mg/kg/day. Thalidomide
2 mg/kg/day was added as an additional anti-inflammatory
drug.
Clinical review one month later revealed marked
improvement of cerebellar function. Two months later, the
cerebellar signs had completely resolved despite unchanged
MR imaging. Three month thereafter, following 6 months of
thalidomide (total dosage 18 g); the patient remained asymp-
tomatic with only a mild left sided hemiplegia evident on
exercise. Repeat MRI showed decrease in size of all TB
abscesses and decreased intensity of the ring-enhancement
(Fig. 3 C) Thalidomide was discontinued, whilst the MDR-TB
regime was continued for another 6 months. (TB was never
cultured). The patient remains clinically well.
5. Case 4
A 21 month old girl presented with an unprovoked right-sided
seizure lasting 10 min. She was known to be HIV-infected and
cART was interrupted due to prolonged poor adherence. She
hadanundocumentedTBcontact during this time forwhichno
preventative therapy was given. cART was reinitiated 3 weeks
prior to her current presentation. On examination she was
afebrile, well-nourished and not acutely ill. Her neurological
examination proved normal. Chest radiography demonstrated
pulmonary hilar and subcarinal lymphadenopathy (chest
radiograph 3weeks agowas normal) and theMantoux skin test
was strongly reactive (>20 mm). Lumbar puncture showed
aclear andcolourlessCSFwitha lymphocyte countof 382/mm3,
protein of 0.95 g/L and glucose of 4.1mmol/L (blood glucosewas
not done at the time of the lumbar puncture). No organisms
wereseenonmicroscopyorcultured.CTbrainshowedmultiple
ring eenhancing lesions with surrounding oedema bilaterally
in the frontal-, temporal-, occipital and cerebellar areas (Fig. 4
(A) and (B)). A single lesion was present in the posterior
midbrain. No basal enhancement or hydrocephalus could be
demonstrated. An absolute CD4 positive T-cell count 10 days
before presentation (about 10 days after cART was reintro-
duced)was1496 m/L (33%). The clinical and radiological features
Fig. 3 e A: Initial contrasted CT imaging showing hydrocephalus with transependymal fluid shift, a right sided basal ganglia
infarct, significant basal meningeal enhancement and multiple ring-enhancing lesions predominantly in the medial aspect
of the right temporal lobe. B: MR imaging after 4 weeks showing multiple intraparenchymal and subarachnoid TB
abscesses. C: Repeat MRI 3 months later showing decrease in size of all TB abscesses and decreased intensity of the ring-
enhancement.
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were consistent with a diagnosis of multiple intracranial
tuberculomas which became symptomatic (unmasked) as
a result of TB-IRIS. cART was discontinued and 4 drug anti-TB
treatment and prednisone (2 mg/kg/day) was started. The
patient responded well to this treatment and no further
seizures or neurological deterioration was noted.
6. Discussion
TB is a common infection in HIV-infected African children
with rates of 53.3 cases/100 patient-years reported in children
not on cART.6 The overall incidence of CNS TB-IRIS in children
is unknown. A study amongst adults from Cape Town found
that neurological TB-IRIS accounts for more than 10% of
paradoxical TB-IRIS cases in a hospital setting.1 The study
reported a mortality rate between 13 and 30%. No data exists
on the mortality rate of CNS TB-IRIS in children. A previously
conducted study from the Western Cape reported a mortality
of 23.5% in children with HIV-associated TBM without IRIS7
who were not treated with cART. The authors documented
full recovery in 10/34 in HIV-infected versus 33/55 in unin-
fected children (OR 0.28, 95% CI 0.11e0.69).
The immunopathogenesis of TB-IRIS remains poorly
understood. Recent studies suggest that cytokine release
contributes to the pathology in TB-IRIS.8,9 Tadokera et al re-
ported higher concentrations of tumour necrosis factor alpha
(TNFa), interleukin 6(IL6) and interferon gamma (IFN g) in TB-
IRIS patients.9 Corticosteroid therapy resulted in decreased IL6
and TNF levels. Specific blockade of selected cytokines may
thus be a rational approach to immunomodulation in TB-IRIS.
Studies are still pending to determine whether inflammatory
biomarkers are useful in predicting or diagnosing IRIS. Risk
factors for TB-IRIS include starting cART within 6 weeks of TB
treatment; disseminated extra pulmonary disease, low base-
line CD 4 count, rise in CD4%; fall in viral load and high
bacillary burden.10,11 Viral load reduction has been associated
with IRIS but is not always present.
Paradoxical IRIS usually occurs soon after start of cART, in
both adults and children.12 All 3 study children with para-
doxical CNS TB-IRIS became symptomatic within 7 days of
cART initiation. In case 4, unmasking TB-IRIS occurred within
10 days of cART initiation. CNS TB-IRIS may also occur in HIV
uninfected patients but tend to occur later with paradoxical
enlargement of tuberculomasmost commonly occurring after
2e3 months on therapy.13 All three children who developed
paradoxical TB-IRIS suffered from severe immunodeficiency
at the time of diagnosis (Table 1) In contrast, case 4 (the child
with unmasking TB-IRIS) was not significantly immunodefi-
cient. However this child was probably recently infected by
a smear positive contact therefore at high risk for disease. In
this case the unmasking of tuberculosis may have occurred
whilst incident disease was in the process of developing.
In all our cases the diagnosis of IRIS was made on the basis
of new clinical signs in proximity of the initiation of cART.
Case 4 had a positive tuberculin skin test (TST); however up
to 60% of children with confirmed TBM diseases have positive
TST. TST conversion is a potential diagnostic tool in TB-IRIS.
However the use of TST to identify persons at risk has not
been studied.
Clinical diagnosis of TB-IRIS remains the gold standard in
poor resource settings.2 Criteria required for diagnosis include
(1) Diagnosis of neurotuberculosis with initial response to
anti-tuberculosis treatment (2) the recurrence/new onset of
tuberculosis disease manifestations within 24 weeks of anti-
tuberculosis treatment, and (3) exclusion of alternative
explanations for clinical deterioration (such as anti-
tuberculosis drug resistance, poor adherence, drug toxicity
or reaction, or an additional infection).
Manifestations of TB-IRIS at other organ sites also support
a diagnosis of CNS TB-IRIS. These include fever, concomitant
transient worsening of chest radiographs (new pulmonary
infiltrates, mediastinal lymphadenopathy) especially if old
radiographs are available for comparison. This is evidenced in
case 4 with unmasking TB-IRIS whose chest radiograph
changed from normal (3 weeks prior) to showing mediastinal
Fig. 4 e A: CT scan of the brain showing multiple tuberculomas, unmasked after 1 week of cART. B: Chest radiograph
showing concomitant IRIS erelated hilar and subcarinal lymphadenopathy.
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lymphadenopathy during the appearance of neurological
symptoms (Fig. 4 c) The diagnosis of TBM is often “probable”
as is illustrated by the initial negative CSF cultures in all 3
cases with paradoxical TB-IRIS. This paucity of positive
culture complicates exclusion of multi-drug resistant tuber-
culosis. Though previous studies report that microbiological
TB cultures are often negative in patientswith paradoxical TB-
IRIS1; all attempts should be made to isolate the organism to
ensure effective antimicrobial therapy.
Antiretroviral therapy is recommended for all HIV infec-
ted children diagnosed with CNS TB. There are no random-
ized studies to guide optimal timing of therapy initiation.
Retrospective reviews suggest that waiting 30e60 days may
be safe, but such data should be interpreted with caution.14
The optimal time to initiate cART in children with HIV-
associated TB meningitis is unknown. Strategy trials exam-
ining the optimum timing of cART in adults with mostly
pulmonary TB report benefit from early cART especially if the
CD4 count is less than 50 cells mm3.15 A recent randomized
double blind placebo-controlled trail of immediate versus
deferred cART in adult Vietnamese patients with TBM
showed that HIV-associated TB meningitis in the study
population had such a poor prognosis that the timing of cART
made no appreciable difference regarding survival proba-
bility.16 Early initiation was not associated with an increased
risk of CNS TB-IRIS. Adverse events where common in both
groups; however the prevalence of hepatitis was higher in the
early therapy group. The authors comment that the
concomitant use of oral steroids may have reduced the risk
for IRIS in these patients. In our 3 children with paradoxical
IRIS, steroids did not prevent deterioration, but we have no
comparative group.
With regards to therapy for patients experiencing IRIS,
a randomized placebo-controlled trial of prednisone for
paradoxical tuberculosis-associated IRIS reported faster
recovery and reduced need for hospitalization.5 The study
excluded patients suffering life-threatening TB-IRIS, including
those with CNS TB-IRIS.
Thalidomide has powerful anti-inflammatory properties
andmediates it action by selectively inhibiting TNFa secretion
by monocytes and macrophages. The routine use of adjunc-
tive high dose thalidomide is not advocated in children with
TB meningitis as a randomized study had to be terminated
early because of adverse events.17 More recently, low dose
(5mg/kg/day) thalidomide has been shown to enhance the
resolution of chronic tuberculous mass lesions (abscesses and
tuberculomas) and optochiasmatic arachnoiditis.18,19 Thalid-
omide failed to halt the progressive tuberculous meningeal
inflammation in case 1. In case 2, thalidomide was temporally
related to an episode of Steven’s Johnson syndrome and had
to be withdrawn. Adjunctive thalidomide therapy hastened
resolution of the tuberculous abscesses in case 3. The ratio-
nale for the use of mycophenolate mofetil in case 2 was that
mycophenolic acid selectively inhibits the synthesis of
guanosine nucleotides in lymphocytes resulting in inhibition
of activated T-cell proliferation.20 This may have allowed re-
introduction of cART without further complications. Myco-
phenolic acid is also a potent inhibitor of the expression of
TNF alpha and tumour necrosis factor-receptor superfamily
costimulatory molecules.21
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Ideally, cART should be continued in children suffering
mild manifestations of TB-IRIS rather than risk the interrup-
tion of treatment. In life-threatening cases, interruption of
cART is unavoidable and safer. Life-threatening neurological
symptoms necessitated interruption of cART in all three study
cases with paradoxical TB-IRIS.
7. Conclusion
As the availability of cART increases in resource poor coun-
tries with high TB burdens, the incidence of CNS TB-IRIS is
likely to increase. Studies are warranted to determine the
optimal time of cART initiation in HIV infected children with
neurotuberculosis. The extrapolation of adult data that
support therapeutic delay may not always be appropriate in
young children who experience higher mortality in the
absence of cART.
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INSTRUCTIVE CASES
Abstract: Neurologic tuberculous pseudoabscesses that clinically pro-
gress despite conventional antituberculosis therapy may be responsive to 
adjuvant thalidomide, a potent tumor necrosis factor-α inhibitor. In this 
study, the addition of thalidomide provided substantial clinical benefit 
in the majority of patients, and magnetic resonance imaging evolution 
of lesions from early-stage “T2 bright” with edema to “T2 black” repre-
sented a marker of cure.
Key Words: tuberculous meningitis, tuberculous pseudoabscess, thalidomide, 
tumor necrosis factor-α
(Pediatr Infect Dis J 2015;34:214–218)
/eurologic tuberculous granulomas (tuberculomas) display-ing evidence of liquefactive necrosis, that is, tuberculosis 
(TB) pseudoabscesses, identified on account of marked computed 
tomography central hypointensity and magnetic resonance (MR) 
T2-weighted hyperintensity, are known to develop or enlarge 
despite appropriate antituberculosis (anti-TB) treatment. This 
form of TB, assumed to be associated with immune reconstitution 
inflammatory syndrome (IRIS), is often more severe in the setting 
of HIV coinfection and can be life threatening.1 It typically occurs 
within the first 3 months of anti-TB therapy.1
Clinical manifestations depend on the size and location of 
the lesion(s) and include focal neurologic signs, ataxia, spastic 
paraplegia and raised intracranial pressure due to cerebrospi-
nal fluid obstruction.1 Most TB granulomas will resolve during 
anti-TB treatment and corticosteroids, and duration of therapy is 
guided by clinicoradiologic response. In contrast, TB pseudoab-
scesses tend to have a more accelerated clinical course and are 
unresponsive to standard therapy. Drainage and excision may 
offer the only chance of cure,2 but lesion location within the basal 
cisterns and inadequate neurosurgical facilities usually combine 
to preclude surgical management. In our experience, TB pseudo-
abscesses respond to thalidomide, a potent tumor necrosis factor 
(TNF)-α inhibitor.3
PATIENTS AND METHODS
Tygerberg Children’s Hospital in the Western Cape province, 
South Africa, provides specialized care to half of the province’s 1.2 
million children. All children (aged 0–14 years) with neurological 
TB mass lesions (including both tuberculomas and TB pseudoab-
scesses) presenting from January 2011 through January 2014 who 
were treated with thalidomide were included in a prospective obser-
vational study.
At Tygerberg Children’s Hospital, children with TB menin-
gitis (TBM) are treated with isoniazid (20 mg/kg, maximum 400 mg 
daily), rifampin (20 mg/kg, maximum 600 mg daily), pyrazinamide 
(40 mg/kg, maximum 2 g daily) and ethionamide (20 mg/kg, max-
imum 750 mg daily) for 6 months.4 Treatment is prolonged to 9 
months in cases with HIV coinfection and isoniazid monoresist-
ance. In children with TB mass lesions, duration of treatment is 
determined by clinicoradiologic response. Corticosteroids (pred-
nisone 2 mg/kg, maximum 60 mg daily) are prescribed for the first 
4 weeks of therapy in all children with suspected TBM. HIV test-
ing is routinely done on all children with suspected TB following 
informed consent from the parent or legal guardian.
Standard practice at our hospital is to prescribe 3–5 mg/
kg/d of thalidomide (50-mg or 100-mg capsules, Thalidomide 
Celgene; Celgene Europe Limited, Stokely, London) to all chil-
dren who develop life-threatening TB mass lesions and TB-related 
optochiasmatic arachnoiditis despite anti-TB treatment and cor-
ticosteroids. Thalidomide, an unregistered drug in South Africa, 
is supplied under section 21 from the South African Medicines 
Control Council. Informed consent to use it was obtained from the 
parents/legal guardians and Tygerberg Hospital Drug-and-Thera-
peutics Committee. Nerve conduction studies were performed in 
all children when the cumulative drug dose exceeded 20 g.
1.5T MR imaging was used for the routine examination of 
T2 weighted imaging, fluid attenuation inversion recovery (FLAIR) 
and T1 weighted imaging without and with contrast, with identi-
cal fields of view. In all children compromised by neurologic TB 
mass lesions, MR imaging is performed at 3 monthly intervals 
or earlier when clinically indicated. The study was approved by 
the Health Research Ethics Committee of Stellenbosch University 
(N12/07/041).
RESULTS
The median age of the 16 consecutive children studied 
was 39 months (range, 8–168 months); 8 (50%) were female and 
4 (25%) were HIV-infected children. No parent/legal guardian 
refused thalidomide treatment. Table 1 illustrates patient demo-
graphics, duration of anti-TB therapy until occurrence of neuro-
logical TB mass lesions, site of the lesions, clinical presentation, 
thalidomide dosages, Mycobacterium tuberculosis culture results, 
duration of TB therapy and outcome of the 4 HIV-infected chil-
dren treated for neurologic tuberculous mass lesions. Table 2 illus-
trates the same information in the 12 HIV-uninfected children. The 
mean duration for development of the TB mass lesion (paradoxical 
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TB-IRIS) after initiation of anti-TB treatment was 3 months (range, 
0–5 months). HIV-related paradoxical TB-IRIS occurred within 8 
weeks of antiretroviral therapy initiation in all of the HIV-infected 
children.5
The most common lesion sites demonstrated by neuroradiol-
ogy were suprasellar cisternal (n = 7), followed by brainstem (n = 
4), temporal lobe (n = 3), cerebellum (n = 3) and spinal cord (n = 
2). Three of the 16 children presented with convexity disease (large 
dural-based lesions) without radiologic evidence of basal menin-
geal disease (cases 1–3).
The median thalidomide dose was 3.8 mg/kg/d (range, 2.2–
5.0 mg/kg/d), the median duration of administration was 6 months 
(range, 2–12 months) and median cumulative dose was 9 g (range, 
3–31.5 g). Nerve conduction studies proved normal in the 4 chil-
dren when the cumulative thalidomide dose exceeded 20 g. None 
of the study children experienced rashes, hepatitis or hematologic 
derangements or complained of leg cramps. The median duration 
of anti-TB treatment was 15 months (range, 6–27 months). Nine 
of the 16 cases (56%) had culture-confirmed TB; 6 children had 
drug-susceptible TB, 2 had isoniazid monoresistant TB and 1 child 
had multidrug-resistant (MDR)-TB (resistance to isoniazid and 
rifampin) (case 3). Four children were treated as MDR-TB without 
culture confirmation due to deterioration on first-line drugs.
Thirteen children (81%) made a complete recovery, but 1 
virally suppressed HIV-infected child had reactivation of disease 
14 months after completing 18 months of MDR-TB treatment and 
is again on treatment (case 4). Two children (13%) are still on treat-
ment and doing well, and 1 child died (case 5). Following introduc-
tion of thalidomide, there was cessation of TB mass lesion-associated 
epilepsy partialis continua within 2 weeks of therapy in both cases, 
resolution of ataxia within 4 weeks and restoration of walking in 
previously paraplegic children after 6 months. Of the 5 children who 
presented with hemiplegia, 3 recovered fully while 2 children have a 
remaining mild motor deficit. One HIV-uninfected child died (case 5): 
this child presented with blindness, initially had clinical and radiologic 
improvement, but then progressed to florid TB-IRIS-related basal 
enhancement (MR T1+C) with brainstem signal alteration consistent 
with ischemia. Two children with extensive suprasellar granuloma-
tous inflammation developed hypopituitarism, which necessitated 
growth hormone and thyroxin replacement therapy (cases 4 and 6).
Despite thalidomide, 2 HIV-infected children developed fur-
ther paradoxical enlargement of pseudoabscesses, requiring surgical 
drainage during treatment (cases 1 and 3). In one of the children, 
enlargement of a right-sided parietal lobe pseudoabscess (central 
T2 hyperintensity, ring enhancement) resulted in obstructive hydro-
cephalus (case 1). This occurred after 4 weeks of anti-TB treatment 
and thalidomide with rapid clinical improvement following drain-
age. The fluid exudate from this lesion contained no visible organ-
isms or neutrophils and was culture-negative and polymerase chain 
reaction-negative for M. tuberculosis (Xpert MTB/RIF; Cepheid, 
 Sunnyvale, CA). In another HIV-infected patient, progression of a large 
dural-based TB mass lesion necessitating surgical drainage occurred 
despite 9 months of MDR-TB treatment, 3 months of thalidomide 
and 4 months of mycophenolate mofetil, another anti- inflammatory 
drug (case 3). The aspirate contained moderate numbers of TB bacilli 
but was culture negative. This child had failed MDR-TB treatment, 
becoming again M. tuberculosis culture positive on sputum specimen 
after being culture negative for 8 months; the drug-susceptibility test 
result showed additional resistance to ofloxacin. His anti-TB treat-
ment regimen was changed, his sputum became culture negative (now 
>15 months culture negative), and he is still on treatment.
In all children, clinical improvement followed a reduction in per-
ilesional edema and preceded regression in lesion size on MR imaging 
(see Figs., Supplemental Digital Content 1–4, http://links.lww.com/ 
INF/C10, http://links.lww.com/INF/C11, http://links.lww.com/
INF/C12, http://links.lww.com/INF/C13). Enlargement of an exist-
ing TB mass lesion and/or appearance of new lesions (TB-IRIS) 
occurred in 5 children on treatment despite clinical improvement.
MR imaging revealed mass lesions in different locations, as 
well as displaying different signal intensities on the T2WI. In the 
majority of cases (n = 13), paradoxically enlarging mass lesions 
arose within the interpeduncular-suprasellar cistern and its imme-
diate environment during the course of the basal meningeal inflam-
matory reaction (TBM). Three of the 16 children presented with 
large, dural-based convexity lesions (see Fig., Supplemental Digi-
tal Content 1, http://links.lww.com/INF/C10), without concomitant 
basal meningeal disease, consistent with origin from a superficial 
meningocerebral necrotic granuloma or Rich focus.6
As has been observed before, the majority of intracranial 
tuberculomas display central, nonenhancing, inhomogeneous 
T2 hypointensity, which has been shown to represent necrosis of 
inflammatory granulation tissue, that is, gummatous necrosis.7 Less 
commonly, the nonenhancing core is strongly, homogeneously T2 
hyperintense, that is, T2 bright, and the fluid necrotic-apoptotic 
substrate is demonstrably macrophage-predominant, neutrophil-
poor, consistent with pseudoabscess formation.7 In all those chil-
dren with such “T2-bright” lesions, treatment resulted in a gradual 
conversion of T2 hyperintensity to hypointensity (see Figs., Sup-
plemental Digital Content 1–4, http://links.lww.com/INF/C10, 
http://links.lww.com/INF/C11, http://links.lww.com/INF/C12, 
http://links.lww.com/INF/C13). These resultant, homogeneous 
“T2-black” granulomas (with peripheral or capsular T1 contrast 
enhancement) tended to persist for many months in asymptomatic 
children without relapse (see Fig. E and F, Supplemental Digital 
Content 1, http://links.lww.com/INF/C11).
DISCUSSION
In all the study patients, marked clinical improvement asso-
ciated with imaging evidence of reduction in perilesional edema 
and regression in lesion size was observed after thalidomide was 
added to the anti-TB regimen (see Figs., Supplemental Digital Con-
tent 1–4, http://links.lww.com/INF/C10, http://links.lww.com/INF/
C11, http://links.lww.com/INF/C12, http://links.lww.com/INF/
C13). In 5 children, enlargement of the mass lesion and appear-
ance of new discrete mass lesions occurred on thalidomide treat-
ment despite clinical improvement and was attributed to further 
IRIS response.
Regression was associated with fibrosis, mineralization 
(calcification) and finally disappearance, usually with no struc-
tural residuum (see Fig. F, Supplemental Digital Content 1, http://
links.lww.com/INF/C12). Neither primary T2 signal shortening in 
“T2-black” granulomas nor its evolution in the course of pseudo-
abscess regression has been explained, although change in the con-
centration of free radicals have been suspected.8 We assume that 
the varying imaging T2-FLAIR signal intensities of these granulo-
mas may be attributed to individual cytokine profiles which deter-
mine the character of the necrotizing process and the extent of the 
surrounding inflammatory edema. Thus, each granuloma may be 
expected to have a different outcome depending on the patient’s 
immunophenotype and the probability that liquefactive necrosis 
is the result of TNF-α production excess. This must represent an 
unsatisfactory immune response, since pseudoabscess formation 
(ie, macrophage-predominant exudation) is known to be rich with 
bacilli, as well as following a progressive, treatment-unresponsive 
course. In the child presenting with blindness, serial MR imaging 
showing resolution of optochiasmatic and perivascular enhance-
ment on the introduction of thalidomide was assumed to represent 
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a specific anti-inflammatory effect (see Fig., Supplemental Digital 
Content 1, http://links.lww.com/INF/C14).
Although the beneficial response of TB pseudoabscesses to 
thalidomide appears to be consistent in our cases, the exact mecha-
nism of action remains unclear. Thalidomide activates natural killer 
T cells, inhibits apoptosis of lymphocytes and ameliorates the 
interaction of T cells and dendritic cells.9 It also affects monocyte 
cytokine levels by inducing Th2 cytokine production (interleukin-4 
and interleukin-5) while concomitantly inhibiting Th1 cytokine 
production (interferon-γ), thereby switching the immune response 
from Th1 to Th2 type.10 Schoeman et al11 reported marked decreased 
levels of TNF-α in the cerebrospinal fluid of TBM patients on tha-
lidomide treatment. Thalidomide also reduced TNF-α levels in the 
lungs of mice and cerebrospinal fluid of rabbits which led to less 
necrosis and decrease in granuloma size.12
Thalidomide can be safely used in HIV-infected TBM chil-
dren as it has been shown to enhance HIV-specific CD8 T-cell 
function without affecting the viral load.13 An additional benefit is 
reduction of HIV-associated wasting.14 Prolonged thalidomide ther-
apy can cause sensory axonal neuropathy, which may be exacer-
bated by the combined use of TB drugs and antiretroviral therapy.15 
This complication was not observed in any of the children in our 
study.
TB reactivation occurred in 1 of the HIV-infected, virally 
suppressed, TB culture-negative study patient (case 4). This child’s 
failure to control M. tuberculosis infection was assumed to be in 
some way associated with HIV infection or possibly drug-resistant 
TB. Studies have shown that the life-long risk of TB disease is 50% 
in subjects coinfected with M. tuberculosis and HIV, compared with 
10% in HIV-uninfected subjects,16 a status directly related to the 
degree of CD4 T cells loss.16 Of interest in this patient was imag-
ing evidence of white-matter signal alteration (see Fig. E, Supple-
mental Digital Content 1, http://links.lww.com/INF/C12) assumed 
to represent inflammatory edema, which preceded the appearance 
of clinical symptoms by 7 months, emphasizing the importance of 
serial MR imaging, even in asymptomatic patients.
It is our experience that adjuvant thalidomide therapy should 
be reserved for children who develop neurologic compromise from 
enlarging TB pseudoabscesses. This complication is most fre-
quently encountered in cisternal and dural-based lesions as they 
expand into areas of lesser resistance. Small, asymptomatic cer-
ebral parenchymal TB pseudoabscesses usually resolve on standard 
TBM therapy. The rate of clinical improvement following initiation 
of thalidomide varies according to the location, number and size of 
the TB pseudoabscesses. In the majority of cases, clinical improve-
ment ensues within 2 weeks of therapy. Local practice is to perform 
serial MR imaging at 3 monthly intervals; satisfactory radiologic 
response represents a reduction in perilesional edema and a lesser 
degree of T2 brightness (after 3 months) and regression in lesion 
size with loss T2 signal (after 6 months). We believe that evolution 
of TB pseudoabscesses from early-stage “T2 bright” with edema to 
“T2 black” lesions represents a marker for cure (see Figs., Supple-
mental Digital Content 1-4, http://links.lww.com/INF/C10, http://
links.lww.com/INF/C11, http://links.lww.com/INF/C12, http://
links.lww.com/INF/C13). Children on thalidomide require regular 
(weekly) monitoring for skin rashes, neutropenia, thrombocytope-
nia and hepatitis. Nerve conduction studies should be performed 
where the cumulative thalidomide dose exceeds 20 g. Neuroendo-
crine evaluation should be performed in all children with supra-
sellar TB pseudoabscesses.
The study highlights the importance of serial MR imaging 
in identifying the nature of the necrotizing process and evaluating 
treatment response and duration. Thalidomide should be consid-
ered as adjunctive therapy in all children with TB pseudoabscesses 
that clinically progress despite conventional anti-TB therapy.
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Figure 1 A-F: Sequential magnetic resonance imaging (MRI) of an 8-year-old HIV-infected male with 
tuberculous meningitis (case 3). Figure 1 A&B. MRI Coronal T1WI post-gadolinium and axial T2WI 
demonstrating a heterogenous lobulated dural-based lesion in the left parafalcine region with intense 
enhancement 9 months after starting TB treatment. Figure 1 C&D. MRI Coronal T1WI post-gadolinium and 
axial T2WI shows the patient 3 months later with an impression of T2 hypo-intense ring lesions, with associated 
hyper-intense centres within the lobulated mass. Post contrast appearance is that of a cluster of ring-enhancing 
smaller lesions. Figure 1 E&F. MRI Coronal T1WI post-gadolinium and axial T2WI done at a further 4-month 
interval demonstrate deterioration with enlargement and posterior extent of the lesion. There are large areas of 
confluence of hyper-intensity within the mass and it now has an appearance similar to large ring-enhancing 
collections. 
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Figure 2A: Magnetic resonance axial T2-weighted imaging on admission (pre-treatment) in a 6-year-old ataxic 
female with a large cerebellar TB abscess surrounded by smaller abscesses (case 13). 1B: Reduction in 
perilesional edema after 3 months of thalidomide. Figure 1C-F demonstrates gradual loss of T2-signal and 
reduction in lesion size after 6, 10, 31 and 41 months. The patient was asymptomatic within 5 months and 
thalidomide was stopped at 9 months and anti-TB drugs at 12 months. Figure 2A-F demonstrates the gradual 
evolution, on sequential studies, of all these abscesses to homogenous hypo-intense lesions with reduction in size 
and perilesional edema. 
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Figure 3A&B: Magnetic resonance Axial T2 and T1-weighted post-gadolinium images on admission in a 14-
year-old HIV-infected male (case 4) demonstrating multiple small T2 hyper-intense, ring-enhancing lesions in 
the suprasellar and right middle cerebral artery cisterns with significant perilesional edema. Figure 3C&D: Axial 
T2 and T1-weighted post-gadolinium images depicts the evolution to T2 hypo-intensity with reduction in 
surrounding edema but significant residual ring enhancement one year later. Figure 3E: Axial T2-weighted 
image shows recurrent increase in the perilesional edema, a further 10 months post treatment in an asymptomatic 
child, with the signal characteristics of the lesions unchanged. Figure 3F: The patient presents 19 months after 
previous imaging and is now symptomatic. Post contrast axial CT demonstrating coarse calcification in the 
evolved lesions although significant oedema is now demonstrated. Figure 3G: Corresponding T2-weighted axial 
image demonstrating no hyper-intense lesions but significant perilesional edema. 
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Figure 4A&B: Magnetic resonance T2WI and T1WI sagittal post-gadolinium images of a 4-year-old female 
(case 7) presenting with a spastic paraplegia demonstrated a lobulated heterogeneous ring-enhancing 
intramedullary TB granulomas extending from T2-T4. An associated syrinx is seen extending from C1-7 level. 
Figure 4C: MRI T2WI after 5 months of thalidomide shows gradual loss of T2 with the syrinx markedly 
decreased in size. The patient is now able to walk. Figure 4D: MRI T2WI 14 months later, 8 months after 
completion of anti-TB treatment and 7 months after completion of thalidomide. The granulomas are now T2 
hypo-intense, with nearly no distinguishable syrinx. The patient is asymptomatic with no functional impairment. 
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Figure 5A&B: Magnetic resonance imaging axial (A) and sagittal (B) T1WI post-gadolinium images of a 2-year-
old male (case 5) with visual impairment secondary to tuberculous optochiasmic arachnoiditis. This shows 
extensive severe suprasellar enhancing exudates involving the optic chiasm and proximal optic nerves as well as 
extending into bilateral middle cerebral artery and interpeduncular cisterns. The sagittal image demonstrates the 
perivascular inflammation in the middle cerebral artery cistern. Figure 5C&D: Repeat MRI axial (C) and sagittal 
(D) T1WI post-gadolinium images following 3 months of thalidomide demonstrating marked interval 
improvement with reduction in the extent of the exudates as well as near complete resolution of perivascular 
inflammation, depicted on the sagittal image (D). 
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Abstract
Purpose Transcranial Doppler imaging (TCDI) is potentially
a valuable investigational tool in children with tuberculous
meningitis (TBM), a condition often complicated by patholo-
gy relevant to Doppler imaging such as raised intracranial
pressure (ICP) and cerebral vasculopathies.
Methods Serial TCDI was performed on 20 TBM children
with the aim of investigating cerebrovascular haemodynamics
and the relationship between pulsatility index (PI) and ICP.
Results We observed a poor correlation between ICP and PI in
children with communicating hydrocephalus (p=0.72). No
decline in PI was noted following 7 days of medical therapy
for communicating hydrocephalus (p=0.78) despite a con-
comitant decline in ICP. Conversely, a decline in PI was noted
in all four children with non-communicating hydrocephalus
who underwent cerebrospinal fluid diversion. High blood
flow velocities (BFV) in all the basal cerebral arteries were
observed in 14 children (70 %). The high BFV persisted for
7 days suggesting stenosis due to vasculitis rather than func-
tional vasospasm. Complete middle cerebral artery (MCA)
occlusion, subnormal mean MCA velocities (<40 cm/s) and
PIs (<0.4) correlated with radiologically proven large cerebral
infarcts.
Conclusions TCDI-derived PI is not a reliable indicator of
raised ICP in children with tuberculous hydrocephalus. This
may be attributed to individual variation of tuberculous vas-
cular disease, possibly compromising cerebral vascular
compliance and resistance. Basal artery stenosis secondary
to vasculitis is observed during the acute stage of TBM in
the majority of children.
Keywords Tuberculousmeningitis . Transcranial Doppler .
Pulsatility index . Intracranial pressure . Mean blood flow
velocity
Introduction
Transcranial Doppler imaging (TCDI) is a safe, portable, non-
invasive, inexpensive and non-ionizing method of assessing
cerebral hydrodynamics and haemodynamics [1]. It can be
repeated multiple times and used for serial monitoring. TCDI
may provide accurate information on intracranial pressure
(ICP) and cerebral blood flow velocities (BFV) which may
help guide therapy in critically ill patients [1]. This applies
especially to resource-poor countries where expensive moni-
toring equipment is often not available. However, controversy
exists whether TCDI-derived pulsatility index (PI) is a reliable
marker of raised ICP. Some studies report a linear relationship
between the PI and measured ICP in hydrocephalic children,
whilst others have failed to find such correlation [2–6].
To date, only one study examined the potential role of
TCDI in tuberculous hydrocephalus [7]. Two groups of 15
children with tuberculous hydrocephalus and congenital hy-
drocephalus were prospectively examined by TCDI before
and after cerebrospinal fluid (CSF) diversion. A clinically
relevant fall in PI after CSF diversion only occurred in chil-
dren with congenital hydrocephalus (p=0.007). In tubercu-
lous meningitis (TBM) patients with infarcts, there was no
statistically significant drop in the PI pre- and post-shunt
procedure.
TCDI also allows evaluation and monitoring of cerebral
basal artery haemodynamics. Studies report an inverse
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relationship between ICP and cerebral blood flow (CBF) in
young children with meningitis and hydrocephalus [8, 9].
Ventricular peritoneal shunting permits a sudden increase in
CBF and BFV, and increases of above 30 % have been
reported [10]. Only one study investigated the use of TCDI
in tuberculous cerebral vasculopathy [11]. This study found
that TCDI allows distinction of three phases of arteriopathy
(i.e. vasospasm, vasodilatation and stenosis). The study found
a good correlation between each of the three stages with
clinical findings (Glasgow coma score), radiological findings
(ischemia on magnetic resonance imaging [MRI]) and
outcome.
The present study sought to investigate the potential
role of serial TCDI in the assessment of tuberculous
hydrocephalus-related raised ICP and interventions aimed
at reducing ICP, and the role of serial TCDI as a dynamic
modality in the assessment of TBM-related vasculopathy
and its possible predictive value in terms of the develop-
ment of infarcts.
Material and methods
The study was conducted at Tygerberg Children’s Hospital, a
tertiary referral hospital in Cape Town, South Africa. The
study population comprised 20 children less than 13 years of
age who were admitted for TBM from June 2012 to June
2013.
A definite diagnosis of TBM was made when Myco-
bacterium tuberculosis was cultured and/or polymerase
chain reaction (PCR)-positive from CSF. In all other
cases, the diagnosis was “probable TBM” based on
clinical signs of meningitis in the presence of charac-
teristic CSF findings (macroscopically clear, pleocytosis
usually with lymphocyte predominance, elevated protein
and reduced glucose). In addition, two of the following
criteria were required: other clinical specimens culture-
positive for M. tuberculosis and/or positive TB histolo-
gy, a positive tuberculin skin test, a chest radiograph
compatible with TB, a cranial computerized tomography
(CT) or MRI compatible with TBM, growth failure with
crossing of weight-for-age percentiles or finally, house-
hold contact with a sputum smear-positive pulmonary
TB case.
The severity of disease was classified according to
the refined Medical Research Council classification [12].
All children underwent contrasted CT imaging at admis-
sion. The degree of hydrocephalus was expressed as the
Evans ratio (maximum ventricular width divided by the
largest biparietal distance between the inner tables of
the skull); a ratio of larger than 0.3 is indicative of
hydrocephalus [13]. The site and size of all infarcts
were recorded.
All children underwent short intensified anti-TB treatment
(6 months of rifampicin, isoniazid, pyrazinamide and ethion-
amide [RHZEth] for HIV-uninfected and 9 months RHZEth
for HIV-infected children. Children with non-communicating
hydrocephalus, as determined by air encephalography, were
referred for immediate ventriculoperitoneal shunting (VPS) or
endoscopic third ventriculostomy (ETV). All children with
communicating hydrocephalus were treated medically with
acetazolamide (50 mg/kg/day) and furosemide (1 mg/kg/
day) during the first month of therapy to expedite normaliza-
tion of ICP.
All TCDI studies were performed by one investigator
(RVT) as a bedside investigation using a GE Healthcare Vivid
S5 high-end Ultrasound machine (General Electric Medical
Systems, Milwaukee, USA) with a 2-MHz probe. Recordings
were performed on admission and repeated after 3 and 7 days.
The transtemporal window was used to isonate the anterior
cerebral artery (ACA), middle cerebral artery (MCA) and
posterior cerebral artery (PCA). The main horizontal section
of the MCA from its origin to the limen insulae was isonated.
This M1 segment of the MCA gives rise to numerous, small
lenticostriate or perforating branches which are most com-
monly affected in TBM. Different depth range, flow direction
and normal age-related flow velocity ranges have been
established for each vessel [14]. The vessels were identified
using these parameters.
Recorded parameters included peak, mean and diastolic
flow velocities and PI. The PI is calculated by the Gosling
index (PI=peak systolic velocity−end diastolic velocity) di-
vided by the mean velocity. The normal range of PI in the
MCA is 0.5–1.1 [14]. Studies evaluating the variability in
normal individuals found the PI to vary between 0.69 and
0.71 for the MCA, ACA and PCA, and there were no signif-
icant (>20 %) side-to-side or day-to-day differences [14]. The
PI is automatically calculated and displayed on the TCDI
instrument. Sample volumes were taken at a standardized
distance from the Circle of Willis in all vessels bilaterally to
allow for meaningful interpretation on follow-up examina-
tions. At least three readings per vessel were made at each
evaluation and the average measurement was used. Indices
were determined using at least three cardiac cycles of visually
and audibly good quality. In children with focal neurological
deficits or radiological proven infarcts, PI measurements from
the unaffected side (cerebral hemisphere) were used.
The peak systolic velocity was used to define the presence
of stenosis. A peak systolic velocity of less than 140 cm/s was
considered to indicate a normal artery [14]. The degree of
stenosis was qualified according to the published criteria and
was graded into three categories: grade I (140–209 cm/s),
grade II (210 to 280 cm/s) and grade III (>280 cm/s). MCA
occlusion was diagnosed if all the basal arteries except the
MCA in question were detectable or if the asymmetry index of
the symptomatic MCAwas <21 % compared with that of the
Childs Nerv Syst
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contralateral MCA. The Lindegaard index (the ratio of the
MCAvelocity to the extracranial internal carotid artery veloc-
ity) was used to distinguish cerebral vasospasm from hyper-
emia [14]. Vasospasmwas diagnosed in cases where the mean
MCA flow velocity exceeded 120 cm/s, and the Lindegaard
ratio was more than 3.
TCDI measurements may be influenced by different phys-
iological and pathological factors such as age, gender, hemat-
ocrit, fever, hypoglycemia, heart rate, blood pressure and
drugs with either vasodilatation or vasoconstriction properties.
All physiological parameters were kept stable during the
TCDI examination. Carbon dioxide (PaCO2) levels were not
measured as angiographic studies have demonstrated that the
larger human basal cerebral arteries are unresponsive (at least
within the tolerances of measurements) to changes in PaCO2,
while arteries that had diameters less than 1 mm responded
[15]. None of the TBM children were ventilated or exhibited
abnormal breathing patterns during the TCDI.
Lumbar CSF pressure was recorded immediately after
TCDI upon admission, after 3 and 7 days. The opening
pressure measurement was determined using the highest rest-
ing CSF level, in centimetres H2O, when sustained for at least
10 s. A CSF baseline pressure of greater than 20 cm H2O was
considered indicative of raised ICP in children with commu-
nicating hydrocephalus.
Neurological outcome at 6 months was divided into the
following four categories: (1) normal, including normal motor
function, intelligence, vision and hearing; (2) mild sequelae,
including hemiparesis, mild intellectual impairment and im-
paired vision and/or hearing; (3) severe sequelae, including
quadriparesis, severe intellectual impairment, blindness and/
or deafness; and (4) death. Clinical outcome was defined as
“good” in the case of normal and mild neurological sequelae
and “poor” in children with severe neurological sequelae or
death.
The study was approved by the Health Research Ethics
Committee of Stellenbosch University (N12/07/041).
Results
Of the 20 children with TBM,median age of 37months (range
4–140 months), 12 (60 %) were male. Sixteen (80 %) of the
children presented with stage II TBM, three (15 %) with stage
III TBM and one (5 %) had stage I TBM; three (15 %) were
HIV-infected. In seven children (35 %), M. tuberculosis was
isolated from gastric aspirates (n=6) or CSF (n=1); six iso-
lates proved drug-susceptible and one was isoniazid-
monoresistant.
Sixteen (80 %) children had communicating hydrocepha-
lus; in the four (20 %) children with non-communicating
hydrocephalus, three underwent VPS and one ETV. Ten of
the 16 (62 %) children with communicating hydrocephalus
had elevated ICP on admission (median ICP 35 cm H2O,
range 22–55). Eight (40 %) had visible infarcts on admission
cranial CT imaging. No correlation was found between the
ventricular size (Evans’ index) on CTand ICP in children with
communicating hydrocephalus (p=0.73).
Figure 1 illustrates the poor correlation between serial ICP
and PI (43 measurements) in the 16 children with communi-
cating tuberculous hydrocephalus (p=0.72). Cases with con-
firmed non-communicating hydrocephalus were not included
in this correlation because lumbar CSF pressure does not
necessarily reflect ICP in this condition. Figure 2 illustrates
the change in ICP on days 1, 3 and 7 in the 16 children who
underwent medical treatment for communicating hydroceph-
alus. In all cases, the ICP normalized within 7 days after
initiation of acetazolamide and furosemide. In contrast, there
was no significant decline in the PI after 7 days of medical
therapy (p=0.78). However, in all four children with non-
communicating hydrocephalus, the PI decreased following
CSF diversion (Fig. 3).
Bilateral MCA stenosis on admission was detected in 14
(70 %) of the 20 TBM children; 10 had grade I stenosis and 4
had grade II stenosis (Fig. 4). Serial TCDI on days 1, 3 and 7
showed no change in the grade of stenosis in 11 children,
improvement in 2 and deterioration in 1. One child initially
presented with a grade II MCA stenosis (Lindegard index >3)
which normalized on day 3 and remained normal on day 7.
This indicates vasospasm. There was no significant difference
in peak systolic flow velocities on day 1 compared to day 7 in
the 20 TBM patients (p=0.80). Similarly, there was no signif-
icant difference in the mean MCA BFVon day 1 compared to
day 7 in the 16 children with communicating hydrocephalus
(p=0.18).
Side-to-side differences in MCA flow velocities were de-
tected in four of the eight children with radiologically proven
infarcts. In two of the children, subnormal mean MCAveloc-
ities (≤40 cm/s) and PI (≤0.4) resulted in ipsilateral infarction.
Complete MCA occlusion (all other basal arteries detectable
except the MCA in question) occurred in the other two chil-
dren; both had large MCA infarcts on CT and severe
hemiplegias.
Eighteen (90 %) of the 20 children had a good outcome
after 6 months of treatment. The two children with poor
outcome both had stage III disease, infarcts on CT and sub-
normal and declining PI and mean MCA velocities on TCDI.
All children with a good outcome had normal TCDI.
Discussion
For optimal management of acute TBM in children, ICP
should be measured in order to determine its contribution to
the patient’s neurological state (e.g. coma) and because it is
treatable. Studies have shown that clinical diagnosis of the
Childs Nerv Syst
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presence and degree of raised ICP is unreliable, especially in
children with closed anterior fontanels [16]. The value of CT
imaging is limited by the poor correlation between the degree
of hydrocephalus (ventricular size) and ICP [16]. Similarly, in
this study, no correlation was found between ventricular size
on CT and the degree of raised ICP (p=0.73).
Many non-invasive techniques of measuring ICP have been
evaluated, such as intraocular pressure, tympanic membrane
displacement and measurement of intracranial blood flow [17].
None has been found reliable enough to replace invasive pro-
cedures. Lumbar CSF pressure measurement in TBM accurate-
ly reflects ICP in children with communicating tuberculous
hydrocephalus. In this condition, it can be repeatedly done to
monitor the course without any danger to the patient; repeated
lumbar puncture has even been advocated as a safe although
invasive treatment option for communicating hydrocephalus in
TBM [18]. In contrast, lumbar CSF pressure does not reflect
ICP in non-communicating tuberculous hydrocephalus; in this
condition, a lumbar puncture may result in cerebral
transtentorial or uncal herniation with dire consequences for
the patient. A non-invasive method of measuring ICP in chil-
dren with TBMwould therefore potentially be of great value, as
it may assist with identification of hydrocephalic children who
require CSF drainage procedures, assist with assessment of
shunt function, confirm fenestration patency in patients with
non-communicating tuberculous hydrocephalus who
underwent ETV and assist with evaluating the therapeutic
effects of ICP-lowering drugs such as mannitol and diuretics.
Fig. 2 Illustration of the ICP on
days 1, 3 and 7 in 16 TBM
children with communicating
hydrocephalus following medical
therapy consisting of
acetazolamide and furosemide
Fig. 1 Fit plot for intracranial
pressure (ICP). Illustration of the
poor correlation between ICP and
pulsatility index in the 16 children
with communicating
hydrocephalus on days 1, 3 and 7
Childs Nerv Syst
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In our study, TCDI-related PI was found not to be an
accurate method of assessing ICP in children with communi-
cating tuberculous hydrocephalus. No linear correlation was
found between PI and ICP (p=0.72). This may be attributed to
individual variation of tuberculous vascular disease, possibly
compromising cerebral vascular compliance and resistance. It
has been suggested that absolute PI values should be read with
extreme caution, even at the extremes of ICP values, and that
TCDI can play an important role as a means of monitoring
pressure changes over time [3]. In our study, no decline in PI
was noted following 7 days of medical therapy for communi-
cating hydrocephalus, despite a confirmed decline in ICP.
Conversely, a decline in PI was noted in all four children with
non-communicating hydrocephalus who underwent CSF di-
version, most likely as a result of a more dramatic fall in ICP
in this group (Fig. 3). Larger studies are warranted to investi-
gate this finding and should ideally include pre- and post-
surgical ICP monitoring.
Carbonic anhydrase inhibitors (acetazolamide) and loop
diuretics (furosemide) exert their effect on ICP by reducing
CSF production at the choroid plexus [19]. Acetazolamide has
a rapid onset of action and has been found to reduce CSF
production in humans by 6–50% [20]. Inhibition of CSF flow
occurs once 99.5 % of choroid plexus carbonic anhydrase is
inhibited [21]. In children with communicating tuberculous
hydrocephalus, acetazolamide and furosemide in combination
have been found to be more effective in achieving normal ICP
than antituberculous drugs alone [16]. In this study, rapid
normalization of ICP occurred within 7 days of therapy in
all 10 cases of communicating tuberculous hydrocephalus
who had elevated ICP (Fig. 2). Acetazolamide has also been
shown not to alter the cerebral metabolic rate of oxygen,
which is beneficial in children with TBM-related ischemic
brain disease [22].
Acetazolamide also increases CBF by 5–80 % [22]. High
bilateral MCA BFVupon admission was observed in 70 % of
the TBM children. This occurred prior to acetazolamide ad-
ministration and CSF sampling and can be ascribed to vessel
narrowing (or stretching on account of acute hydrocephalus
(ventricular dilatation) or spasm because of meningeal in-
volvement (as in acute subarachnoid haemorrhage)). In almost
all the children, high BFV persisted after 1 week which
supports vessel narrowing secondary to organic stenosis rather
than functional vasospasm. Functional vasospasm was ob-
served in only one child. In this child, no infarcts were
observed on CT and outcome after 6 months was normal.
Information regarding the sensitivity and specificity of
TCDI in the diagnosis of cerebral ischemia in general is
limited [23]. In this study, subnormal mean MCA BFV
(≤40 cm/s) and PI (≤0.4) were associated with CT infarction
in two children. The diminished MCABFV reflects decreased
perfusion (demand) to the infarcted area. Tuberculous vascu-
lopathy of the distal internal carotid artery may also account
for the diminished MCA BFV. In four children with territory
infarcts on admission, no side-to-side differences in MCA
BFV or subnormal PIs were detected. This can be attributed
to the occlusion of a limited number (one or two) of the nine
MCA perforators which has been shown not to affect the
haemodynamics of the MCA [23]. This could unfortunately
not be confirmed due to lack of concomitant MR angiography.
Fig. 4 Illustration of the peak middle cerebral artery systolic blood flow
velocity on admission compared to day 7 in 20 children with TBM
Fig. 3 Illustration of the change
in pulsatility index before and
after cerebrospinal fluid diversion
in four tuberculous meningitis
childrenwith non-communicating
hydrocephalus. Patients 1–3
underwent ventriculoperitoneal
shunting and patient 4 underwent
endoscopic third ventriculostomy
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Chapter 7 
General Conclusions 
 
Prognosis in tuberculous meningitis (TBM) is directly related to the clinical stage of disease. 
Other factors associated with poor outcome are multidrug-resistant tuberculosis (MDR-TB) 
and human immunodeficiency virus (HIV) co-infection.  
 
My first study concluded that outcome prognostication in childhood TBM can be improved 
by usage of the refined MRC staging system.1 This staging system has the highest predictive 
value (84%, 95% confidence interval [CI] 81-88) of all TBM staging systems. The modified 
MRC stage 2 disease-category is too inclusive as children without neurological deficit and 
only slight drowsiness (Glasgow Coma Scale [GCS] 14/15) are grouped together with 
children with neurological deficit and GCS of 10-13/15. This was confirmed by our study 
which found that the risk of severe motor deficit (spastic quadriplegia; p=0.028) and the 
degree of intellectual disability (p=0.001) were higher in children classified as stage 2b 
compared to stage 2a. The excellent predictive power of the simplified staging system 
(Tygerberg Children’s Hospital staging system) that I proposed makes it ideal for use in 
resource-poor settings. It is based on the patient’s ability to visually fixate and follow and the 
motor response to pain on both sides. The importance of early diagnosis in TBM is 
highlighted by the decline of 10 development quotient (DQ) points with every change to a 
lower disease category.  
 
Limitations of the TBM outcome study are the short period of follow-up (6 months), failure to 
evaluate behavioural outcome and lack of baseline neuroimaging. Long-term TBM outcome 
studies are lacking and no study has yet explored the effect of childhood TBM on adult 
survivors. Very few studies have investigated behavioural outcome after TBM. One study 
reported general behavioral disinhibitions as well as internalized emotional disorder are long-
term complications in more than 10% of TBM survivors.2 Accurate cognitive assessment is 
also notoriously difficult in young children. About a third of all children with advanced TBM 
will develop stroke.3 Most of these strokes are due to infarcts located in the middle cerebral 
artery (MCA) territories, particularly in the so-called “TB zone” which comprised of the 
caudate, anterior thalamus, anterior limb and genu of the internal capsule.4 Dysfunction of the 
basal ganglia may produce changes in a variety of behavioural and cognitive functions 
including learning, language, personality and social behaviour. This suggests that prospective 
TBM outcome studies should include baseline and sequential MRI imaging.     
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 The optimal anti-TB drug regimen and duration of treatment for TBM remains unknown. 
A recent health review on “Evidence behind the WHO guidelines: hospital care for children: 
what is the most appropriate treatment for tuberculous meningitis?” emphasized the need for 
further studies that investigate the efficacy and safety of intensive short-course chemotherapy 
in children with TBM residing in resource-poor settings.5 This review found that there were 
no published studies that investigated relapse rate in children who completed anti-TB 
treatment. The authors recommended that all trials assessing anti-TB treatment for TBM 
should include death and sequelae as primary outcome measures and a follow-up period of at 
least two years to assess relapses.5 
 
A recent systematic review and meta-analysis of childhood TBM studies published up to 
October 2012 reported a 19.3% (95% CI 14.0-26.1) risk of death and probability of survival 
without neurological sequelae of 36.7% (95% CI 27.9-46.4).6 Among survivors, risk of 
neurological sequelae was 53.9% (95% CI 42.6-64.9). The overall mortality of our short 
intensified regimen (3.8% at completion of treatment and good outcome in 80% of survivors) 
compares favorably with the above reported outcome.6 No relapses were encountered in any 
of the 179 study patients who survived treatment; 29 patients were lost to follow-up between 
treatment completion and the two-year follow-up period, which was the censoring period for 
relapse. Our short intensified regimen appears to be safe as anti-TB drug induced 
hepatotoxicity occurred in only 5% (8 out of 143 children tested) of the children, all tested 
negative for viral hepatitis; in all 8 cases the original regimen was restarted without 
recurrence.  
 
The short intensified treatment study, despite demonstrating good outcomes and a shorter 
duration of treatment, is observational without a randomized control group for comparison. It 
thus may provide insufficient evidence to change international policy. Our anti-TBM regimen 
also employs a drug (ethionamide) usually reserved for second-line treatment. This could 
have implications for acceptability by TB programmes.  
 
The potential benefit of intensified anti-TBM treatment was recently explored in two adult 
TBM randomized controlled trials (RCT). In an open-label, phase 2 trial with a factorial 
design, patients (aged > 14 years) with TBM were randomly assigned to receive, according to 
a computer-generated schedule, first rifampicin standard dose (450 mg, about 10 mg/kg) 
orally or high dose (600 mg, about 13 mg/kg) intravenously, and second oral moxifloxacin 
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400 mg, moxifloxacin 800 mg, or ethambutol 750 mg once daily.8 All patients were given 
standard-dose isoniazid, pyrazinamide, and adjunctive corticosteroids. After 14 days of 
treatment all patients continued with standard treatment for tuberculosis. Intensified treatment 
was associated with lower 6-month mortality (35% versus 65%) without increased toxicity 
which could not be explained by HIV status or severity of disease at the time of presentation.  
 
In another open-label, RCT from India, sixty patients on standard therapy consisting of 
isoniazid, pyrazinamide, ethambutol and adjunctive corticosteroids and aspirin, were 
randomized to receive either levofloxacin (10 mg/kg, maximum 500 mg) or rifampicin (10 
mg/kg, maximum 450 mg).9 The primary outcome was death and secondary outcome 
measures were 6 month disability and serious adverse effects. Levofloxacin was superior to 
rifampicin in reducing 6 months death but not disability.  The preliminary findings from adult 
studies highlight the need for a childhood RCT, evaluating alternative, and better palatable 
anti-TB drugs with fewer adverse effects but with at least similar efficacy to the regimen we 
currently advocate.  
 
Flouroquinolones possibly offer an alternative option to ethionamide as they demonstrate in 
vitro activity, tolerability, good bioavailability also in the cerebrospinal fluid and ease of 
administration.10 Increasing the dose of rifampicin may result in higher mycobacteriocidal 
activity in the brain and possibly greater survival.8       
 
Immune reconstitution inflammatory syndrome (IRIS) is a potentially life-threatening 
complication of antiretroviral therapy (ART) in HIV associated TBM.11 Little is known about 
the incidence, case fatality, underlying immunopathology and treatment approaches in HIV-
infected children with neurological TB-IRIS. In my case series, I found that neurological TB-
IRIS should be considered when new neurological signs develop after initiation of ART in 
children with TBM.12 Manifestations of neurological TB-IRIS include headache, seizures, 
meningeal irritation, decreased level of consciousness, ataxia and focal motor deficit.  
 
The mainstay of therapy in TB-IRIS in adults are corticosteroids with interruption of ART 
reserved for patients with severe life threatening complications or where the complication can 
cause disability.13 Other immune-modulating treatments are only described in adults with no 
reports in children. Studies are thus warranted to determine the optimal time of ART initiation 
in HIV-infected children with TBM. The extrapolation of adult data that support therapeutic 
76
Stellenbosch University  https://scholar.sun.ac.za
delay may not always be appropriate in young children who experience higher mortality in the 
absence of ART.  
 
Neurological TB mass lesions (tuberculomas/TB pseudo-abscesses) are known to develop or 
enlarge despite appropriate anti-TB treatment.14 This form of TB, assumed to be associated 
with IRIS, is often more severe in the setting of HIV co-infection and may be life threatening. 
It typically occurs within the first three months of anti-TB therapy.12 These lesions respond 
poorly to anti-TB treatment, and may require surgical excision, but may be responsive to 
thalidomide, a potent tumour necrosis factor-alpha (TNF-α) inhibitor.15 I found that serial 
magnetic resonance imaging (MRI) is of critical importance in identifying the nature of the 
necrotizing process, and evaluating treatment response and duration.16 The rapid clinical 
response of our patients supports our interpretation that thalidomide provides substantial 
clinical benefit. I also identified a MRI marker of cure i.e. evolution of lesions from early 
stage “T2 bright” with oedema to “T2 black.” This finding will be useful to clinicians 
managing these patients. 
 
The thalidomide study was an uncontrolled study by choice as a control group receiving a 
placebo would have been ethically unjustified. All the TB pseudo-abscess children were 
critically ill and the lesion location within the basal cisterns precluded surgical management. 
A study limitation was failure to evaluate CSF cytokine profiles (especially TNF-α and 
interferon [IFN]-γ levels) at baseline (onset of disease), onset of TB-IRIS and after adjuvant 
thalidomide therapy. Studies have shown that hypercytokinemia contribute to the pathology 
of TBM-IRIS.17  Recently, a combination of high CSF TNF-α and low IFN–γ concentrations 
was found to be predictive of TBM-IRIS. 18 Larger prospective studies are needed to elucidate 
the predictive and diagnostic value of IRIS biomarkers in children with TBM and advance 
them to clinical practice.  
 
The in-vitro down-regulating ability of thalidomide has not always been reproducible in-
vivo.19  Some studies even report no reduction in plasma TNF-α level in patients on 
thalidomide treatment. 20-21 Accurate measurement of TNF-α is difficult as it has a short half 
life; the normal circulating level has not been defined, its release in response to systemic 
infection is often phasic and serum or CSF levels may not accurate reflect TNF-α activity.19 
The latter is due to the fact that only the circulating form (not the membrane bound fraction) 
is typically measured. It furthermore remains a mystery how the brain-blood-barrier (BBB) is 
breached in human TBM infected patients. No animal study has yet achieved breach of the 
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BBB from experimental systemic infection as is the case in natural human infection. Animal 
studies thus represent artificial models of infection and TNF-α levels obtained from animal 
TBM studies should be interpreted with caution.  
 
Host genetics (polymorphisms in TLR2, TIRAP and LTA4H genes) has been shown to 
influence susceptibility to TBM.22 Recently, a functional single nucleotide polymorphisms 
(SNP) was identified in a gene (LTA4H locus) which controls the balance of pro-and anti 
inflammatory eicosanoids.23 In TBM patients, the SNP (LTA4H-high genotype) was 
associated with inflammatory cell recruitment, increased TNF-α production and patient 
survival. In this study, only those patients with the LTA4H-high genotype benefited from 
adjunctive corticosteroids. The impact of LTA4H genotype on corticosteroid effect requires 
further exploration. If validated, it opens up the exciting prospect of genotype-directed 
adjunctive therapy. These findings lend support to the assertion that future adjunctive 
therapies should target eicosanoids and TNF-α more precisely. It is my experience that 
thalidomide (a TNF-α antagonist) might be effective in controlling the adverse inflammatory 
complications of TBM where other treatment modalities such as corticosteroids have failed. 
 A previously conducted RCT evaluating adjunctive thalidomide therapy for childhood TBM 
at our site had to be terminated early because all adverse events and deaths occurred in the 
thalidomide study group.24 Of importance, is that all the deaths (n=4) in this study occurred in 
children with severe neurological compromise on admission and that the prescribed 
thalidomide dose was 24 mg/kg/day. Subsequent studies at our site suggest that low dose 
thalidomide (3-5 mg/kg/day) is safe and effective in the treatment of TB mass lesions and 
vision-threatening optochiasmic arachnoiditis.15, 25 In the near future, we hope to obtain 
funding and ethical approval to carry out a RCT evaluating efficacy of low dose adjunctive 
thalidomide (with LTA4H genotyping) in children with TBM.  
 
The value of aspirin’s antithrombotic, anti-ischemic and anti-inflammatory properties in TBM 
was explored in two studies. An adult TBM study reported a significant reduction in mortality 
at 3 months.26 In contrast, a RCT in children found no significant benefit in mortality and 
morbidity at 6 months.27 Acetylsalicylic acid (ASA), the active ingredient of aspirin, has been 
shown to decrease infection in LTA4H-high animals while increasing it in their LTA4H-low 
siblings.23 This finding highlights the importance of LTA4H-genotyping in future aspirin 
intervention trials.  
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My Transcranial Doppler imaging (TCDI) study found that the pulsatility index (PI) is not a 
useful index of identifying raised intracranial pressure (ICP) in children with TBM.28 No 
decline in PI was noted in all four children who underwent CSF diversion. Larger studies are 
warranted to investigate this finding and should ideally include pre-and post surgical ICP 
monitoring. The study re-affirmed my previous experience that diuretic and anti-TBM therapy 
rapidly normalizes ICP in children with tuberculous hydrocephalus.  
 
Previously, opinion was divided as to whether narrowing of the large basal arteries in TBM 
represents functional spasm or organic stenosis.29 Angiographic studies do not differentiate 
stenosis or spasm as a cause of vessel narrowing. Our finding of persistent high blood flow 
velocities (BFV) in all the basal cerebral arteries suggests stenosis due to vasculitis rather than 
functional vasospasm.  
 
Regarding the use of TCDI in children with tuberculous cerebral vasculopathy, complete 
middle cerebral artery (MCA) occlusion, subnormal mean MCA velocities (less than 40 cm/s) 
and reduced PI (less than 0.4) correlated with radiological proven large cerebral infarcts. 
TCDI is therefore not sensitive enough to detect smaller territory infarcts; a finding that I 
attributed to the fact that the hemodinamics of the MCA is not affected by occlusion of a 
limited number (one or two) of the 9 MCA perforators.  
 
A limitation of the TCDI study was the small sample size and the fact that only 4 children 
with non-communicating tuberculous hydrocephalus were included. Another limitation was 
that blood flow velocities in the basal cerebral arteries were only monitored for 7 days. 
Prolonged monitoring may have provided additional information on the duration of the 
stenosis. Lack of concomitant magnetic resonance angiography (MRA) also limited our 
ability to identify occlusion of the MCA perforators.     
 
Even with the best medicines and diagnostic/treatment modalities, outcomes in TBM will 
remain poor if diagnosis is delayed. Our efforts should be on increased awareness and earlier 
diagnosis.  
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